University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
2020

Chimeric Antigen Receptor T Cell Therapy For The Treatment Of
Hiv
Colby Maldini
University of Pennsylvania

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Allergy and Immunology Commons, Immunology and Infectious Disease Commons,
Medical Immunology Commons, and the Microbiology Commons

Recommended Citation
Maldini, Colby, "Chimeric Antigen Receptor T Cell Therapy For The Treatment Of Hiv" (2020). Publicly
Accessible Penn Dissertations. 4201.
https://repository.upenn.edu/edissertations/4201

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/4201
For more information, please contact repository@pobox.upenn.edu.

Chimeric Antigen Receptor T Cell Therapy For The Treatment Of Hiv
Abstract
Due to the success of antiretroviral therapy (ART), Human Immunodeficiency Virus (HIV) infection has
transformed from a terminal disease into a manageable chronic illness. However, ART is not curative, and
individuals must endure the side-effects of long-term treatment and the social stigma associated with
HIV infection. As such, the development of therapeutic strategies capable of eradicating HIV would
improve the lives of infected individuals. Herein, we investigated the in vivo therapeutic potential of HIVspecific Chimeric Antigen Receptor (CAR) T cell therapy as a means to reconstitute and optimize the
antiviral T cell response. Through iterative in vivo development, we generated a novel T cell product that
expressed two independent CD4-based CARs containing distinct costimulatory domains (4-1BB and
CD28) on the T cell surface. These Dual-CAR T cells accentuated in vivo antigen-driven proliferation
mediated by 4-1BB costimulation and preserved ex vivo effector functions mediated by CD28
costimulation. Notably, Dual-CAR T cells mitigated disease pathogenesis by reducing both plasma
viremia and tissue viral burden, as well as preserving CD4+ T cells from virus-induced depletion.
Moreover, through extensive in vitro and in vivo characterization, we uncovered the antiviral role of HIVspecific CAR-modified CD4+ T cells including their ability to both directly suppress virus replication and
confer T cell-help to other virus-specific lymphocytes. Lastly, we developed an image-based cytometry
method used to measure several quality control metrics of the CAR T cell manufacturing process,
including ex vivo expansion criteria and cytotoxic function. We demonstrated that image-based cytometry
overcomes several limitations associated with industry-standard equipment and assays, which could
serve to improve the efficiency for identifying high-quality CAR T cell products with therapeutic utility.
Collectively, our work focused on cell-based immunotherapy for the treatment of HIV; however, both the
development of a next-generation CAR T cell product and the in-depth characterization of CAR-modified
CD4+ T cells has broad applications for other disease indications.
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ABSTRACT
CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY FOR THE TREAMTNET OF HIV
Colby R. Maldini
James L. Riley

Due to the success of antiretroviral therapy (ART), Human Immunodeficiency
Virus (HIV) infection has transformed from a terminal disease into a manageable chronic
illness. However, ART is not curative, and individuals must endure the side-effects of
long-term treatment and the social stigma associated with HIV infection. As such, the
development of therapeutic strategies capable of eradicating HIV would improve the
lives of infected individuals. Herein, we investigated the in vivo therapeutic potential of
HIV-specific Chimeric Antigen Receptor (CAR) T cell therapy as a means to reconstitute
and optimize the antiviral T cell response. Through iterative in vivo development, we
generated a novel T cell product that expressed two independent CD4-based CARs
containing distinct costimulatory domains (4-1BB and CD28) on the T cell surface.
These Dual-CAR T cells accentuated in vivo antigen-driven proliferation mediated by 41BB costimulation and preserved ex vivo effector functions mediated by CD28
costimulation. Notably, Dual-CAR T cells mitigated disease pathogenesis by reducing
both plasma viremia and tissue viral burden, as well as preserving CD4+ T cells from
virus-induced

depletion.

Moreover,

through

extensive

in

vitro

and

in

vivo

characterization, we uncovered the antiviral role of HIV-specific CAR-modified CD4+ T
cells including their ability to both directly suppress virus replication and confer T cellhelp to other virus-specific lymphocytes. Lastly, we developed an image-based
cytometry method used to measure several quality control metrics of the CAR T cell
manufacturing process, including ex vivo expansion criteria and cytotoxic function. We
iv

demonstrated that image-based cytometry overcomes several limitations associated with
industry-standard equipment and assays, which could serve to improve the efficiency for
identifying high-quality CAR T cell products with therapeutic utility. Collectively, our work
focused on cell-based immunotherapy for the treatment of HIV; however, both the
development of a next-generation CAR T cell product and the in-depth characterization
of CAR-modified CD4+ T cells has broad applications for other disease indications.
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CHAPTER 1 - Adoptive T cell-based Strategies to Treat HIV Infection
Parts of this chapter were previously published in:
Maldini C.R., Ellis, G.I., and Riley, J.L. (2018). CAR T cells for infection, autoimmunity
and allotransplantation. Nat Rev Immunol 18: 605-616.
&
Zhou Y., Maldini, C.R., Jadlowsky, J., and Riley, J.L. (2020). Challenges and
Opportunities of Using Adoptive T cell Therapy as Part of an HIV Cure Strategy. J Infect
Dis (in press).
Overview
Human Immunodeficiency Virus (HIV) induces profound loss of CD4+ T cells
throughout all compartments of the body, increasing the susceptibility to AIDS-related
opportunistic infections.1 However, in the era of antiretroviral therapy (ART), successfully
treated individuals are expected to have a normal lifespan characterized by low levels of
viremia, and restored CD4+ T cell counts. Despite effective treatment, ART is not
curative as HIV largely persists within quiescent memory CD4+ T cells2 that can reignite
a systemic infection within weeks after individuals stop therapy. Unfortunately, existing
HIV-specific CD8+ T cells (CTLs) are generally compromised, even in the presence of
ART, and are ill-prepared to eliminate latently infected cells upon virus reactivation.3 As
such, the HIV cure field has placed increased emphasis on developing novel
immunotherapeutic strategies aimed to both reduce the size of the latent reservoir and
engender durable control over virus replication in the absence of ART. One attractive
strategy employs the adoptive transfer of ex vivo expanded autologous HIV-specific T
cells to bolster antiviral immunity. These T cell products mainly fall into three categories:
i) the ex vivo expansion and re-infusion of natural HIV-specific CTLs, or infusion of ii)
gene-engineered T cells expressing an HIV-specific T cell receptor (TCR) or iii)
Chimeric Antigen Receptor (CAR) (Fig. 1-1). Currently, these approaches are at various
stages of evaluation for therapeutic efficacy in HIV-infected individuals.
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HIV-specific CTL Response to HIV Infection
HIV infection induces a CTL response that fails to fully eradicate infection in most
individuals, but numerous lines of evidence support that the de novo generation of CTLs
directly impact disease progression. For instance, CTLs are readily identified during the
acute phase of infection prior to the presence of detectable antibodies, and their
emergence associates with the resolution of peak viremia.4,5 However, the HIV genome
rapidly accumulates mutations leading to the outgrowth of virus escape variants that
render infected cells insensitive to CTL-mediated recognition and killing.6,7 In addition,
unless ART is initiated early, CTL escape mutations dominate the proviral DNA
landscape,8 which can contribute to failed immune clearance of the latent reservoir.
Moreover, unmitigated HIV replication and persistent exposure to viral antigen induces
CTL exhaustion characterized by a progressive decline in effector functions, including
proliferative capacity, cytokine secretion, and cell-mediated cytotoxicity.9 Exhausted
CTLs preferentially express checkpoint inhibitors such as CTLA-4, 2B4, CD160 and PD1,9-11 which can attenuate immune activation and function. Indeed, there is considerable
interest in evaluating the therapeutic effects of disrupting PD-1 signaling to reinvigorate
exhausted CTLs in chronically infected individuals (clinical trial identifier, NCT03767465),
given the positive clinical responses observed in patients with advanced melanoma
undergoing checkpoint blockade therapy.12,13
In rare instances, asymptomatic HIV-infected individuals known as elite
controllers (ECs) spontaneously suppress virus replication (<50 RNA copies/mL of
blood) and maintain CD4+ T cells (>350 cells/L blood) in the absence of ART.14,15
Slower disease progression in ECs is predominately associated with the induction and
2

maintenance of polyfunctional CTLs restricted to particular HLA class I alleles, including
HLA-B57 and HLA-B27.16-18 Evidence from rhesus macaques that similarly control
pathogenic SIV infection demonstrate that in vivo depletion of CD8+ T cells results in
virus re-emergence and systemic infection,19 indicating that CTLs from ECs actively
patrol the body and control infection, but stop short of eradicating latent reservoirs. Thus,
the protective role of CTLs in ECs provides immense promise that treatment
interventions aiming to augment HIV-specific T cell immunity can improve disease
outcomes for the broader population of infected individuals.

Adoptive Transfer of Ex Vivo Expanded Natural HIV-specific CTLs
Several groups have explored the therapeutic efficacy of ex vivo expanded,
naturally-derived antigen-specific T cells following adoptive transfer into humans
diagnosed with chronic viral infections.20 In this process, autologous T cells are
harvested from the donor and expanded by ex vivo stimulation in the presence of viralderived peptides and exogenous cytokines prior to infusion.21 Early on, this approach
showed limited value in HIV-infected individuals as these CTLs showed poor in vivo
persistence, primarily due to rapid virus escape from HIV-specific CTL clones with one
epitope specificity,22 as well as intrinsic functional deficits associated with the ex vivo
manufacturing process.23 Since these early attempts, the immunoncology field has
significantly advanced this technology. For instance, the infusion of ex vivo expanded,
polyclonal CTLs targeting multiple viral-derived epitopes have reduced the rates of
morbidity and mortality caused by EBV, CMV and adenovirus reactivation in
immunocompromised individuals following hematopoietic stem cell transfer.24 Indeed,
researchers have leveraged these advances to overcome the hurdles that were
identified in the first clinical assessment of adoptive T cell therapy for viral infection.
3

Recently, polyclonal HIV-specific CTLs have been generated from both HIV-infected and
seronegative individuals after ex vivo stimulation with peptide mixes that comprise the
most conserved and least mutable regions of the HIV genome.25 This approach complies
with good manufacturing practice (GMP) standards and does not require genome
engineering, which mitigates the risk of genotoxicity. Furthermore, since these mature T
cells underwent normal development in the body, it is unlikely that there will be any offtarget reactivity by infusing more of these naturally-derived T cells. However, it remains
unclear whether increasing the frequency of pre-existing HIV-specific CTLs alone,
despite targeting conserved regions of the virus, will ultimately suppress HIV replication
after ART cessation. Currently, a clinical trial (NCT03485963) is underway infusing multiHIV-specific CTLs into individuals to test the safety and feasibility of this approach.
Notably, this study is designed to test whether these cells can reduce the size of the
latent reservoir in the presence of ART, rather than the ability to delay or control viral
rebound during an analytical treatment interruption.

TCR Gene Therapy Confers HIV Specificity
In addition to infusing ex vivo expanded, naturally-derived HIV-specific CTLs,
researchers are actively exploring approaches to restore the HIV-specific response by
introducing a virus-specific TCR into polyclonal T cells. In fact, several HIV-specific CTL
responses associate with lower viremia during untreated infection, particularly T cell
responses targeting the HIVGAG protein, whereas HIVENV and accessory/regulatory
protein-specific responses correlate with higher viremia.26-28 In practice, TCRs that
confer effective immunity can be sequenced and incorporated into a gene transfer vector
(i.e. retroviral- or lentiviral-based) that confers expression of an HIV-specific TCR into a
heterogeneous population of T cells. These re-directed TCR-transgenic T cells are then
4

expanded, typically though CD3/CD28 ligation, and infused into HIV-infected individuals
thereby reconstituting antiviral immunity. However, this therapy is HLA-restricted, and in
principle, participation is limited to individuals expressing specific HLA alleles, which has
restricted widespread clinical evaluation. To further complicate this issue, a majority of
the HIV-specific TCRs that exhibit enhanced control of infection are derived from ECs,
and are restricted to relatively rare HLA alleles including HLA-B57 and HLA-B27,
whereas more prevalent alleles, such as HLA-A2, are not associated with reduced
viremia.26 Thus, emphasis has been placed on engineering affinity enhanced HIVspecific TCRs restricted to common HLA alleles. In cancer, affinity-optimized tumorspecific TCRs show improved efficacy compared to their natural counterpart, 29 in part by
conferring class I HLA/peptide specificity and reactivity to both CD8+ and CD4+ T cell
subsets.30
An affinity-enhanced HIV-specific TCR targeting the SL9 epitope in HIVGAG and
restricted by HLA-A2 was reported by Varela-Rohena and colleagues.31 Unlike the wildtype SL9-specific TCR, the affinity-enhance variant conferred T cells with superior in
vitro effector functions and reactivity to common SL9 escape mutants. In 2009, a clinical
trial was initiated (NCT00991224) to test the ability of both the wild-type and affinityenhanced

SL9-specific TCRs to reconstitute

HIV-specific immunity.

However,

recruitment into the trial was challenging as 4 out of 40 individuals screened positive for
HLA-A2, and only 2 people consented to be part of the trial. However, this trial was
suspended to due to the unfortunate death of two participants treated with an affinityenhanced HLA-A1-restricted MAGE-A3-specific TCR for myeloma and melanoma.
Follow-up analysis of these two individuals revealed that affinity-enhancement of the
MAGE-A3 TCR caused off-tissue recognition of an epitope within titan, an unrelated
protein expressed in cardiac tissue that was not predicted by preclinical testing.32 The
5

findings from this trial underscored that extensive epitope screening is required to
identify and characterize on-target, off-tissue reactivity brought about by TCR affinityenhancement. As a result, the adoptive transfer of T cells expressing a high-affinity HIVspecific TCR offers some direct advantages to the infusion of ex vivo expanded HIVspecific CTLs, but the therapeutic potential of this approach remains unknown.

CAR T Cell Therapy for HIV Infection
Chimeric antigen receptor (CAR) technology has emerged as a promising
approach to reprogram T cells to overcome the barriers that confront naturally occurring
T cells. Because CARs alter how T cells recognize antigen by directly binding to cell
surface proteins without requiring peptide presentation by MHC molecules, there are
fewer available targets for CARs to recognize relative to TCRs. However, in the setting
of HIV, redirecting T cell specificity with a CAR may avoid many of the CTL escape
mechanisms employed by HIV (Table 1-1). The concept of CAR T cells emerged in the
1990s when investigators showed that T cell specificity could be redirected by fusing a
targeting moiety that recognizes a cell surface protein with a T cell activation domain
such as the CD3- cytoplasmic tail. The first example of this technology fused the CD4
extracellular region to the CD3- chain. When expressed in T cells, this construct
conferred T cell specificity to recognize HIV-infected cells by taking advantage of the
interaction between the HIVENV protein and CD4.33 This concept was brought to the clinic
in the late 1990s; although it was shown to be safe and feasible, durable control of virus
infection was not observed.34-36 These findings raised concerns about the ability of firstgeneration CAR T cells, which only contain the CD3- signaling domain, to function in
vivo. Since then, the cancer immunotherapy field has advanced the design and
6

manufacturing of CAR T cells to generate optimal antitumor responses.37 A key
improvement in the design from first- to second-generation CARs has been the inclusion
of costimulatory domains, such as those derived from 4-1BB and CD28, which modulate
T cell function, persistence and susceptibility to exhaustion.37-39 Costimulatory domains
can also influence memory development and metabolism of CAR T cells. For example,
signaling from a CAR containing a 4-1BB domain promotes a central-memory phenotype
in T cells and reliance on oxidative phosphorylation for energy, whereas signaling from a
CAR containing a CD28 domain promotes an effector-memory phenotype in T cells and
an augmented rate of glycolysis.39 These findings help to reconcile the differential
persistence of CAR T cells that has been observed in vivo, whereby different types of
costimulation can reprogram T cell metabolism to generate long-lived memory cells or
short-term effector cells.
Recently, we applied the lessons learned from CAR design in the cancer field to
re-engineer the CD4-based CAR described in the first in-human clinical trial. The original
CAR underwent substantial modifications including alterations to the vector backbone,
promoter, and the structural and signaling domains. Optimized CD4-based CAR T cells
containing the 4-1BB-CD3 intracellular signaling domain were at least 50-fold more
potent at suppressing HIV replication in vitro than were T cells expressing the original
CAR. Moreover, when the optimized CAR T cells were evaluated in a humanized mouse
model of HIV infection, they preserved the CD4+ T cell count, reduced the HIV burden,
and expanded in response to HIV to a much greater extent than did their first-generation
counterparts.40 Moreover, several groups have explored targeting HIV-infected cells
using second-generation CARs with alternative antigen-binding moieties. CARs
containing single-chain variable fragments (scFvs) derived from broadly neutralizing
antibodies have been developed that target conserved sites within the HIVENV protein,
7

including the CD4-binding site, the gp41 membrane-proximal external region and
variable region glycans.41-43
Despite the in vitro antiviral capacity exhibited by both CD4- and scFv-based
CAR T cells, several factors may limit their therapeutic potential in humans. For
instance, the over-expression of the CD4-based CAR on the T cell surface renders
transduced cells susceptible to HIV infection,40 which may ultimately mitigate the
persistence CAR T cells and limit the overall efficacy of treatment. Moreover, to become
a broadly applicable therapy, scFv-based CAR T cells must overcome HIV escape, be
effective against the diversity of HIV strains, and be non-immunogenic so that they can
persist for decades. Despite the advantages and potential drawbacks of each type of
antigen-targeting moiety, it is clearly possible that highly potent HIV-specific T cells can
be generated by improving CAR design. This will likely impact the durability and function
of CAR T cells in HIV-infected individuals going forward into clinical trials.

8

Figure

Figure 1-1. Schematic of adoptive T cell-based strategies to treat HIV infection.
Adoptive T cell-based strategies to treat HIV infection fall largely into 3 categories: i) ex
vivo expansion and infusion of existing naturally-derived HIV-specific T cells, ii) infusion
of polyclonal T cells engineered to express a single HIV-specific T cell receptor, and iii)
infusion of T cells stably transduced with an HIV-specific chimeric antigen receptor.

9

Table
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CHAPTER 2 - Dual CD4-based CAR T cells with Distinct Costimulatory
Domains Mitigate HIV Pathogenesis In Vivo
Parts of this chapter were previously published in:
Maldini C.R., Claiborne D.T., Okawa K., Chen T., Dopkin D.L., Shan X., Power K.A.,
Trifonova R.T., Krupp K., Phelps M., Vrbanac V.D., Tanno S., Bateson T., Leslie G.J.,
Hoxie J.A., Boutwell C.L., Riley J.L., Allen T.M. (2020) Dual-CD4-based CAR T cells with
Distinct Costimulatory Domains Mitigate HIV Pathogenesis In Vivo. Nat Med (in press).

Abstract
An effective strategy to cure HIV will likely require a potent and sustained
antiviral T cell response. Here, we explored the utility of Chimeric Antigen Receptor
(CAR) T cells expressing the CD4 ectodomain to confer specificity for the HIV envelope
to mitigate HIV-induced pathogenesis in bone marrow, liver, thymus (BLT) humanized
mice. CAR T cells expressing the 4-1BB/CD3- endodomain were insufficient to prevent
viral rebound and CD4+ T cell loss after the discontinuation of antiretroviral therapy
(ART). Through iterative improvements to the CAR T cell product, we developed DualCAR T cells that simultaneously expressed both 4-1BB/CD3- and CD28/CD3-
endodomains. Dual-CAR T cells exhibited expansion kinetics that exceeded 4-1BB-,
CD28- and 3rd-generation costimulated CAR T cells, elicited effector functions equivalent
to CD28-costimulated CAR T cells, and prevented HIV-induced CD4+ T cell loss despite
persistent viremia. Moreover, when Dual-CAR T cells were protected from HIV infection
through expression of the C34-CXCR4 fusion inhibitor, these cells significantly reduced
acute phase viremia, as well as accelerated HIV suppression in the presence of ART
and reduced tissue viral burden. Collectively, these studies demonstrate the enhanced
therapeutic potency of a novel Dual-CAR T cell product with the potential to effectively
treat HIV infection.
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Introduction
Chimeric Antigen Receptor (CAR) T cell immunotherapies, in which engineered T
cells are infused into patients, have induced durable remissions for treatment-refractory
malignancies.44 Although a potent and sustained T cell response of the kind that CAR T
cells can afford is likely to be essential for the development of an effective HIV cure 45, a
successful CAR T cell therapy for HIV infection has remained elusive. CARs redirect T
cell specificity by expressing an extracellular antigen recognition domain linked to an
intracellular T cell costimulatory domain and the CD3- chain.37,46 The costimulatory
domains for second-generation CARs are derived from the intracellular signaling
domains of either CD28 or 4-1BB, which is one of the key differences between the two
FDA-approved CD19-targeting CAR T cell therapies.47,48 Preclinical cancer models
demonstrate that CD28-costimulated CAR T cells exhibit profound effector function
resulting in rapid tumor clearance, but have limited persistence in vivo.49,50 In contrast, 41BB-costimulated CAR T cells have a slower antitumor response but sustained
proliferation and survival.51-54 The distinct signaling pathways used by CD28 and 4-1BB
cause distinct metabolic, phenotypic and functional T cell profiles that can elicit optimal
CAR T cell activity for specific diseases,39,55-58 and there is great interest in tuning
costimulatory signals to optimize CAR T cell function.59,60
The earliest clinical trials of CAR T cell therapy utilized first-generation, CD4based CARs targeting the HIV Envelope glycoprotein via surface expression of the CD4
ectodomain and proved ineffective for treatment of either chronic or antiretroviral therapy
(ART)-suppressed infection.36,61,62 However, subsequent significant improvements in
CAR technology by the cancer immunotherapy field has renewed interest in applying
these advances to HIV treatment.40-43,63-65 The continued investigation of the mechanistic
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underpinnings of successful and failed CAR T cell therapy, particularly in a model
system that recapitulates HIV pathogenesis, will be critical for the development of a CAR
T therapy for HIV cure initiatives.
Here, we utilized the bone marrow, liver, thymus (BLT) humanized mouse model
of HIV infection to iteratively test CD28 and 4-1BB costimulation in the context of
optimizing HIV-specific CAR T cell therapy. We leveraged the BLT mouse model’s ability
to support HIV infection, including high viral loads, rapid human CD4+ T cell depletion,
and ultimately T cell exhaustion,66-69 to make stepwise improvements to the CAR T cell
product. This effort culminated in the development of HIV-resistant (C34-CXCR4+), DualCAR T cells that express two CD4-based CARs independently encoding the CD28/CD3 and 4-1BB/CD3- endodomains. Collectively, these data provide important insight
regarding the development of an engineered T cell-based therapy of HIV infection and
highlight the novel function of a Dual-CAR T cell product that mitigates HIV-induced
disease.

Results
BLT mouse-derived CAR T cells are multifunctional and suppress HIV replication
in vitro
To determine whether T cells isolated from BLT mice generate potent CAR T cell
products, we manufactured HIV-specific (CD4-based) CAR T cells expressing the CD3-
endodomain (CAR.) from BLT mouse tissues and adult human PBMCs (Fig. 2-1A).
BLT mouse- and human-derived CAR. T cells exhibited comparable in vitro expansion
kinetics and CAR surface expression levels (Fig. 2-1B and Fig. 2-2A). Antigen-specific
stimulation with K562 cells expressing HIVYU2 Envelope (K.Env) induced similar cytokine
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expression and polyfunctionality profiles between the CAR T cell sources (Fig. 2-2B,C
and Fig. 2-1C-E). Furthermore, CAR. T cells from both donors suppressed viral
outgrowth down to a 1:50 effector-to-target ratio in vitro (Fig. 2-2D,E), and induced
similar levels of cleaved caspase-3 in HIV-infected CD4+ T cells (Fig. 2-1F and Fig. 22F,G). The induction of caspase-3 combined with the co-upregulation of granzyme B
and perforin by CAR. T cells (Fig. 2-1G,H) indicate that elimination of virus-infected
cells likely occurred via granule-mediated cytolysis. In total, the in vitro functional profile
of BLT mouse-derived CAR. T cells was indistinguishable from that of human-derived
CAR. T cells, demonstrating that highly functional CAR T cells can be manufactured
from BLT mice.

Costimulation modulates CAR T cell persistence and function in vivo
To identify a CAR T cell product capable of long-term persistence against HIV,
we compared the contribution of costimulatory domains to in vivo engraftment of T cells
by creating an infusion product comprising equal frequencies of HIV-specific CAR.CD3 (CAR.), 4-1BB/CD3- (CAR.BB), and CD28/CD3- (CAR.28) T cells, each of which
was linked to a distinct fluorescent protein (Fig. 2-3A). After infusion, CAR.BB T cells
exhibited significantly greater survival in the absence of HIV antigen (Fig. 2-3B-D), and
constituted approximately 80% of total CAR T cells in tissues (Fig. 2-3E). Consistent
with reports from the cancer field,51-54 CAR.BB T cells also demonstrated superior in
vivo antigen-driven proliferation upon infusion of K.Env cells (Fig. 2-3F). In contrast,
CAR.28 T cells only exhibited a transient expansion followed by a progressive decline,
and CAR. T cells steadily declined demonstrating no evidence of expansion. Notably,
however, CAR.28 T cells exhibited greater effector functions when stimulated ex vivo
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with K.Env cells, upregulating more MIP-1, TNF and IL-2, and co-expressing greater
levels of granzyme B and perforin than CAR.BB T cells from the same mice (Fig. 23G,H and Fig. 2-4). Finally, we confirmed the in vivo cytotoxic potential of BLT mousederived CAR T cells by infusing CD19-specific CAR.BB T cells into recipient mice. We
observed rapid and profound B cell aplasia in the blood (Fig. 2-3I), as well as in the
spleen, lung, liver, and bone marrow, consistent with a sustained cytotoxic CAR T cell
response (Fig. 2-3J,K). Together, these data demonstrate the suitability of BLT mice for
studying in vivo CAR T cell function, and the degree to which costimulation can
modulate CAR T cell activity.

CAR.BB T cells fail to control HIV rebound upon ART discontinuation
After determining that the 4-1BB/CD3- endodomain confers superior in vivo
antigen-driven CAR T cell expansion and persistence, we sought to test the therapeutic
potential of CAR.BB T cells in the context of ART-suppressed HIV infection. To do so,
we infected BLT mice with CCR5-tropic HIVJRCSF and after 3 weeks initiated ART. Two
weeks later ART-suppressed mice were allocated into groups that received an infusion
of either CAR.BB T cells (G1 and G3), or inactive control CAR.BB T cells (G2 and
G4), which express a truncated CD3- chain. In G1 and G2, ART was ceased
immediately after infusion, whereas in G3 and G4 ART was continued for an additional 3
weeks to test whether the timing of ART interruption impacted the efficacy of CAR T cell
therapy. In all groups, HIV rebounded by 2 weeks after treatment interruption, regardless
of timing, and there were no observable differences in the kinetics or magnitude of
viremia in CAR.BB-treated mice compared to matched control mice (Fig. 2-5A).
Moreover, CAR.BB T cell therapy did not prevent memory CD4+ T cell loss in peripheral
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blood or tissues (Fig. 2-5B,C and Fig. 2-6), which in BLT mice represent the CD4+ T cell
subset preferentially infected and depleted by HIV due to high levels of CCR5
expression (Fig. 2-7). Together, these data indicate that CAR.BB T cell therapy did not
impact HIV progression.

CAR.BB T cells display features of T cell exhaustion during uncontrolled HIV
replication
Despite the lack of efficacy following ART discontinuation, we observed profound
CAR.BB T cell expansion during viral recrudescence with a median 75-fold increase in
the blood (Fig. 2-5D,E). As expected, the control T cells did not expand in response to
viral rebound (Fig. 2-5D,E), and the CAR.BB T cells were substantially more abundant
throughout the body 12 weeks after infusion (Fig. 2-5F). These findings suggested that
the inability of CAR.BB T cells to control viremia and HIV pathogenesis was not the
result of poor proliferation, persistence, or lack of migration to relevant anatomical
compartments of virus replication.70-72
The proliferation of CAR.BB T cells was associated with upregulation of
inhibitory receptors including PD-1, TIGIT, and 2B4, which increased over time (Fig. 25G and Fig. 2-8A-D). Importantly, these inhibitory receptors were not expressed to the
same extent on endogenous CAR- T cells within the same mice, suggesting a CAR T
cell-specific effect rather than generalized activation from inflammation or viral load (Fig.
2-8E,F). Notably, elevated inhibitory receptor expression on CAR.BB T cells from
chronically infected mice was associated with the expression of TOX (Fig. 2-5H,I), a
transcription factor that regulates the T cell exhaustion program.73-77 Further supporting
the gradual emergence of a dysfunctional CAR T cell phenotype, T-bet expression in
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CAR.BB T cells waned as HIV infection progressed culminating in a population of
EomeshiT-betdim CAR T cells that were enriched in TOX expression and accumulated in
tissues with higher viral burden (Fig. 2-5J,K and Fig. 2-9). In addition, expression of
multiple inhibitory receptors on CAR.BB T cells from chronic infection was linked to a
transitional memory state that also displayed an EomeshiT-betdim phenotype (Fig. 2-5L),
all of which is congruent with prior studies identifying dysfunctional HIV-specific CD8+ T
cells within this compartment in chronic human HIV infection.11,78
Finally, we compared the ex vivo functions of CAR.BB T cells isolated during
chronic infection to the pre-infusion CAR T cell product (TCP). Although the CD8+
CAR.BB T cells from chronic infection retained the ability to upregulate MIP-1 and
granzyme B, and degranulate based on CD107a expression, the degree of -chemokine
production and cytotoxic potential was attenuated (Fig. 2-10). Taken together, these
data indicate that CAR.BB T cells recognize HIV-infected cells, rapidly expand and
upregulate markers of cellular activation, but that uncontrolled virus replication ultimately
drives an exhaustion program that may diminish T cell function and subvert efficacy.

Augmented HIV-specific CAR T cell product reduces CD4+ T cell loss during acute
infection
We hypothesized that combining the superior in vivo expansion and persistence
of CAR.BB T cells with enhanced effector function could provide the necessary
improvement to control HIV replication. To this end, we co-transduced CAR.BB T cells
with the CD4-based, CD28-costimulated CAR that exhibited notable effector function
(Fig. 2-4) to create a novel Dual-CAR T cell product (TCP). Due to co-transduction
probabilities, the Dual-CAR TCP comprises three populations: CAR.BB, CAR.28 and
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Dual-CAR T cells, the latter of which simultaneously expresses both CD4-based CARs
(Fig. 2-11A). Inclusion of the CD28-costimulated CAR increased in vitro cytokine
production of Dual-CAR T cells over CAR.BB T cells (Fig. 2-12). To evaluate the DualCAR TCP in vivo, we used an acute infection model in which mice received CAR T cells
48 hours after HIVJRCSF challenge to provide a more rapid model to test therapeutic
efficacy. Although we observed no differences in acute viremia between the Dual-CAR
TCP-treated and untreated groups (Fig. 2-11B), CAR T cell-treated mice exhibited a
significant, albeit transient delay in the loss of peripheral memory CD4+ T cells (CAR-),
which coincided with peak expansion of total CAR T cells in peripheral blood (Fig. 211B,C and Fig. 2-13A), Notably, this delay in CD4+ T cell loss was observed in central,
transitional, and effector memory subsets (Fig. 2-13B), an effect that was not observed
after ART discontinuation in the CAR.BB-treated mice in the prior study (Fig. 2-11B,C).
We next assessed the efficacy of the Dual-CAR TCP in the context of a more
physiologically relevant strain of HIV. To do so, we infected additional mice from the
same cohort as above with HIVMJ4, which exhibits slower acute phase replication kinetics
than HIVJRCSF, but ultimately achieves equivalent set-point viremia (Fig. 2-14). Although
the infusion of CAR T cells 48 hours post-infection, again, did not alter viremia (Fig. 211D), we now observed more profound CD4+ T cell preservation and maintenance of the
Dual-CAR TCP in peripheral blood as compared to the CAR T cell-treated mice infected
with HIVJRCSF (Fig. 2-11E,F and Fig. 2-15A). The preservation of CD4+ T cells was
particularly accentuated in transitional and effector memory populations, which express
greater levels of CCR5 (Fig. 2-15B). Similarly, the percentage of all memory CD4+ T cell
subsets in the tissues at necropsy were substantially preserved in Dual-CAR TCPtreated compared to untreated HIVMJ4-infected mice (Fig. 2-11F and Fig. 2-15C),
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whereas there was no difference between CAR T cell-treated and control HIVJRCSFinfected mice (Fig. 2-11F and Fig. 2-13C). Thus, treatment with the Dual-CAR TCP can
effectively limit HIV-induced depletion of memory CD4+ T cells, an effect that is
modulated by the pathogenicity of the infecting virus.

Dual-CAR T cells exhibit vigorous in vivo proliferation in a competitive
environment
The linkage of each CAR to a unique fluorescent protein allowed for independent
quantification of each CAR T cell type within the Dual-CAR TCP and revealed increased
in vivo expansion of Dual-CAR T cells relative to either of the single costimulatory
domain-expressing CAR T cells (Fig. 2-11G). Notably, significant differences were
observed in the peak expansion and cumulative proliferation of Dual-CAR T cells (Fig. 211H,I), which remained significant after correcting for the baseline absolute count of
each population (Fig. 2-16A). In addition, we compared the proliferative capacity of
Dual-CAR T cells to 3rd-generation (3G) CAR T cells, which express CD28 and 4-1BB
linearly in the same construct (Fig. 2-16B). Here, we combined an equal amount of
Dual-CAR and 3G-CAR T cells prior to adoptive transfer into recipient mice (Fig. 2-16C).
After infusion, Dual-CAR T cells showed significantly greater antigen-independent
engraftment (Fig. 2-16D), and also demonstrated superior antigen-driven proliferation
after infusion of K.Env cells (Fig. 2-16E). In contrast, 3G-CAR T cells marginally
expanded and then progressively declined. Notably, during HIVMJ4 infection, Dual-CAR T
cells exhibited profound proliferation (Fig. 2-11J,K) and long-term survival (Fig. 211L,M) relative to 3G-CAR T cells within the same mice. Together, these studies reveal
the striking proliferative capacity exhibited by Dual-CAR T cells in a competitive setting
under both antigen scarce and abundant in vivo environments.
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Engineering HIV-resistance augments CAR T cell persistence and function
Despite the CD4-based CAR’s ability to more efficiently suppress in vitro HIV
replication versus several HIV-specific antibody-based CARs,40 and the reduced
likelihood for viral escape due to the requirement for HIV to bind CD4 for infection, this
CAR results in the over-expression of the CD4 extracellular domain on the T cell surface
potentially increasing susceptibility to infection. Indeed, HIV-infected CAR T cells were
detected in vivo, although the extent of total infection appeared to be indistinguishable
from endogenous CAR- T cells (Fig. 2-17A,B). More importantly, ex vivo stimulation
revealed functional deficits in the capacity of HIV-infected CAR T cells to co-upregulate
granzyme B and perforin (Fig. 2-17C,D). To confer HIV resistance, we co-transduced
the Dual-CAR TCP with the surface-expressed HIV fusion inhibitor C34-CXCR479 (Fig.
2-18A and Fig. 2-19A). C34-CXCR4 was expressed on up to 50% of cells in the DualCAR TCP and provided protective benefit as the C34-CXCR4+ CAR T cells harbored
significantly less HIV DNA than their unprotected counterparts (Fig. 2-18B), and were
selected for over time in chronically infected mice (Fig. 2-20A,B). Importantly, C34CXCR4+ CAR T cells from chronic infection had markedly improved cytotoxic potential
and MIP-1 expression relative to unprotected CAR T cells within the same mice (Fig. 220C,D). Somewhat paradoxically, however, infusion of a Dual-CAR TCP where 50% of
all cells were HIV-resistant was still insufficient to reduce acute virus replication (Fig. 219B). These results demonstrate that CD4-based CAR T cells can be protected from
HIV infection by the C34-CXCR4 fusion inhibitor and that such protection can preserve
CAR T cell functionality during persistent exposure to HIV.
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HIV-resistant Dual-CAR T cells are responsible for mitigating HIV-induced CD4+ T
cell loss
To determine whether an infusion product of Dual-CAR T cells alone exhibits
enhanced virus-specific responses during HIV infection, we infused a low dose of C34CXCR4+, purified Dual-CAR T cells, CAR.BB, or CAR.28 T cells into separate groups
of HIVMJ4-infected mice. Dual-CAR T cells exhibited notable in vivo expansion kinetics
that exceeded both single CAR-transduced T cell populations (Fig. 2-18C,D), and
mitigated HIV-induced CCR5+ CD4+ T cell loss (Fig. 2-21). However, to more stringently
control for CAR surface expression we performed an additional study in another cohort
of mice where HIV-resistant, purified Dual-CAR T cells were compared to HIV-resistant,
purified CAR T cells transduced with two independent CAR.BB or CAR.28 constructs
(Fig. 2-22). Dual-CAR T cells again demonstrated remarkable sensitivity to acute virus
replication expanding 300-fold to represent 30% of total human cells in blood 3 weeks
post-infection, whereas CAR.BB.BB and CAR.28.28 T cells reached only 3% and
1%, respectively (Fig. 2-18E and Fig. 2-23A). In addition, Dual-CAR T cells sustained
greater long-term proliferation and maintenance in blood and tissues than CAR.28.28
or CAR.BB.BB T cells (Fig. 2-18F,G and Fig. 2-23B). Importantly, the infusion of
purified Dual-CAR T cells resulted in the greatest protection against CD4+ T cell loss
during HIVMJ4 infection (Fig. 2-18H-J), reflected in the preservation of total memory and
CCR5+ CD4+ T cells especially late in the infection (Fig. 2-23C,D). Furthermore, the
magnitude of early CAR T cell expansion across all groups, but exemplified by DualCAR T cells, was positively correlated with CD4+ T cell preservation (Fig. 2-23E).
Together, these data indicate that after controlling for CAR surface expression, DualCAR T cells exhibit the greatest in vivo antiviral effect.
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Ex vivo effector function of Dual-CAR T cells exceeds 4-1BB-costimulated CAR T
cells
We next interrogated the ex vivo effector functions of CAR T cells from
chronically infected mice. Dual-CAR T cells were superior to CAR.BB.BB T cells and
equivalent to CAR.28.28 T cells in their ability to produce MIP-1 and degranulate
based on CD107a expression (Fig. 2-18K,L). Notably, a majority of CD107a+ Dual-CAR
T cells co-expressed granzyme B and perforin compared to CAR.BB.BB T cells,
indicating these cells possess cytotoxic potential (Fig. 2-18M,N). In further support of
cytolytic function, CAR T cells comprising the Dual-CAR TCP induced active caspase-3
expression in K.Env cells after ex vivo stimulation (Fig. 2-24). Moreover, comparison of
IL-2, TNF, MIP-1 and CD107a expression revealed distinct effector profiles between
these CAR T cell populations (Fig. 2-25A,B). Dual-CAR and CD28-costimulated CAR T
cells clustered in a similar fashion, with CD4+ CAR T cells expressing more TNF and IL2, and CD8+ CAR T cells upregulating more CD107a and MIP-1. In contrast, CD4+ and
CD8+ 4-1BB-costimulated CAR T cells clustered together and exhibited attenuated
levels of effector molecules (Fig. 2-25C). Together, these findings support our
hypothesis that Dual-CAR T cells harness both the antigen-driven proliferation and
effector functions mediated by 4-1BB- and CD28-costimulation, respectively, for
improved potency.

Protecting CAR T cells from HIV infection improves control over virus replication
We hypothesized that the contribution of HIV-infected CAR T cells to viremia may
be significant, in that virus secreted from infected CAR T cells could mask reductions in
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viral load caused by clearing infected CD4+ T cells. Indeed, after aggregating the data
from all infection studies, we observed that infusion of HIV susceptible CAR T cells
significantly magnifies plasma viremia (Fig. 2-27A), as well as viral burden in tissues
(Fig. 2-28A,B). Thus, to test whether HIV infection of CD4-based CAR T cells negates
CAR T cell-mediated reductions in viremia, we compared the outcomes of infusing a
fully-protected (>98% C34-CXCR4+) or a partially-protected (<20% C34-CXCR4+) DualCAR TCP into HIVMJ4-infected, ART-suppressed mice followed by ART cessation.
Strikingly, infusion of the partially-protected Dual-CAR TCP increased rebound viremia
over untreated mice to an average peak rebound of 4.6 log HIV RNA copies/mL versus
3.8 log copies/mL, whereas the fully-protected Dual-CAR TCP significantly reduced viral
load to 3.0 log copies/mL (Fig. 2-28C). We confirmed this result by infusing the fullyprotected, Dual-CAR TCP into a larger cohort of BLT mice and observed significant
reductions in acute viremia compared to untreated mice (Fig. 2-27B). Notably, treatment
with the C34-CXCR4+ Dual-CAR TCP reduced the frequency of HIV-infected cells in
tissues (Fig. 2-27C,D), contrasting the effect of unprotected CAR T cells on tissue viral
burden in viremic mice (Figure 2-28A,B). Together, these data demonstrate the
importance of safeguarding CAR T cells as HIV infection of unprotected CAR T cells can
contribute to plasma viremia and potentially overwhelm CAR T cell-mediated control
over virus replication.
Although C34-CXCR4 reduces HIV infection of CAR T cells, we have shown that
the protection is not sterilizing in the presence of persistent viremia (Fig. 2-18B). To test
whether providing ART to prevent new rounds of infection at the time of CAR T cell
infusion could further reveal CAR T cell-mediated viral load reduction we challenged
mice with HIVJRCSF and initiated combination therapy (ART and Dual-CAR TCP) at peak
viremia. After one week of combination therapy, the Dual-CAR TCP-treated mice
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achieved approximately a 1-log greater reduction in viral load relative to the ART only
control group, which corresponded to a 50% reduction in viremia from pre-treatment
levels (Fig 2-26E,F). We confirmed the suppressive effect of the Dual-CAR TCP in a
separate cohort of mice infected with a different HIV strain (HIVBAL) (Fig. 2-28D,E).
Aggregation of the data from the two studies showed that the magnitude of early viral
load reduction was associated with the contemporaneous concentration of CAR T cells
in peripheral blood (Fig. 2-26G), and that CAR T cell treatment significantly accelerated
HIV suppression, with nearly all combination therapy-treated mice reaching full
suppression by 2 weeks after treatment initiation versus 4 weeks for ART-treated control
mice (Fig. 2-26H). Furthermore, the Dual-CAR TCP reduced tissue viral burden in mice
with suppressed plasma viremia, evidenced by fewer HIV-infected CD8- T cells (CAR-)
and CD14+ macrophages in the tissues (Fig. 2-26I,J). Notably, central memory CD4+ T
cells (CAR-) sorted from mice treated with the Dual-CAR TCP exhibited a significant,
albeit modest, reduction in cell-associated HIV DNA load compared to the control group
(Fig. 2-26K), suggesting that CAR T cell therapy is capable of reducing the size of the
virus reservoir that forms during ART. Together, these findings highlight the potential for
the HIV-resistant Dual-CAR TCP to mediate direct antiviral activity to clear infected cells
in vivo.

Discussion
Here, we use the BLT humanized mouse model to iteratively develop a novel
CD4-based CAR T cell treatment of HIV infection. Although initially, 4-1BB-costimulated
CAR T cells demonstrated marked in vivo antigen-driven proliferation and survival, they
failed to control viremia after ART cessation. In order to increase effector function, we
created a novel Dual-CAR T cell that simultaneously expresses two CD4-based CARs
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independently encoding 4-1BB/CD3- and CD28/CD3- endodomains. These Dual-CAR
T cells exhibited both the cytotoxic potential and cytokine expression of CD28costimulated CAR T cells and the proliferative capacity of 4-1BB-costimulated CAR T
cells, suggesting concurrent contribution by both costimulatory signals. In contrast, 3rdgeneration (3G) CD4-based CAR T cells exhibited the more limited expansion of
CAR.28 T cells despite containing a 4-1BB costimulatory domain within the same
construct, likely the result of a dominant effect of the membrane proximal CD28 domain
as described for 3G cancer-specific CAR T cells.80-83 This novel Dual-CAR approach
introduces the potential to produce a CAR T cell with the benefits of both 4-1BB and
CD28 costimulation.
The immunodeficiency caused by HIV infection is characterized by infection of
CD4 T cells and concomitant immune activation and dysfunction.84 Importantly, the rapid
antigen-driven proliferation of CAR T cells makes them susceptible to these same
pathogenic mechanisms. In particular, the CD4-based CAR’s extracellular domain
renders both CD4+ and CD8+ CAR T cells infectable, resulting in a substantial
contribution to plasma viremia, as well as functional deficits. To combat this, we coexpressed a C34-CXCR479 fusion inhibitor, which significantly improved CAR T cell
survival and effector function during early HIV infection. Notably, the HIV-resistant DualCAR T cell treatment also resulted in a reduction in HIV burden in a variety of tissues
and cell types, including long-lived memory CD4+ T cells, which suggests for the first
time that a CAR T cell therapy targeted the HIV reservoir. However, the benefit of C34CXCR4 waned over time, which highlights the need to confer complete and permanent
HIV resistance, perhaps through the deletion of CCR5.85-88
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The HIV-resistant Dual-CAR T cell treatment resulted in substantial protection of
memory and CCR5+ CD4+ T cells from HIV-induced depletion despite failing to durably
control viremia. Interestingly, the degree of protection was associated with the viral
replication capacity (vRC) of the infecting strain. This is consistent with prior findings that
vRC affects many aspects of HIV-associated pathogenesis, including the kinetics of
CD4+ T cell loss in acute infection.89 Since the vRC of transmitted/founder viruses can
vary by orders of magnitude across infected individuals,90-92 vRC may become an
important clinical consideration for the efficacy of CAR T cell treatment of HIV.
The HIV/BLT mouse model recapitulates key characteristics of HIV infection that
are necessary to explore the efficacy of HIV-specific CAR T cell therapy. This small
animal model may actually provide an overtly stringent test of CAR T cell efficacy given
the general inability of BLT mice to develop affinity-matured antibodies,93-95 We have
used this model to develop a Dual-CAR T cell that successfully exhibits the
functionalities mediated by both CD28 and 4-1BB costimulation, and was capable of
reducing viremia, limiting HIV-induced CD4+ T cell loss, and diminishing viral tissue
burden in the context of a fully disseminated infection. Collectively, these findings
provide critical insight into the iterative development of an engineered T cell-based
therapy for HIV and describe a novel product that not only mitigates HIV pathogenesis
but also has broad utility for viral infections and malignancies.

Materials and Methods
Ethics:
Anonymized human fetal tissue (17-19 weeks of gestational age) was acquired
with informed consent from healthy donors by Advanced Bioscience Resources (ABR,
Alameda, CA), and used under Partners Healthcare Institutional Review Board26

approved protocols. Humanized mouse experiments performed at the Ragon Institute
and at UPenn were approved by the Massachusetts General Hospital and UPenn
Institutional

Animal Care

and Use

Committee

under

the approved

protocol

2016N000483 and 805606, respectively. Animal studies were performed following the
instructions detailed in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. Purified CD3+ and CD4+ T cells from anonymous healthy
human donors were obtained by the UPenn Human Immunology Core/CFAR
Immunology Core.

Humanized mice:
Male and female NOD/SCID/IL2R-/- (NSG) mice (Jackson Laboratory) were
maintained in pathogen-free facilities at the Ragon Institute of MGH, MIT and Harvard or
the University of Pennsylvania. Microisolator cages were used to house mice and were
fed autoclaved food and water. Animal rooms were maintained at 72 ± 2 °F (22.2 ± 1.1
°C) and 30% to 70% relative humidity and were on a 12:12-hour light:dark cycle. BLT
humanized mice were generated at the Ragon Institute as previously described68,96,97.
Briefly, 6-8-week-old NSG mice were anesthetized, whole-body irradiated (2 Gy),
followed by implantation with 1 mm3 fragments of human fetal liver and thymus tissue
under the murine kidney capsule. Following, 105 autologous fetal liver-derived CD34+
hematopoietic stem cells were injected intravenously (IV) within 6 hours of
transplantation. BLT humanized mice were also generated at the UPenn as previously
described98. Briefly, 1-1.5x105 human fetal liver-derived CD34+ HSCs were administered
IV into 7 to 10-week old NSG mice 24 hours after busulfan (30 mg kg-1) conditioning. 3 to
6 days following stem cell transplant, mice were surgically implanted with 3 to 5
fragments of autologous human fetal thymus tissue measuring 3 to 5 mm3 under the
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murine kidney capsule. For all BLT humanized mice, human immune reconstitution was
assessed from 12 to 17 weeks after transplantation. Mice were included in experiments
when over 50% of cells in the lymphocyte gate were positive for human CD45 and, of
those human cells, greater than 40% were CD3+ T cells.

Flow Cytometry and Cell Sorting:
Washed cells were resuspended in 50 L PBS containing 2mM EDTA and 2%
fetal calf serum, and then surface stained with anti-human antibodies from BioLegend:
CD45 (HI30 and 2D1), CD19 (HIB19), CD3 (OKT3), , CD45RA (HI100), CD27
(LG.3A10), CD8 (RPA-T8), CCR7 (G043H7), CCR5 (J418F1), CD4 (OKT4), CD271
(ME20.4), PD-1 (EH12.2H7), TIGIT (VSTM3), 2B4 (C1.7), CD107a (H4A3); BD
Biosciences: CD45 (HI30), CD3 (UCHT1), CD8 (SK1), CD45RA (HI100), CCR7 (3D12);
and R&D: Human EGFR (Cetuximab Biosimilar, Hu1). Live cells were identified through
staining negative for Fixable Viability Dye eFlour 780 (eBioscience) or LIVE/DEAD
Fixable Blue (Invitrogen). For the detection of intracellular proteins, the cells were
treated with Cell Fixation & Cell Permeabilization Kit (Invitrogen) or True-Nuclear
Transcription Factor Buffer Set (BioLegend) in accordance with the manufacture’s
protocol with antibodies from: BioLegend: IL-2 (MQH-17H12), Perforin (B-D48); BD
Biosciences: TNF (Mab11), IFN- (4S.B3), Granzyme B (GB11), MIP-1 (D21-1351),
GM-CSF (BVD2-21C11), Active Caspase-3 (C92605); Beckman Coulter: HIV-1 Core
Antigen (KC57); eBioscience: T-bet (4B10), EOMES (WD1928), TOX (TXRX10). Flow
cytometry data were acquired on a BD LSR II, BD LSRFortessa, and BD FACS
Symphony instruments using BD FACSDiva Software version 8.0.1 (BD Biosciences).
Data were analyzed using FlowJo software version 10 (TreeStar). Sorting of C3428

CXCR+ and C34-CXCR4- CAR T cells for quantitation of viral burden by digital-droplet
PCR was performed by sorting live C34-CXCR4+ and C34-CXCR4- CAR T cells from
splenocytes after surface staining with the following Biolegend antibodies: CD45 (2D1),
CD3 (OKT3), CD8 (RPA-T8), CD4 (OKT4). Living CAR T cells were identified by staining
negative for Fixable Viability Dye eFlour 780 (Fig. 2-29A). Sorting

of endogenous

central memory CD4+ T cell populations for quantitation of viral burden by droplet-digital
PCR was performed by staining splenocytes with the following antibodies from
BioLegend: anti-mouse CD45 (30-F11), anti-human CD45 (HI30), CD20 (2H7), CD14
(HCD14), CD56 (HCD56), CD3 (OKT3), CD4 (RPA-T4), CD8 (SK1), CCR7 (G043H7),
CD45RA (HI100). Live cells were discriminated using LIVE/DEAD Fixable Blue
(Invitrogen). FACSAria II (BD Biosciences) was used for all cell sorting (Fig. 2-29B). A
complete list of antibodies used including additional technical information for flow
cytometry experiments can be found in the Life Sciences Reporting Summary.

HIV inoculum preparation:
Viral stocks of the molecular clones, HIVJRCSF and HIVMJ4, were generated
through transfections of HEK293T cells (ATCC: CRL-3216) and tittered as previously
described99. HIVBAL virus stocks were generated by passage in anti-CD3/CD28
Dynabead stimulated human CD4+ T cells as previously described40.

Viral (HIV) load quantification:
Peripheral blood plasma-derived HIV RNA was isolated using the QiaAmp Viral
RNA Mini Kit (Qiagen). Quantitative RT-PCR using the QuantiFast Syber Green RTPCR kit (Qiagen) was used as previously described to measure viral loads99. Data was
collected on a LightCycler 480 Sysytem (Roche) or a ViiA 7 real-time PCR system
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(Applied Biosystems) using Lightcycler 480 software release 1.5.1.62 SP3 or Viia 7
QuantStudio Real-time PCR Software v1.3, respectively.

Plasmid construction:
Amino acid sequences specific to the CD4-based CAR constructs containing the
intracellular signaling domains: CD3-, 4-1BB/CD3-  and CD28/CD3-  are described
elsewhere40.

Each

CAR

was

amplified

CACGTCCTAGGATGGCCTTACCAGTG

from

their

parent
and

plasmid

with

5’5’-

GTGGTCGACTTATGCGCTCCTGCTGAAC and inserted into the AvrII and SalI
restriction enzyme sites of the pTRPE transfer plasmid downstream of GFP, mCherry or
iRFP670, and an intervening T2A linker permits expression of both proteins. To
construct the plasmids for CAR T cell selection, double-stranded DNA fragments (IDT)
encoding NGFR (CD271)100 and truncated EGFR101 were custom synthesized, flanked
with suitable restriction enzyme sites and cloned into the second position of the pTRPE
plasmid preceded by the CAR-BB and CAR-28 gene and T2A linker. The C34-CXCR4
construct’s sequence is denoted elsewhere79. We A previously described102 Asp
mutation (D97N) in CXCR4 was introduced to impair SDF-1 binding and limit receptor
internalization.

Lentivirus production and transfection:
Lentiviral particles were generated using packaging expression vectors that
encode VSV or Cocal glycoprotein, HIV Rev, and HIV Gag/Pol (pTRPE pVSV-g, pCocalg, pTRPE.Rev, and pTRPE g/p, respectively), and synthesized using DNA 2.0 or ATUM
(Newark, CA). The packaging plasmids along with the appropriate pTRPE transfer
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vector

were

transfected

into

HEK293T

using

Lipofectamine

2000

(Life

Technologies)40,103. At 24 and 48 hours after transfection, the HEK293T cell supernatant
was harvested, filtered through a 0.45 m syringe-driven filter, and then concentrated by
ultracentrifugation for 2.5 hours at 25,000 rpm at 4°C. The supernatant was aspirated
and the virus pellet was resuspend in 800 L of complete RPMI and stored at -80°C.

Cell Culture:
For preparation of CAR T cells: de-identified human donor T cells were isolated
by negative selection with RosetteSep Human CD3+ Enrichment Cocktails (Stem-Cell
Technologies) following manufacturer’s protocol. T cells from BLT humanized mice were
purified by processing spleen, bone marrow, and liver tissues into a single-cell
suspension. Density gradient centrifugation using Lymphoprep (Stem-Cell Technologies)
was used to isolate Mononuclear cells. Human CD2+ cells were purified by CD2
Microbeads (Miltenyi Biotec) per the manufacturer’s protocol. T cells were placed in
culture at 106 cells mL-1 in either complete RPMI: RPMI 1640, 1% PenicillinStreptomycin, 2mM GlutaMax and 25mM HEPES buffer from Life Technologies, and
10% fetal calf serum (Seradigm), or CTS OpTmizer T-Cell Expansion SFM (Gibco) with
1% Penicillin-Streptomycin, 2mM GlutaMax and 25mM HEPES buffer. T cell expansion
medium was complemented with human IL-15 (5 ng mL-1, Biolegend) and IL-7 (10 ng
mL-1, R&D). T cells were stimulated at a 3:1 (bead to cell) ratio with antiCD3/CD28Dynabeads (Life Technologies), and incubated at 37°C, 5% CO2 and 95%
humidity. 18 hours after stimulation the medium was reduced by and replaced with 300
L of the appropriate lentivirus supernatant for CAR transduction. 5 days after T cell
activation, magnetic separation was used to remove Dynabeads. Throughout CAR T cell
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manufacturing medium was changed every second day, which spanned 8 to 10 days, or
as needed to adjust cell counts to 0.5x106 cells mL-1.
Two-step immunomagnetic selection of CAR T cells during manufacturing: On
day 4 after initial T cell activation, anti-CD3/CD28 Dynabeads were removed by
magnetic bead separation. T cells were counted and then incubated at a 1:2 cell-to-bead
ratio with CELLection Biotin Binder Dynabeads (Life Technologies) conjugated to antiEGFR (Cetuximab) antibody. Truncated EGFR+ T cells were isolated according to the
manufacturer’s protocol. The cell concentration was adjusted to 0.5x106 cells mL-1 with
medium and expanded as described above. 7 days after initial activation, EGFRt+ T cells
were counted and incubated with CD271 Microbeads (Miltenyi Biotec) to positively select
for NGFR+ T cells according to the manufacturer’s instructions. The eluted fraction of T
cells contained 85% to 95% EGFR+NGFR+ T cells. Prior to infusion into BLT mice the T
cells were cultured for an additional day at the adjusted cell concentration.

HIV treatment and ART discontinuation mouse model:
BLT humanized mice were administered 2 mg of medroxyprogesterone
(McKesson) subcutaneously 1 week prior to intravaginal challenge with 20,000 TCID50
HIVJRCSF in 20 L total volume. 75 to 100 L of blood was obtained through puncture of
the retro-orbital sinus weekly to quantify viral load and immunophenotype circulating
blood cells. 3 weeks post-HIV challenge all infected mice were administered daily IP
injections of antiretroviral therapy (ART) consisting of 10 mg kg-1 EFdA (4′-ethynyl-2fluoro-2′-deoxyadenosine, LeadGen Labs) and 50 mg kg-1 Dolutegravir (Sigma) for 1
week and then every second day thereafter. Following 2 weeks of ART, four treatment
groups were defined based on normalization of plasma viral load, body weight, and
human reconstitution percentages. Group 1 (G1; n=6) and group 3 (G3; n=10) are
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treatment groups that were infused with 107 CAR-BB T cells, while group 2 (G2; n=6)
and group 4 (G4; n=9) are control groups that were infused with 107 CAR-BB T cells
that express a defective CD3- endodomain. T cells were administered in a 300 L
volume via tail vein injection. ART was interrupted immediately after adoptive T cell
transfer for G1 and G2, while ART discontinuation was delayed for 3 weeks in G3 and
G4. At necropsy, 17 weeks after HIV challenge, various tissues were collected to
analyze the CAR T cells.
BLT humanized mice were infected via the intraperitoneal (IP) route with 20,000
TCID50 HIVMJ4. At 3 weeks post-infection, all mice received ART and either an HIVresistant (<20% C34-CXCR4+) Dual-CAR T cell product (n=7), an HIV-resistant DualCAR T cell product with further magnetic bead selection to obtain a >98% C34-CXCR4+
transfer product (n=5), or no CAR T cells (n=9). After plasma viremia was fully
suppressed in all 3 groups, ART was discontinued and virus rebound was monitored via
weekly blood draws from the retro-orbital sinus.

Acute HIV infection treatment model:
BLT humanized mice were challenged with 20,000 TCID50 HIVJRCSF or HIVMJ4 via
IP injection. For the study comparing the replication capacity of HIVJRCSF and HIVMJ4:
HIVJRCSF-infected mice (n=6) and HIVMJ4-infected mice (n=6) were infused with the DualCAR T cell product consisting of 2x107 total CAR T cells. T cells were administered via
tail vein injection 48 hours after HIV challenge. Control mice that were infected with
HIVJRCSF (n=5) or HIVMJ4 (n=6) received no T cells. For the study comparing Dual-CAR T
cells and 3rd-generation (3G) CD4-based CAR T cells: Dual-CAR TCP was combined
with 3G-CAR T cells, normalizing the frequency of Dual-CAR and 3G-CAR T cells prior
33

to infusion into mice. 9 HIV-uninfected mice were infused with this mixture, where each
mouse received 2.5x106 Dual-CAR T cells and 2.5x106 3G-CAR T cells via tail vein
injection. After 2 weeks, 6 mice were infused via IV injection with 107 irradiated K.Env
cells and 3 mice received 107 irradiated K.WT cells. Additional mice (n=6) were
challenged with 20,000 TCID50 HIVMJ4 and infused 48 hours later with same Dual-CAR
TCP/3G-CAR T cell mixture described above.
HIVMJ4-infected mice were allocated into 4 groups. The groups were infused with
106 C34-CXCR4+, CAR.BB

(n=6), CAR.28

(n=5), or purified Dual-CAR (n=4) T cells,

while the remaining mice were untreated (n=6). For the study comparing purified DualCAR and double CAR-transduced BB.BB and 28.28 T cell populations: HIVMJ4infected mice were distributed into 4 groups and normalized based upon body weight
and the absolute count of CD4+ T cells in blood. The groups were infused with 106 C34CXCR4+, purified CAR.BB.BB (n=5), CAR.28.28 (n=5) or Dual-CAR (n=5) T cells via
tail vein injection 48 hours after HIV challenge. Control mice did not receive T cells
(n=5). For the study evaluating efficacy of enriched C34-CXCR4+ (>98%) Dual-CAR T
cells. HIVMJ4-infected mice were divided into two groups that received 107 C34-CXCR4enriched Dual-CAR T cell product (TCP) (n=12) or were untreated (n=12). In all studies
mice were bled by retro-orbital puncture 1 day after adoptive T cell transfer, and then
weekly thereafter until their respective endpoint and tissue collection.

CAR T cell therapy and ART model:
In the study described in, BLT humanized mice were challenged with 20,000
TCID50 HIVJRCSF via IP injection. 3 weeks post-HIV challenge all infected mice were given
low-dose ART consisting of 1 mg kg-1 EFdA and 25 mg kg-1 Dolutegravir every other day
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by IP injection for 4 weeks. At the time of ART initiation, HIV-infected mice were
allocated into 3 groups. Treated mice (n=11) were infused with an HIV-resistant (C34CXCR4+) Dual-CAR TCP consisting of 107 total CAR T cells. Control mice were infused
with either 107 total CAR T cells from the HIV-resistant Dual-CAR T cell product which
expresses defective CD3- signaling domains (n=5) or were untreated (n=7). The mice
were euthanized and tissues were harvested for analysis 7 weeks post-infection. For the
study described in, BLT humanized mice were challenged with 20,000 TCID50 HIVBAL via
IP injection. 3 weeks post-HIV challenge all infected mice were administered ART
consisting of 10 mg kg-1 EFdA and 25 mg kg-1 Dolutegravir every other day by IP
injection for 2 weeks. At the time of ART initiation, HIV-infected mice were distributed
into 2 groups. Treated mice (n=6) were infused with an HIV-resistant (C34-CXCR4+)
Dual-CAR TCP comprising of 107 total CAR T cells, or untreated (n=6).

C34-CXCR4 protection of CAR T cells in vivo:
BLT humanized mice were challenged with 20,000 TCID50 HIVJRCSF via IP
injection. 48 hours after challenge, mice received the HIV-resistant (C34-CXCR4+) DualCAR TCP consisting of 2x107 total CAR T cells. In one-week intervals after challenge,
mice were euthanized and tissues were collected at necropsy. Splenocytes were
prepared and freshly sorted; isolated cells were used to quantify the amount of cellassociated HIV DNA harbored within C34-CXCR4+ and C34-CXCR4- CAR T cells.

HIV suppression assay:
Seven days following initial activation with anti-CD3/CD28 Dynabeads, we
infected primary CD4+ T cells with CCR5-tropic HIVJRCSF at an MOI of 1. After one day,
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we washed HIV-challenged CD4+ T cells with complete RPMI supplemented with 100 U
mL-1 IL-2 and mixed with CAR. or control untransduced (UTD) T cells at effector-totarget (E:T) ratios of 1:12.5, 1:25, 1:50, 1:100 and 1:200. The E:T ratios reflect the
number of CAR. T cells to HIV-challenged, CD4+ T cells. Mixtures of cells were plated
in triplicate and HIV replication was measured by sampling 100 L per well for flow
cytometric detection and intracellular cytokine staining for HIV-1 Core Antigen at 2, 4
and 6 days post-coculture. We added fresh media to each well following staining.

HIV-infected cell elimination assay:
A similar target cell elimination assay was performed as described104. Here, we
prepared HIV-infected CD4+ T cells as described above. Once 30% of total cells
positively stained for HIV-1 Core Antigen, cells were membrane labeled using CellTrace
Violet (CTV) (ThermoFisher) to identify HIV-infected cells from CAR or UTD T cells. For
characterizing the cytotoxic function of the pre-infusion T cell product, CAR- and UTD T
cells were cultured with CTV-labelled HIV-infected cells at 0.25:1, 1:1 and 4:1 E:T ratios.
For ex vivo stimulation, single cell suspensions of bone marrow from HIV-infected mice
treated with the Dual-CAR T cell product were cultured with CTV-labelled HIV-infected
target cells at 1:1, 5:1 and 10:1 E:T ratios. HIV-infected cells were assessed for the
induction of active caspase-3 24 hours later by flow cytometry. Active caspase-3 was
identified in living CTV+ HIVGAG+ T cells.

Cytotoxicity, CD107a degranulation, and cytokine assays:
In vitro CAR T cell functionality was assessed following stimulation of 2x105
CAR- or UTD T cells with 2x105 wild-type K562 cells (K.WT) or K562 cells engineered to
36

express the extracellular and transmembrane regions of HIVYU2 (K.Env). Anti-CD107a
antibody was included at the beginning of the stimulation followed by 1X Brefeldin A and
Monensin Solution (BioLegend) an hour later. In total, cells incubated for 6 hours at
37°C. Cytokine production was measured by flow cytometry and intracellular staining
with anti-human antibodies specific for IL-2, IFN-, MIP-1, TNF and GM-CSF, while
cytotoxic potential was measured by staining with antibodies specific for granyzme B
and perforin. Cytokine-positive CAR T cells were reported as the difference in the
production of cytokines after stimulation with K.Env and K.WT cells.

Measurement of CAR T cell responses ex vivo:
Functionality of CAR T cells from HIV-infected BLT humanized mice was
measured after ex vivo stimulation with K562 target cells. Density gradient centrifugation
was used to isolate mononuclear cells after preparing a single-cell suspension from
tissues. Between 0.5–1x106 mononuclear cells were cultured with 2x105 K562.WT or
K562.Env cells. The assessment of cytotoxic potential, degranulation and cytokine
production was performed using the same protocol described above.

Cell-associated HIV DNA quantitation:
Mononuclear cell suspensions obtained from spleens were stained and sorted as
described above. After sorting, samples were frozen as cell pellets and stored at -80°C.
To obtain genomic DNA, cell pellets were thawed and total DNA was extracted using the
QIAamp DNA Mini Kit (QIAGEN) per the manufacturer’s protocol. Total HIV DNA was
measured in each sample using a multiplexed droplet-digital PCR (ddPCR) assay
specific for HIV gag and the human RPP30 gene. Gag forward and reverse amplification
primer sequences were 5’- AGTGGGGGGACATCAAGCAGCCATGCAAAT and 5’37

TGCTATGTCAGTTCCCCTTGGTTCT-CT, respectively. Gag sequence was detected
using

a

5’

HEX-labeled

hydrolysis

probe

(HEX-

CCATCAATGAGGAAGCTGCAGAATGGGA). RPP30 forward and reverse amplification
primer

sequences

were

5’-

GATTTGGACCTGCGAGCG

and

5’-

GCGGCTGTCTCCACAAGT, respectively. Human RPP30 sequence was detected with
a 5’ 6-FAM-labeled hydrolysis probe (6-FAM-CTGACCTGAAGGCTCT). The RPP30
primer/probe set has been described previously105. ddPCR reactions were performed
using the manufacturer recommended consumables and the ddPCR supermix for
probes (No UTP) (Bio-Rad). Thermal cycling conditions are as follows: 1 cycle of 95°C
for 10 minutes, 45 cycles of 94°C for 30 seconds followed by 60°C for 1 minute, 1 cycle
of 98C for 10 minutes. Droplets were generated using a QX100 droplet generator and
subsequently analyzed on a QX200 droplet reader (Bio-Rad) using the QuantaSoft
version 1.7.4.0917 software (Bio-Rad). All samples were run in duplicate.

Viral replication capacity assay:
In vitro replication assays were performed essentially as previously described92.
Human PBMCs were isolated from whole blood by density gradient centrifugation using
Histopaque-1077 (Sigma). PBMCs were stimulated with 3 g mL-1 PHA in complete
RPMI (1% Penicillin-Streptomycin, 2mM L-Glutamine, 25mM HEPES buffer, and 10%
fetal calf serum) supplemented with 20 U mL-1 of recombinant human IL-2 at a
concentration of 1x106 cells mL-1. After 72 hours of stimulation, PBMCs were washed
twice with complete RPMI, and resuspended in complete RPMI supplemented with 50 U
mL-1 IL-2 at a concentration of 5x106 cells mL-1. Cells were infected by combining 1000
TCID50 HIVJRCSF or HIVMJ4 with 5x105 cells and a final concentration of 5 g mL-1
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polybrene in 200 L total volume. Cells were infected by spinoculuation at 1200 rpm and
25°C for 2 hours. Cells were then washed 5 times to remove excess virus, and plated in
500 L of complete RPMI including 50 U mL-1 IL-2 in a 48-well plate. Infections were
incubated at 37°C and 5% CO2, and 50 L of media was removed every 2 days and
frozen. Supernatant Gag p24 levels were measured using the Alliance HIV-1 p24
antigen ELISA kit per the manufacturer’s instructions (Perkin Elmer). Plates were read
on a Tecan Infinite 200 Pro plate reader (Tecan Life Sciences) using the Magellan
software version 7.2. All infections were carried out in triplicate.

Statistical analysis:
Statistical analyses were performed using JMP Pro, version 14.2.0 (SAS Institute
Inc.) and Prism, version 7 for PC v7.05 and Prism, version 8 for macOS v8.2.1
(GraphPad). Spearman’s rank correlation was used to test for all bivariate continuous
correlations. Wilcoxon rank sum test was conducted to test for all one-way comparison
of means from unpaired samples, and Wilcoxon matched pairs signed rank test used for
comparing means of paired samples. Kaplan-Meier survival curves were performed
using an endpoint defined as the limit of detection of the viral load quantification assay
(1.81 log RNA copies mL-1), and statistics are generated from the log-rank test. K-means
clustering was performed using the JMP Pro version 12 statistical package to generate
principal component plots with circles denoting where 90% of the observations would
fall. We performed area under the curve calculations in GraphPad Prism version 7 using
cell concentration data normalized to 1 L of blood.
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Figures

Figure 2-1. BLT-mouse derived HIV-specific CAR T cells are multifunctional in
vitro. (a) Schematic for the manufacturing of BLT mouse-derived CAR T cells. (b)
Representative growth kinetics of BLT mouse-derived and adult human PBMC-derived
CAR. T cells following activation with anti-CD3/CD28 Dynabeads. (c) FACS plots of
CD4+ CAR. T cells expressing MIP-1, TNF, IL-2 and GM-CSF after in vitro stimulation
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with HIVYU2 GP160+ K562 cells (K.Env). (d) Quantification of intracellular expression of
the indicated effector molecules by CD8+ CAR. T cells and (e) CD4+ CAR. T cells.
Data shows expression of each molecule from 3 distinct donors per source. (f)
Schematic of gating strategy used to identify active caspase-3+ HIVGAG+ target cells for
analysis of HIV elimination assay. (g) FACS plots and (h) cumulative data demonstrating
the coordinated upregulation of granzyme B and perforin in BLT mouse-derived and
human donor-derived CAR. T cells following in vitro stimulation with K.Env (stim) or
K.WT (unstim) cells. Data shows expression from 3 distinct donors per source. For data
in (c), line and error bars indicate mean ± SEM.
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Figure 2-2. BLT mouse-derived HIV-specific CAR T cells are functionally
indistinguishable from human-derived CAR T cells in vitro. CD3/CD28 Dynabeads
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were used to activate purified human T cells from a BLT mouse and healthy human
donor, and then cells were transduced with the CD4-based CAR. construct coexpressing GFP. (a) FACS plots identify CAR. T cells from each T cell source as GFP+
and CD4+. (b) Following 10 days of culture, CD8+ CAR. T cells were mixed with HIVYU2
Envelope+ K562 cells (K.Env) and upregulation of human cytokines was measured. (c)
Polyfunctionality profiles for combinatorial subsets of CD4+ and CD8+ CAR. T cells
producing 0 to 5 of the human cytokines GM-CSF, IFN-, IL-2, MIP-1, and TNF.
Average of 3 unique donors per T cell source. (d-e) HIV suppression assay as described
in Materials and Methods. (d) FACS plots indicating the frequency of HIV-infected cells 6
days after co-culturing with BLT mouse- or human-derived CAR. T cells at denoted
effector-to-target (E:T) ratios. (e) Summary of frequency of HIV-infected cells (live CARCD8- cells) at 2, 4 and 6 days after co-culture with BLT mouse- or human-derived CAR.
and untransduced (UTD) T cells at indicated E:T ratios. (f,g) HIV elimination assay as
described in Materials and Methods. (f) FACS plots and (g) summarized data for
frequency of active caspase-3 within HIV-infected cells (live CTV+ HIVGAG+ cells) 24hours after co-culture with BLT mouse- or human-derived CAR. and UTD T cells at 1:1
E:T ratio. Each symbol represents the average of technical duplicates per donor (n=3
biologically independent donors). (e,g) Symbols and lines reflect mean and error bars
indicate ± SEM.
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Figure 2-3. CAR T cells expressing the 4-1BB costimulatory domain exhibit a
proliferative advantage and induce B cell aplasia in vivo. (a-e) BLT mouse-derived T
cells were transduced with either mCherry.T2A.CAR., iRFP670.T2A.CAR.BB, or
GFP.T2A.CAR.28. 5x106 CAR-transduced T cells of each type were mixed prior to
infusion into syngeneic mice (n=8). (a) Frequency of each CAR T cell type within the preinfusion T cell product. (b) Frequency of peripheral CAR T cells within the same mouse
5 weeks post-infusion. (c) Peripheral concentration and (d) cumulative persistence of
each CAR T cell type over 5 weeks of engraftment. (e) Relative tissue frequency of each
CAR T cell type 7 weeks post-infusion. (f) In a separate study, 2 weeks after infusion of
the CAR T cell mixture described in (a), BLT mice received 107 irradiated wild-type K562
(K.WT; n=8) or HIVYU2 Envelope+ K562 (K.Env; n=8) cells. Peripheral concentration of
each CAR T cell type following K.WT or K.Env infusion. (g) FACS plots indicating
frequency of MIP-1+ and TNF+ CAR.BB and CAR.28 T cells within the same mouse
after ex vivo stimulation. CAR. T cells were too infrequent for analysis. (h) Frequency of
granzyme B+ perforin+ CD8+ CAR T cells within the same mice ex vivo. (i-k) Mice were
infused with 5x106 CD19-specific CAR.BB (n=4) or control CD4-based CAR.BB T cells
(n=3). (i) Concentration of peripheral CD19+ cells following infusion. (j) FACS plots
showing frequency of CD19+ cells, and (k) number of CD19+ cells in tissues 7 weeks
post-infusion. For all data, symbols and bars reflect mean and error bars show ± SEM,
except (d,k) where symbols represent individual mice. (d) Friedman’s test with Dunn’s
multiple corrections test, and (f,h), two-sided Wilcoxon matched-pairs signed rank test
was performed to calculate significance. Sample size for all mouse groups indicate
biologically independent animals.
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Figure 2-4. CD28 costimulation enhances the ex vivo effector function of CAR T
cells. HIV-uninfected mice were infused with an equal mixture of CD4-based CAR T
cells expressing either CD3-, 4-1BB/CD3- and CD28/CD3- costimulatory domains
linked to unique fluorescent proteins to facilitate identification in vivo as described in
Figure 2-3. Cumulative data indicating the frequency of TNF+, IL-2+ and MIP-1+
CAR.BB and CAR.28 T cells within the same mice after ex vivo stimulation with K.Env
(stim) or K.WT (unstim) cells. Data represents the aggregate of cytokine producing cells
from liver and terminal blood (n=8). CAR. T cells were too infrequent for analysis. Data
shows box and whisker plots and bars indicate min and max values. Significance was
calculated using Wilcoxon matched-pairs signed rank test (**P<0.01). Symbols represent
individual mice.
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Figure 2-5. HIV-specific CAR.BB T cells display features of T cell exhaustion after
failing to control viral rebound. (a) Mean log plasma viral RNA (copies mL-1) in
HIVJRCSF-infected mice treated with ART from week 3 to 5 (G1 and G2 mice; gray box) or
from week 3 to 8 (G3 and G4 mice; brown box). At 5 weeks post-infection, mice in G1
(n=6) and G3 (n=10) received 107 CAR.BB T cells, and mice in G2 (n=6) and G4 (n=9)
received 107 inactive control CAR.BB T cells. Thin dotted line denotes limit of
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quantification. Sample sizes in these studies indicate biologically independent animals.
(b) FACS plots and (c) summary data illustrate the frequency of total memory CD4+ T
cells (CAR-) following ART cessation in CAR.BB and CAR.BB T cell-treated mice. (d)
Concentration of peripheral CAR T cells for G1/G2 and (e) G3/G4. (f) Frequency of CAR
T cells in tissues 12 weeks post-CAR T cell infusion for G1/G3 and G2/G4. (g) PD-1 and
TIGIT expression on peripheral CAR.BB or CAR.BB T cells from G1/G2 after ART
discontinuation. (h-l) FACS analysis of splenic tissue of BLT mice (G1 and G2) 12
weeks after ART cessation. (h) Co-expression of TOX and 2B4, PD-1 or TIGIT on
peripheral CAR.BB or CAR.BB T cells. (i) Frequency of TOX- and TOX+ CAR.BB T
cells positive for indicated inhibitory receptors. (j) Frequency of T-bet and Eomes
expressing CAR.BB and CAR.BB T cells. (k) Frequency of TOX expression within Tbet+ and Eomes+ CAR.BB and CAR.BB T cells. (l) Memory distribution of 2B4+PD1+TIGIT+ and EomeshiT-betdim CAR.BB T cells. For all data, symbols and bars reflect
mean and error bars indicate ± SEM, except (f,i-l) where symbols represent individual
mice. (a,f,i-k) Significance was calculated using a two-sided Wilcoxon rank-sum test..
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Figure 2-6. CAR.BB T cells fail to prevent CD4+ T cell loss after the
discontinuation of ART. (a) Schematic of gating strategy used to identify total memory
CD4+ T cells (CAR-). (b) Percentage of CD4+ T cells (CAR-) out of total CD3+ cells from
the indicated tissues in BLT mice treated with CAR.BB T cells (G1) or control
CAR.BB (G2) T cells, 12 weeks after the discontinuation of ART, and (c) 9 weeks
after the discontinuation of ART for G3/4. Symbols represent individual mice. Bars
indicate mean and error bars show ± SEM. N/A denotes tissue samples where viable
human cells were too infrequent for analysis.
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Figure 2-7. HIV infection preferentially depletes memory CD4+ T cells in BLT mice.
(a) Mean plasma viral RNA (copies mL-1) for mice in G1 (thick line; right axis) and
frequency of post-challenge peripheral memory (CD45RA-) CD4+ T cells in HIV- mice
(white circles) and HIV+ mice (G1; black circles) (left y-axis). Thin dotted line denotes
limit of viral load quantification. Shaded box indicates window of ART. Symbols indicate
mean and error bars show ± SEM. (b) Frequency of CCR5 expression on the indicated
populations of CD4+ T cells from the peripheral blood of BLT mice.
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Figure 2-8. CAR.BB T cells accumulate multiple inhibitory receptors as disease
progresses. (a) Frequency of CD4+ and (b) CD8+ CAR.BB T cells (G1) and control
CAR.BB T cells (G2) co-expressing TIGIT and PD-1 after infusion. Shaded box
indicates the window of ART. Symbols indicate mean and error bars show ± SEM. (c)
Frequency of CD4+ and (d) CD8+ CAR.BB T cells (G1) and control CAR.BB T cells
(G2) co-expressing TIGIT, PD-1 and 2B4 in tissues 12 weeks post-infusion. (e)
51

Cumulative data indicating the frequency of 2B4+, PD-1+ and TIGIT+ CD4+ CAR.BB T
cells (G1) compared to CAR- CD4+ T cells (G1) within the spleens of the same mice, and
(f) CD8+ CAR.BB T cells (G1) compared to CAR- CD8+ T cells (G1) within the spleens
of the same mice. (c-f) Bars indicate mean, error bars show ± SEM and symbols
represent individual mice. Significance was calculated using Wilcoxon rank sum test
(*P<0.05 and **P<0.01).

52

Figure 2-9. EomeshiT-betdim CAR.BB T cells accumulate from acute to chronic
phases of infection. Mice were infected with HIVJRCSF and infused 48 hours later with
either 2x107 CAR.BB T cells (n=5) or inactive control CAR.BB T cells (n=3). (a)
FACS plots show the change in Eomes and T-bet expression within the different CAR T
cell types over time. (b) Summary data indicating the longitudinal frequency of
EomeshiT-betdim CD8+ (left panel) and CD4+ (right panel) CAR T cells (left y-axis), and
mean log plasma viral RNA (copies mL-1) (right y-axis). Thin dotted line denotes limit of
viral load quantification. Symbols indicate mean and error bars show ± SEM. (c)
Spearman correlation analysis of frequency of EomeshiT-betdim CD8+ CAR.BB T cells
compared with viral burden measured as the frequency of HIVGAG+ CD8- T cells in
various tissues 10 weeks post-infection.
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Figure 2-10. CAR.BB T cells from chronic infection exhibit attenuated ex vivo
function compared to CAR T cell product. CAR.BB T cells (n=14) and inactive
control CAR.BB T cells (n=10) were isolated from the livers of chronically infected
mice 12 weeks post-infusion, and the pre-infusion CAR.BB T cell product (TCP) were
ex vivo stimulated. (a) FACS plots and (b) cumulative data for the expression of MIP-1,
CD107a and granzyme B in CD8+ CAR.BB or CAR.BB T cells. The dotted line
indicates the frequency of CD8+ CAR.BB T cells from the pre-infusion TCP expressing
the indicated protein. The bars indicate mean and the error bars show ± SEM.
Significance was calculated using Wilcoxon rank sum test (*P<0.05 and ***P<0.001).

54

55

Figure 2-11. Dual-CAR T cell product mitigates CD4+ T cell loss and exhibits
superior proliferative capacity. (a-j) Mice were challenged with HIVJRCSF (n=12) or
HIVMJ4 (n=12) and 48 hours later 6 mice from each group were infused with Dual-CAR T
cell product (TCP, green lines) or were untreated (Untx, black lines). (a) Dual-CAR TCP
comprises CAR.BB, CAR.28 and Dual-CAR T cells. (b,d) Concentration of total
peripheral CAR T cells in individual mice (green dotted lines; left y-axis) and mean log
plasma viral RNA (copies mL-1) (solid lines; right y-axis) in HIVJRCSF- and HIVMJ4-infected
mice, respectively. Thin black dotted line denotes limit of quantification. (c,e) Frequency
of peripheral memory CD4+ T cells (CAR-). (f) Frequency of CD4+ T cell (CAR-) memory
subsets in tissue from HIVMJ4- (left) HIVJRCSF-infected mice (right) 8 weeks post-CAR T
cell infusion. Six distinct tissues were analyzed from 3 biologically independent animals
per infection cohort. (g) Peripheral longitudinal frequency of each CAR T cell type
present in the Dual-CAR TCP. (h) Peak peripheral frequency and (i) cumulative
persistence of CAR T cells. Data is aggregated from both infection cohorts (n=12). (j-m)
Equal frequencies of Dual-CAR TCP and 3rd-generation (3G) CD4-based CAR T cells
were combined (Supplementary Fig. 12c) prior to infusion into HIVMJ4-infected mice
(n=6).

(j)

Overlaid

FACS

plots

showing

frequency

of

peripheral

Dual-CAR

(iRFP670+NGFR+) and 3G-CAR (GFP+) T cells within the same mouse. (k)
Concentration of peripheral CAR T cells. (l) Total number of splenic CAR T cells and (m)
cumulative CAR T cell persistence 5 weeks post-infection. For all data, bars and error
bars show mean ± SEM, and symbols represent individual mice, except (c,e) where
symbols represent mean. Two-sided Wilcoxon rank-sum test was used to calculate
significance, except (h,i) where Friedman’s test with Dunn’s multiple corrections test was
used. Sample sizes in these studies indicate biologically independent animals.
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Figure 2-12. Dual-CAR T cells exhibit similar in vitro effector functions as CAR.28
T cells. The Dual-CAR T cell product comprises CAR.BB, CAR.28 and Dual-CAR T
cells, where each population is identified by a unique fluorescent protein. Upregulation of
cytokines was measured after in vitro stimulation with K.Env and K.WT cells. Each
symbol represents a unique donor.
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Figure 2-13. Dual-CAR T cell product transiently delays CD4+ T cell loss despite
persistent HIVJRCSF infection. Mice received Dual-CAR T cell product (TCP) (n=6) 48
hours post-HIVJRCSF challenge, while control mice were untreated (Untx) (n=5). (a)
Concentration of peripheral total memory CD4+ T cells (CAR-). (b) Concentration of
peripheral central memory (CD45RA-CD27+CCR7+; left panel), transitional memory
(CD45RA-CD27+CCR7; middle panel), and effector memory (CD45RA-CD27-CCR7-;
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right panel) CD4+ T cells (CAR-). Significance was calculated using Wilcoxon rank sum
test (*P<0.05, **P<0.01). (c) Frequency of memory CD4+ T cell (CAR-) subsets in tissues
8 weeks post-infection. Symbols and bars indicate mean, while error bars show ± SEM.
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Figure 2-14. HIVJRCSF and HIVMJ4 exhibit different replication kinetics in vitro and in
vivo. (a) In vitro replication assay comparing the replication kinetics of HIVJRCSF and
HIVMJ4 in human PBMCs stimulated with PHA and infected at a matched multiplicity of
infection of 0.002. Virus replication was assessed by measuring p24 antigen in culture
supernatants. (b) Mean log plasma viral RNA (copies mL-1) in BLT mice challenged with
HIVJRCSF (n=3) or HIVMJ4 (n=4). Thin dotted line denotes limit of quantification. Symbols
indicate mean values and error bars show ± SEM. Significance was calculated using
Wilcoxon rank sum test (*P<0.05).
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Figure 2-15. Dual-CAR T cell product prevents CD4+ T cell loss despite persistent
HIVMJ4 infection. Mice were infused with Dual-CAR T cell product (TCP) (n=6) 48 hours
post-HIVMJ4 challenge, while control mice were untreated (Untx) (n=6). (a) Concentration
of peripheral total memory CD4+ T cells (CAR-). (b) Concentration of peripheral central
memory

(CD45RA-CD27+CCR7+;

right

panel),

transitional

memory

(CD45RA-

CD27+CCR7-; middle panel), and effector memory (CD45RA-CD27-CCR7-; left panel)
CD4+ T cells (CAR-). Significance was calculated using Wilcoxon rank sum test
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(**P<0.01). (c) Frequency of memory CD4+ T cell (CAR-) subsets in tissues 8 weeks
post-infection. Symbols and bars indicate mean, while error bars show ± SEM.
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Figure 2-16. Dual-CAR T cells exhibit superior in vivo expansion compared to 41BB, CD28, and 3rd-generation CAR T cells. (a) BLT mice were challenged with either
HIVJRCSF (n=6) or HIVMJ4 (n=6) and infused with 2x107 Dual-CAR T cell product (TCP).
Fold-change in CAR T cell concentration from baseline to peak levels in peripheral
blood. Data is the aggregate of both infection cohorts. (b) Schematic shows the
components of the 3rd-generation (3G) CD4-based CAR construct. (c-e) Dual-CAR T cell
product and 3G-CAR T cells were combined, equalizing the frequency of Dual-CAR and
3G-CAR T cells prior to infusion into uninfected mice (n=9). (c) FACS plots indicate the
frequency of Dual-CAR and 3G-CAR T cells present within the pre-infusion T cell
product. (d) Longitudinal concentration of peripheral CAR T cells following adoptive
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transfer into HIV-negative mice. Symbols indicate mean and error bars show ± SEM. (e)
At 2 weeks post-infusion, mice received either 107 irradiated K.Env cells (n=6) or 107
irradiated K.WT cells (n=3). Fold change in the concentration of peripheral CAR T cells
1-week post-K562 boost from baseline concentration prior to K562 infusion. Bar
indicates mean, error bars show ± SEM and symbols represent individual mice. (a,d,e),
Wilcoxon rank sum test was used to calculate significance (*P<0.05, **P<0.01).
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Figure 2-17. CD4-based CAR T cells are susceptible to infection in vivo. (a) FACS
plots and (b) cumulative data show the frequency of HIVGAG+ T cell populations sampled
within the same mice (n=5) 10 weeks post-HIVJRCSF infection. Data in (b) is the
aggregate of tissues: bone marrow, liver, lung, lymph node, terminal blood, and spleen
from 5 mice. (c) FACS plots and (d) cumulative data showing the expression of
granzyme B and perforin within HIVGAG+ and HIVGAG- CAR T cell populations from
HIVJRCSF-infected mice after ex vivo stimulation with K.Env (stim) or K.WT (unstim) cells.
For data in (d), the data is represented as the average of 3 distinct CAR T cell
populations. Significance was calculated using paired t test (*P<0.05). Symbols and bars
indicate mean and error bars show ± SEM.
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Figure 2-18. HIV-resistant Dual-CAR T cells mediate superior virus-specific
immune responses. (a) Schematic of HIV-resistant (C34-CXCR4+) Dual-CAR T cells.
(b) HIVJRCSF-infected BLT mice received 107 CAR T cells 48 hours post-challenge. HIV
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DNA load in sorted CAR T cells from individual mouse splenic tissue (n=8). (c-d) HIVMJ4infected mice were infused 48 hours post-challenge with 106 C34-CXCR4+, CAR.BB
(n=6), CAR.28 (n=5), or purified Dual-CAR (n=4) T cells. (c) Longitudinal peripheral
concentration and (d) peak peripheral CAR T cell concentration. (e-n) HIVMJ4-infected
mice were

infused 48 hours

post-challenge with 106 C34-CXCR4+,

purified

CAR.BB.BB (n=5), CAR.28.28 (n=5) or Dual-CAR (n=5) T cells, or were untreated
(n=4). Purification strategy is described in Supplementary Figure 17. (e) Frequency of
CAR T cell populations out of total human CD45+ cells 2 and 3 weeks post-infection. (f)
Longitudinal concentration and (g) cumulative peripheral CAR T cell persistence. (h)
FACS plots showing CCR5 expression within peripheral memory CD4+ T cells (CAR-). (i)
Concentration of total memory and (j) CCR5+ CD4+ T cells (CAR-) at 6 weeks postinfection. (k) FACS plots and (l) frequency of MIP-1+ and CD107a+ CD8+ CAR T cells
from tissue at 8 weeks post-infection after ex vivo stimulation. (m) Distribution and (n)
frequency of granzyme B+ perforin+ cells within CD107a+ CAR T cells from tissues after
ex vivo stimulation. (b) Two-sided Wilcoxon matched pairs signed rank test was used to
calculate significance. For remaining analyses, significance was calculated using a twosided Wilcoxon rank-sum test. Bars and error bars indicate mean ± SEM, and symbols
represent individual mice, except for (c) where symbols indicate mean. Sample sizes in
these studies indicate biologically independent animals.
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Figure 2-19. HIV-resistant Dual-CAR T cell product fails to inhibit acute HIV
replication. (a) Dual-CAR T cell product (TCP) was co-transduced with C34-CXCR4
linked to mCherry by an intervening T2A sequence. FACS plots indicate the frequency of
C34-CXCR4+ cells within each cell population comprising the Dual-CAR TCP prior to
infusion. (b) Log plasma viral RNA (copies mL-1) in individual BLT mice challenged with
HIVJRCSF and 48 hours later mice were infused with HIV-resistant (C34-CXCR4+) DualCAR TCP (n=7) or were untreated (Untx; n=7). Thin dotted line denotes limit of
quantification.
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Figure 2-20. C34-CXCR4+ CAR T cells are selected for during chronic infection and
exhibit superior ex vivo effector functions. (a) Mice were infected with HIVJRCSF and
48 hours later infused with 107 C34-CXCR4+ Dual-CAR T cell product (TCP). FACS plots
indicate the frequency of C34-CXCR4+ throughout infection. (b) Mice were infected with
HIVMJ4 and 48 hours later were infused with 106 C34-CXCR4+ CAR.BB (n=5), CAR.28
(n=5), or purified Dual-CAR (n=4) T cells. Frequency of C34-CXCR4+ CAR T cells in
tissue 8 weeks post-infection. Thin dotted line indicates the frequency of C34-CXCR4+
CAR T cells in the pre-infusion TCP for the indicated CAR T cell type. (c-d) Mice were
infected with HIVMJ4 and 48 hours later received 106 C34-CXCR4+, purified
CAR.BB.BB (n=3), CAR.28.28 (n=4), or Dual-CAR (n=3) T cells. c) FACS plots and
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(d) cumulative data show the frequency of each CD8+ CAR T cell population expressing
MIP-1 and CD107a, and the frequency of CAR T cells with cytotoxic potential
(granzyme B+ perforin+ CD107a+). CAR T cells were isolated from the spleen and bone
marrow of mice 8 weeks post-infection and ex vivo stimulated. Significance was
calculated using Wilcoxon matched-pairs signed rank test (**P<0.01). For all data,
symbols represent individual mice.
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Figure 2-21. Low dose Dual-CAR T cells mitigate CD4+ T cell loss during HIVMJ4
infection. HIVMJ4-infected mice were infused 48 hours post-challenge with 106 C34CXCR4+, CAR.BB (n=6), CAR.28 (n=6), or purified Dual-CAR (n=4) T cells. For each
group of mice, the change in peripheral cell concentration of CCR5+ CD4+ T cells (CAR-)
was measured from the indicated time post-infection to pre-infection levels. Bars indicate
mean and error bars show ± SEM. Symbols represent individual mice.
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Figure 2-22. Two-step immunomagnetic selection process yields purified T cells
expressing two independent CARs. (a) Schematic of lentivirus constructs used to
generate dual CD4-based CAR-transduced T cells. The CD4-based CARs with the 41BB/CD3- or CD28/CD3- endodomains were linked with NGFR or truncated EGFR
(EGFRt) to enable two-step positive magnetic selection during the T cell manufacturing
process. (b) Time line for CAR T cell manufacturing. One day after T cell activation with
CD3/CD28 Dynabeads, the cells were transduced with an equivalent MOI of lentivirus
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depicted in (a). On days 4 and 7 after activation, the CAR T cells were positively
selected using anti-EGFR and anti-NGFR coated magnetic beads, respectively, as
described in Materials and Methods. (c) Representative FACS plots illustrating the purity
of dual CAR-transduced T cells after EGFR and NGFR selection. (d) FACS plots
indicate the frequency of CAR.BB.BB, CAR.28.28 and Dual-CAR T cells postselection in their respective pre-infusion T cell products, prior to adoptive transfer into
mice described in Figure 2-18E-N.
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Figure 2-23. Dual-CAR T cells mediate superior expansion and protection of CD4+
T cells during HIV infection in vivo. BLT mice were infected with HIVMJ4 and 48 hours
later received 106 C34-CXCR4+, purified CAR.BB.BB (n=5), CAR.28.28 (n=5), DualCAR (n =5) T cells, or were untreated (Untx; n=4). (a) Fold-change in the concentration
of CAR T cells in peripheral blood between weeks 2 and 3 post-infection. The number
above the bars indicate mean fold-change. Symbols represent individual mice. (b)
Absolute count of each CAR T cell population in tissues 8 weeks post-infection. (c)
Concentration of peripheral total memory (CD45RA-) and (d) CD45RA- CCR5+ CD4+ T
cells (CAR-). Symbols represent mean. (e) Association between fold-change in the
concentration of CAR T cells and change in total memory (CD45RA-) CD4+ T cells (CAR74

) in peripheral blood between weeks 2 and 3 post-infection. Symbols represent individual
mice. Spearman correlation test was used to calculate significance. (b-d) Error bars
show ± SEM and Wilcoxon rank sum test was used to calculate significance (*P<0.05
and **P<0.01).
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Figure 2-24. CAR T cells from HIV-infected mice exhibit ex vivo cytotoxic function.
HIVJRCSF-infected mice (n=3) treated with the Dual-CAR TCP were euthanized and the
bone marrow cells were ex vivo stimulated with K.Env or K.WT cells for 24 hours at the
indicated E:T ratios. (a) Representative FACS plots and (b) cumulative data shows the
induction of active caspase-3 within target cells. Symbols indicate mean and error bars
show ± SEM.
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Figure 2-25. Dual-CAR and CAR.28 T cells exhibit similar ex vivo functional
profiles. Mice were challenged with HIVJRCSF (n=5) and infused with 2x107 Dual-CAR T
cell product (TCP) 48-hour post infection. (a) Frequency of CD8+ and (b) CD4+ CAR T
cell populations from tissue at necropsy (8-weeks post-infection) within the same mice
expressing CD107a, MIP-1, IL-2 and TNF after ex vivo stimulation. Bars indicate mean,
error bars show ± SEM and symbols represent individual mice. Significance was
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calculated using Wilcoxon rank sum test (**P<0.01). (c) Principle Components Analysis
(PCA) of IL-2, TNF, MIP-1, and CD107a expression in ex vivo stimulated CD8+ and
CD4+ CAR T cells from PBMCs of HIVJRCSF-infected mice (n=5).
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Figure 2-26. Mitigating CAR T cell infection improves control over HIV replication.
(a) Mean log plasma viral RNA (copies mL-1) of active, unprotected CAR T cell-treated
mice (n=38), and untreated/inactive CAR T cell-treated mice (n=36). Data are
aggregated across 6 independent studies. Thin dotted line denotes limit of quantification.
(b) Mean log plasma viral RNA (copies mL-1) in mice infused 48 hours post-HIVMJ4
challenge with 107 protected (>98% C34-CXCR4+) Dual-CAR TCP (n=12) or untreated
mice (n=12). (c) Frequency of splenic HIV-infectedCD8- T cells (CAR-) and (d) cellassociated HIV DNA load in lymph nodes 6-8 weeks post-infection. (e-k) HIVJRCSFinfected mice were ART-treated and simultaneously infused with 107 HIV-resistant DualCAR TCP (n=12), inactive Dual-CAR TCP (n=5), or were untreated (n=7). (e) Mean log
plasma HIV RNA (copies mL-1). Shaded box indicates ART and arrow indicates CAR
TCP infusion. (f) Percent log reduction in plasma HIV RNA from pre-ART (week 3) to 1
and 1.5 weeks post-ART. (g,h) Data are aggregated from HIVJRCSF- and HIVBAL-infected
cohorts. (g) Correlation between percent viral load reduction at first post-ART time-point
and contemporaneous peripheral CAR T cell concentration. (h) Kaplan-Meier curve of
time to viral suppression after treatment initiation for Dual-CAR TCP versus control mice.
(i) Frequency of HIV-infected CD8- T cells (CAR-) and (j) HIV-infected CD14+
macrophages aggregated from various tissues of plasma viremia suppressed mice. (k)
Cell-associated HIV DNA load in sorted central memory (CAR-CD45RA-CCR7+) CD4+ T
cells. Statistical significance calculated for (a,b) by one-sided unpaired Student’s t-test,
(c-f,i-k) two-sided Wilcoxon rank-sum test, (g) Spearman correlation, and (h) Log-rank
test. Bars and error bars indicate mean ± SEM. Symbols represent individual mice.
Sample sizes in these studies indicate biologically independent animals.

80

Figure 2-27. HIV-resistant Dual-CAR TCP reduces virus replication in vivo. (a)
Frequency of HIVGAG+ CD8- T cells (CAR-) within the bone marrow and spleen of
HIVJRCSF-infected mice and (b) HIVMJ4-infected mice that were treated 48 hours postchallenge with the Dual-CAR T cell product (TCP) or were untreated (Untx). (c) Mean
log plasma HIVMJ4 RNA (copies mL-1) after ART discontinuation of mice infused at ART
initiation with 107 fully-protected >98% C34-CXCR4+ (n=5) or partially-protected <20%
C34-CXCR4+ (n=7) Dual-CAR TCP, or were untreated (n=9). (d,e) HIVBAL-infected mice
were ART-treated and simultaneously infused with 107 HIV-resistant Dual-CAR TCP
(n=6) or were untreated (n=6). (d) Mean log plasma HIV RNA (copies mL-1). Shaded box
indicates ART and arrow indicates TCP infusion. (e) Percent log reduction in plasma
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viral RNA from pre-ART (week 3) and 0.5 and 1 week post-ART. For all data, bars
indicate mean, error bars show ± SEM and symbols represent individual mice.
Significance was calculated using Wilcoxon rank sum test (*P<0.05, **P<0.01,
****P<0.0001).
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Figure 2-28. Gating strategy for FACS sorting of CAR T cells and endogenous
central memory CD4+ T cells. (a) For the study described in Figure 5b, C34-CXCR4+
and C34-CXCR4- CAR T cells were bulk sorted by FACS following the depicted gating
strategy. (b) For the study described in Figure 6e, endogenous central memory CD4+ T
cells (CAR-) were sorted from splenocytes harvested at necropsy (7 weeks post
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infection) following the depicted gating strategy. For all data, cell-associated HIV DNA
load was quantified on sorted cell populations by droplet-digital PCR.
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CHAPTER 3 - HIV-specific CAR-modified CD4+ T Cells Mitigate HIV Disease
Progression and Confer CD4+ T Cell Help In Vivo
Parts of this chapter were previously published in:
Maldini C.R., Gayout K., Leibman R.S., Dopkin D.L., Mills J.P., Shan X., Glover J.A.,
Riley J.L. (2020) HIV-resistant and HIV-specific CAR-modified CD4+ T Cells Mitigate HIV
Disease Progression and Confer CD4+ T Cell Help In Vivo (in press).

Abstract
HIV infection preferentially depletes HIV-specific CD4+ T cells thereby impairing
antiviral immunity. Here, we explore the therapeutic utility of adoptively transferred CD4+
T cells expressing an HIV-specific Chimeric Antigen Receptor (CAR4) to restore CD4+ T
cell function to the global HIV-specific immune response. We demonstrated that CAR4 T
cells directly suppressed in vitro HIV replication and eliminated virus-infected cells.
Notably, CAR4 T cells containing intracellular domains (ICDs) derived from the CD28
receptor family (ICOS and CD28) exhibited superior effector functions compared to
TNFR family ICDs (CD27, OX40 and 4-1BB). However, despite demonstrating limited in
vitro efficacy, only HIV-resistant CAR4 T cells expressing the 4-1BB ICD exhibited
profound expansion, concomitant with reduced rebound viremia after ART cessation and
protection of CD4+ T cells (CAR-) from HIV-induced depletion in humanized mice.
Moreover, CAR4 T cells enhanced the in vivo persistence and efficacy of HIV-specific
CAR-modified CD8+ T cells expressing the CD28 ICD, which alone exhibited poor
survival. Collectively, these studies demonstrate that HIV-resistant CAR4 T cells can
directly control HIV replication and augment the virus-specific CD8+ T cell response,
highlighting the therapeutic potential of engineered CD4+ T cells to engender a functional
HIV cure.
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Introduction
HIV infection induces profound CD4+ T cell loss resulting in impaired antiviral
immunity, and the onset of overt immunodeficiency.106 In particular, HIV-specific CD4+ T
cells are preferentially infected and exhibit defective immune responses characterized by
poor proliferative capacity and IL-2 secretion.107-110 The collapse of CD4+ T cell-help
during chronic infections compromises the generation of cytotoxic and memory CD8+ T
cells,111-113 leads to pronounced CD8+ T cell exhaustion,111,114 and diminishes effective
antibody production.115,116 Moreover, CD4+ T cells exhibit direct cell-to-cell mediated
effector functions that contribute to disease resolution.117-120 Indeed, subjects that
spontaneously control HIV replication demonstrate a significant expansion of cytolytic
CD4+ T cells that associate with slower disease progression and improved clinical
outcomes.120,121 Given the functional heterogeneity of HIV-specific CD4+ T cells and their
ability to coordinate global antiviral immunity, therapeutic interventions that restore or
augment CD4+ T cell function will likely be critical for the development of effective HIV
cure strategies.
Emerging data from cancer models demonstrate that CD4+ T cells redirected with
a Chimeric Antigen Receptor (CAR4) can eradicate tumors in the absence of other
immune cells,

122-124

indicating that CAR4 T cells can act as primary effectors in addition

to providing help to other leukocytes. CARs confer novel T cell specificity through
expression of an extracellular antigen-binding domain fused to the intracellular CD3
chain and one or more costimulatory domains.37,46 The choice of costimulatory domain
alters the metabolic, phenotypic, and functional CAR T cell profile.57,60 For instance, the
CD28 costimulatory domain promotes glycolytic metabolism and the acquisition of an
effector memory T cell phenotype capable of exhibiting rapid antitumor activity, whereas
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the 4-1BB domain supports the long-term in vivo persistence and development of central
memory T cells reliant on oxidative phosphorylation for energy.39,52,80 As such, the ability
of CARs to engender unique T cell traits suggests that adoptively transferred HIVspecific CAR4 T cells can restore many of the functions lost by HIV-induced destruction
of CD4+ T cells.
However, since CD4+ T cells are the primary targets of HIV, efforts to make CAR4
T cells resistant to infection must be employed to ensure durable responses.125 Several
approaches

including

HIV

coreceptor

disruption,85,126,127

restriction

factor

overexpression,103,128 and fusion inhibitors129,130 have been developed to confer HIV
resistance. Of these, the fusion inhibitor C34 linked to CXCR4 is particularly potent and
interferes with the entry of diverse HIV strains regardless of their tropism.79 Because of
the need to protect and redirect CD4+ T cells, progress to engineer the best CD4+ T cells
to control HIV replication has lagged behind studies examining CD8+ T cells.
Nonetheless, HIV-specific CAR8 T cells have showed promise to inhibit virus replication,
thereby providing the tools necessary to study CAR4 T cells. For instance, we recently
reported on an HIV-specific CAR that expresses CD4 as the HIVENV binding motif and
contains the 4-1BB costimulatory domain.40 This CAR was re-engineered from the
original construct employed during the first in-human clinical trials,34-36 and was selected
for its improved antiviral potency in CD8+ T cells,40 and potential to minimize virus
escape.131 Other approaches have incorporated a similar CD4-based CAR into CD34+
hematopoietic stem cells to provide long-term in vivo production of HIV-specific immune
cells,64,132

or

have

targeted

infected

cells

using

alterative

antigen-binding

moieties.42,43,65,133 Together, these strategies highlight the promise of CAR T cell-based
therapies against HIV; however, critical knowledge gaps remain, especially in our
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understanding of whether CAR4 T cells need to be engineered separately from CAR8 T
cells to achieve the optimal HIV-specific response.
Here, we explored the therapeutic potential of CAR4 T cell therapy to mitigate
HIV pathogenesis. Data from cancer studies indicate that CAR4 T cells require different
costimulatory signals than CAR8 T cells to engender superior immune responses.81,134
However, using a panel of HIV-specific (CD4-based) CARs expressing distinct
intracellular domains (ICDs), we show that only HIV-resistant, 4-1BB-costimulated CAR4
T cells limit in vivo HIV infection, congruent with our previous work identifying 4-1BB as
the optimal ICD for HIV-specific CAR8 T cells.40 Notably, ICDs derived from the CD28
receptor family (ICOS and CD28), which conferred the greatest CAR4 T cell effector
function in vitro, did not induce protective responses in humanized mice, suggesting that
favorable disease outcomes associate with factors beyond in vitro efficacy. These
results, together with the observation that HIV-specific CAR4 T cells augment the CD8+ T
cell response to infection, highlight the importance of exploiting engineered CD4+ T cells
in immunotherapies intended to treat chronic infections.

Results
Costimulatory domains differentially modulate HIV-specific CAR4 T cell cytokine
production.
To engineer optimal HIV-specific CD4+ T cells for use in HIV cure strategies, we
first generated an array of CAR4 T cells that expressed CD4, the natural ligand of
HIVENV, as the extracellular antigen-binding moiety fused to an intracellular domain (ICD)
comprising the TCR CD3 () chain and one costimulatory domain derived from CD27,
OX40, 4-1BB, ICOS, or CD28. The CAR containing the CD28 ICD was linked to the
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CD28 transmembrane (TM) domain, while the remaining CARs contained the CD8 TM
domain. All of the HIV-specific CARs were efficiently expressed on the cell surface and
could be identified by both the overexpression of CD4 relative to untransduced CD4+ T
cells (UTD4) and co-expression of GFP, which was linked to each CAR by an intervening
T2A sequence (Fig. 3-1A).
We then assessed the effects of individual ICDs on the in vitro effector function
of CAR4 T cells after antigen-specific stimulation with target cells expressing HIVENV. All
of the CAR4 T cell types upregulated TNF, MIP-1β, GM-CSF, IL-2 and IFN-γ following
antigen exposure; however, CAR4 T cells containing the CD28 receptor family ICDs
exhibited the greatest production of these cytokines (Fig. 3-1B,C and Fig. 3-2). In
particular, over 75% of CD28-costimulated CAR4 T cells elicited a cytokine response to
stimulation, exemplified by IL-2 and TNF expression. Interestingly, we observed low
expression levels of other cytokines associated with T-helper phenotypes including IL17A, IL-21, IL-22, IL-4 and IL-13 (Fig. 3-3). Moreover, combinatorial cytokine analysis
indicated that ICDs from the CD28 receptor family increased the frequency of
polyfunctional responses (Fig. 3-1D), where exhibiting ≥ 3 cytokine functions contributed
over 20% of the total response, and was mainly driven by the GM-CSF+IL-2+TNF+
subset, compared to less than 10% by the TNFR family ICDs (CD27, OX40 and 4-1BB)
(Fig. 3-1D,E). Somewhat paradoxically, in the absence of costimulation the CD3 ICD
induced robust cytokine production (Fig. 3-1C-E), which may result from the high
expression of this CAR on the CD4+ T cell surface (Fig. 3-4). Together, these data
demonstrate that HIV-specific CARs redirect CD4+ T cell specificity, and distinct
costimulatory signals within the CAR differentially modulate the magnitude and breadth
of cytokine expression.
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HIV-specific CAR4 T cells durably suppress in vitro HIV replication
To determine whether HIV-specific CAR4 T cells could limit the spread of HIV
infection, we performed an in vitro suppression assay comparing the ability CAR4 T cells
containing different ICDs to inhibit virus outgrowth. Here, activated CD4+ T cells were
infected with HIVBAL for 24 hours before co-culture with CAR4 or UTD4 T cells at different
effector-to-target (E:T) ratios, and virus replication was measured over 8 days by
determining the frequency of intracellular HIVGAG+ (CAR-) cells.

We observed

widespread virus replication when infected cells were cultured with UTD4 T cells,
whereas each CAR4 T cell population durably suppressed HIV at a 1:25 and 1:50 E:T
ratio (Fig. 3-5A,B and Fig. 3-6A,B). However, further dilution of CAR4 T cells expressing
the TNFR family ICDs resulted in rapid loss of virus control (Fig. 3-6A,C and Fig. 3-5C).
In contrast, CAR4 T cells containing the CD28 receptor family and CD3 ICDs potently
suppressed virus spread at lower E:T ratios (Fig. 3-5C,D and Fig. 3-5D).
At the same time, we compared the protective role of CAR4 T cells to that of HIVspecific CAR8 T cells expressing the 4-1BB ICD. We previously demonstrated that 41BB costimulation conferred optimal CAR8 T cell antiviral activity in vivo,40 and now this
construct is currently employed in a Phase I clinical trial (NCT03617198). CAR8 T cells
exhibited potent HIV suppression below a 1:100 E:T ratio (Fig. 3-6E and Fig. 3-7A), and
notably, CAR4 T cells expressing the CD28 and CD3 ICDs controlled virus spread to
the same extent (Fig. 3-6F). For a direct comparison, we noted that CAR4 T cells
expressing the 4-1BB ICD were approximately 3-fold less suppressive than CAR8 T
cells harboring the same ICD (Fig. 3-7B). These results indicated that HIV-specific CAR4
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T cells can solely control in vitro HIV replication, and that the ICD integrated into the
CAR modulates the ability of CAR4 T cells to directly inhibit virus outgrowth.

HIV-specific CAR4 T cells directly eliminate HIV-infected cells in vitro
The effector mechanisms employed by CD4+ T cells largely fall into two
categories: first, the production of broad-acting soluble factors, such as IFN- and TNF, that promote an antiviral state in surrounding tissue,135 and second, direct cytotoxic
activity.136-138 In the context of CD19-targeted CAR T cell therapy, CAR4 T cells directly
engage and kill tumor cells in vitro to the same extent as CAR8 T cells, but exhibit slower
kinetics of cytotoxicity.139 Similarly, we examined whether HIV-specific CAR4 T cells elicit
cytotoxic function by performing a short-term killing assay using primary HIV-infected
cells as targets.104 CAR4 T cells expressing the CD3 ICD eliminated target cells in a
dose-dependent manner, achieving an 80% reduction in the frequency of HIVGAG+ cells
(30% to 6% HIVGAG+ cells) after 24 hours (4:1 E:T ratio) (Fig. 3-8A,B). The killing
exhibited by CAR4 T cells was HIV-specific as indicated by the lack of infected cell lysis
when cultured with UTD4 T cells (Fig. 3-8B). Furthermore, when we expanded the killing
assay to include CAR4 T cells encoding distinct costimulatory domains, we observed
marked reductions in the number of HIVGAG+ cells mediated by CAR4 T cells expressing
the CD28 receptor family ICDs or CD3. Notably, the level of infected cell killing was
equivalent between these CAR4 T cell types and CAR8 T cells (Fig. 3-8C and Fig. 3-9).
In addition, inclusion of the TNFR family ICDs conferred cytolytic activity to CAR4 T cells,
but not to the same magnitude (Fig. 3-8C and Fig. 3-9).
We next examined whether CAR4 T cells could trigger activation of caspase-3 in
HIV-infected cells, which acts as the primary executioner in the cell-death apoptosis
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pathway140 and is a direct substrate of Granzyme B.141 Indeed, CAR4 T cells induced
cleavage of caspase-3 in HIVGAG+ cells (Fig. 3-8D,E), suggesting that virus-infected cell
death is mediated in part by caspase-dependent mechanisms. Furthermore, we
assessed the expression of cytolytic effector molecules including Granzyme (Gzm) B,
GzmA and GzmM in all CAR4 T cell populations. CAR4 T cells containing the CD28
receptor family ICDs or CD3 harbored the greatest level of GzmB and GzmA (Fig. 3-8F
and Fig. 3-10A), while GzmM expression was negligible (Fig. 3-10B), suggesting that
signaling from ICDs influences the cytotoxic potential of CAR4 T cells independent of
antigen exposure. However, these molecules were differentially regulated following in
vitro antigen-specific stimulation, where after we observed a substantial increase in
GzmB expression by all CAR4 T cell types, exemplified by the CD28 receptor family
ICDs or CD3 (Fig. 3-8F and Fig. 3-10C), while GzmA expression waned (Fig. 310A,D). Moreover, stimulation of CAR4 T cells resulted in the detection of CD107a,
which occurs as cytotoxic granules mobilize from the cytosol to the cell surface (Fig. 38G,H),142 and was coupled with the coordinated upregulation of perforin and GzmB (Fig.
3-8I,J). Together, these data demonstrate that CAR4 T cells exhibit in vitro cytotoxic
function that can at least be partially attributed to granule-mediated cytolysis.

4-1BB-costimulated CAR4 T cells mitigate HIV pathogenesis in vivo
We next sought to determine the in vivo therapeutic potential of distinct HIVspecific CAR4 T cell populations using a humanized mouse model of HIV infection.40 To
do so, we humanized NSG mice by adoptively transferring normal donor, CD8-depleted
PBMCs. Two weeks later, the mice were infused with autologous, HIVBAL-infected CD4+
T cells that were treated with ART in vitro prior to infusion and the mice received daily
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antiretroviral therapy (ART) (Fig. 3-11A). After 3 days, mice were allocated into groups
based on the level of CD4+ T cells in peripheral blood (Fig. 3-11B), and infused with
either one of the six CAR4 T cell types, or control CAR4 T cells expressing a truncated
CD3 ICD (CD3) (Fig. 3-11A). We rendered each CAR4 T cell product HIV-resistant
by co-transduction with the HIV fusion inhibitor C34-CXCR4,79 which was linked to
NGFR by an intervening T2A sequence (Fig. 3-12A). Prior to CAR4 T cell infusion, the
cells were positively selected for NGFR expression, achieving ≥ 90% NGFR+ (C34CXCR4+) T cell products (Fig. 3-12B). Of note, expression of C34-CXCR4 did not
augment the functional potency of CAR T cells, as unprotected CAR T cells suppressed
in vitro HIV replication to the same extent as CAR4 T cells expressing C34-CXCR4 (Fig.
3-12C).
We interrupted ART immediately after CAR4 T cell infusion and measured the
kinetics of HIV rebound. In this model, the magnitude of virus replication directly
correlates with the number of CD4+ T cells,143,144 thus to ensure fair comparison among
treatment groups, we normalized plasma HIV RNA at each time point to the
contemporaneous level of peripheral blood CD4+ T cells (CAR-). We observed that only
CAR4 T cells expressing the 4-1BB ICD reduced the magnitude of rebound viremia for
26 days after ART removal compared to control CAR4 T cell-treated mice (Fig. 3-11C-E
and Table 3-1). This difference remained significant without normalizing viral load,
particularly when assessing cumulative viral burden in plasma (Fig. 3-13). Furthermore,
mice treated with 4-1BB-costimulated CAR4 T cells exhibited durable protection against
HIV-induced CD4+ T cell (CAR-) depletion (Fig. 3-11F). These observations were striking
given that the 4-1BB ICD underperformed in every in vitro measure of CAR4 T cell
function, especially compared to the CD28 receptor family ICDs.
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4-1BB-costimulated CAR4 T cells exhibit profound in vivo expansion post-ART
removal
Next, we characterized the immunologic response inherent of each CAR4 T cell
type to viral recrudescence after ART cessation. CAR4 T cells were readily detected in
peripheral blood by the co-expression of GFP and NGFR (Fig. 3-14A). 4-1BBcostimulated CAR4 T cells exhibited rapid and profound expansion reaching a median
peak concentration of 511 cells uL-1 blood (34 to 2732 cells uL-1) (Fig. 3-14B), and
maintained greater long-term survival compared to the other CAR4 T cell populations
(Fig. 3-14C). Surprisingly, CAR4 T cells expressing CD28 receptor family ICDs, which
demonstrated superior in vitro potency, exhibited poor in vivo expansion kinetics and
persistence (Fig. 3-14B,C). Moreover, CAR4 T cells containing the TNFR family ICDs
expressed lower levels of inhibitory receptors including TIGIT and PD-1 early after ART
cessation, which may have, in addition to the ICD, modulated early in vivo proliferation
kinetics (Fig. 3-14D,E and Fig. 3-15). Notably, the magnitude of CAR4 T cell expansion
across all types, but exemplified by the 4-1BB ICD, correlated with reductions in plasma
viremia (Fig. 3-14F) and CD4+ T cell (CAR-) preservation (Fig. 3-14G). Together, these
data demonstrate that CAR4 T cells expressing the 4-1BB costimulatory domain possess
superior antiviral activity, and highlight that factors such as expansion potential are
critical to mitigate HIV pathogenesis.

HIV-specific CAR4 T cells improve the proliferation and survival of co-injected
CAR8 T cells in vivo
We hypothesized that HIV-specific CAR4 T cells will exhibit T cell-help to other
lymphocytes in vivo. To test this, we examined whether CAR4 T cells expressing the 494

1BB ICD could augment the antiviral function of HIV-specific CAR8 T cells after ART
removal in HIV-infected humanized mice. We recapitulated the study as described in
Figure 3-11A, but here, mice were allocated into groups that received an HIV-resistant
(C34-CXCR4+) CAR T cell product consisting of either CAR8 T cells alone (2.5x106 CAR+
cells), a 1:1 mixture of CAR4 and CAR8 T cells (1.25x106 CAR+/cell type), or a 1:1
mixture of inactive control CAR4 and CAR8 T cells (1.25x106 CAR+/cell type) expressing
the CD3 ICD. Of note, CAR8 T cells expressed the CD28 ICD, which previously
demonstrated marginal in vivo expansion and protection against HIV infection.40 We
observed that co-injection of CAR4 T cells enhanced the expansion (Fig. 3-16A,B) and
persistence (Fig. 3-16C) of CD28-costimulated CAR8 T cells despite infusing half the
dose, whereas alone these cells exhibited limited proliferation relative to control CAR8 T
cells (Fig. 3-17). In a separate study CAR4 T cells also accelerated the early expansion
kinetics of CAR8 T cells expressing the 4-1BB ICD (Fig. 3-18); this effect was surprising
given the remarkable proliferation these cells exhibit on their own after ART cessation.40
We next determined if the co-infusion of CAR4 T cells improved virologic
outcomes following ART withdrawal. Notably, in this study we observed faster HIV
rebound kinetics as viremia was detectable in mice 5 days after ART interruption (Fig. 316D) compared to 12 days in our prior study (Fig. 3-11C). Nevertheless, combination
therapy with CAR4 T cells and CD28-costimulated CAR8 T cells reduced rebound
viremia (Fig. 3-16E) and effectively limited HIV-induced depletion of CD4+ T cells (CAR-)
(Fig. 3-16F). In contrast, treatment with CAR8 T cells alone exhibited a transient
reduction in viral load (Fig. 3-16E), but were unable to mitigate CD4+ T cell loss relative
to control CAR T cell-treated mice (Fig. 3-16F). Together, these findings highlight that
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CAR4 T cells provide T cell-help by improving the in vivo expansion and survival of CAR8
T cells, and that combination therapy improves control over HIV pathogenesis.

Discussion
HIV preferentially infects HIV-specific CD4+ T cells leading to the collapse of
CD4+ T cell-help and impaired antiviral immunity.106,107 Thus, therapeutic approaches
that restore CD4+ T cell function, such as adoptive T cell therapy, will likely be a critical
component of any HIV functional cure or eradication strategy.145 Here, we interrogated
the therapeutic potential of HIV-specific CAR4 T cells to limit HIV infection in vitro and
after ART withdrawal in humanized mice. Given how costimulation tunes the functional
heterogeneity of CD4+ T cells,146,147 we initially characterized how distinct ICDs modulate
in vitro CAR4 T cell functions. We demonstrated that the CD28 receptor family ICDs
(ICOS and CD28) induced potent functional profiles compared to the TNFR family ICDs
(CD27, OX40 and 4-1BB), exemplified by polyfunctional cytokine responses and direct
suppression of in vitro virus replication, which rivaled CAR8 T cell-mediated control of
HIV. However, we did not observe an association between ICDs that conferred optimal
in vitro function and the ability to mitigate HIV pathogenesis in humanized mice,
suggesting that factors driving in vivo CAR4 T cell-mediated efficacy are not solely
predicted in vitro.
We identified CAR4 T cell expansion as a correlate of in vivo antiviral efficacy,
supporting observations that CAR T cell persistence is necessary to engender long-term
remission of certain B cell malignancies.47,148,149 Despite demonstrating limited in vitro
efficacy, only HIV-resistant (C34-CXCR4+) CAR4 T cells expressing the 4-1BB ICD
exhibited profound expansion and survival, and inhibited disease progression after ART
removal. The remaining ICDs induced marginal proliferation notwithstanding abundant
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HIV antigen, contrasting other studies that demonstrate ICOS81,122, CD27150 and
CD28151,152 costimulatory signals mediate in vivo CAR4 T cell expansion and tumor
eradication. Together, these data show that the 4-1BB ICD is necessary to potentiate
rapid in vivo proliferation and long-term survival of CAR4 T cells during HIV infection.
This finding is critical given that the stability of the latent reservoir in humans 2,153 likely
necessitates the persistence of CAR T cells for months, years or decades after infusion
to respond to HIV reactivation.154
Although the humanized mouse model described herein is well-suited to evaluate
therapeutic interventions that mitigate active HIV replication and CD4+ T cell depletion,
these animals eventually develop graft versus host disease (GVHD).155 This
xenoreactivity induces substantial cellular activation and proliferation, resulting in the
clinical manifestation of disease within 3-4 weeks after infusion,156 which diminishes the
time to study the durability of CAR T cell therapy, and limits our ability to recapitulate all
aspects of treatment performed in HIV-infected individuals. For instance, the constant
immune activation drives supraphysiologic levels of virus replication and precludes the
establishment of a latent HIV reservoir, which in humans, is comprised of a
heterogeneous population of HIV-infected, transcriptionally quiescent memory CD4+ T
cells.2,157 In contrast, treatments specifically targeting the latent reservoir may instead be
accurately reflected in humanized BLT mice, a more complex small-animal model of HIV
infection, which supports the generation of a latent reservoir under ART.158,159
Nevertheless, our in vivo model enabled us to directly compare the ability of multiple
CAR T cell products side-by-side to mitigate hallmarks of HIV disease progression
following ART cessation, which is congruent with the study objectives being investigated
by in-human clinical trials (NCT03617198).
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Moreover, these findings along with our previous studies indicate that 4-1BB
costimulation is essential for both CAR4 and CAR8 T cells to mitigate in vivo HIV
pathogenesis after ART cessation,40 which contrasts recent data demonstrating that
mesothelin-specific CAR4 and CAR8 T cells rely on distinct costimulatory signals for
optimal function.81 However, within this study, we did observe the CD28 ICD
differentially impact the efficacy of CAR4 and CAR8 T cell therapies in vivo. For instance,
CD28-costimulated CAR4 T cells failed to proliferate and mount effective immunity
against viral recrudescence compared to mice treated with 4-1BB-costimulated CAR4 T
cells (Fig. 3-11D-F). In contrast, the data described herein supports our previous work,40
showing that CAR8 T cells expressing the CD28 ICD were capable of reducing viremia
and delaying CD4+ T cell (CAR-) depletion to the same extent as 4-1BB-costimulated
CAR8 T cells early after ART cessation. These findings reinforce the notion that
costimulatory signal(s) that engender favorable CAR T cell responses are likely both
disease- and cell type-specific.60
In addition to CAR4 T cells exhibiting direct control of in vitro HIV replication, we
reasoned that they could also restore CD4+ T cell-help that is lost as a consequence of
viral infection. To this end, we demonstrated that co-injection of CAR4 T cells enhanced
the in vivo proliferation kinetics and survival of CD28-costimulated CAR8 T cells,
concomitant with reduced HIV replication. Moreover, we have shown that in vitro
activation of 4-1BB-costimulated CAR4 T cells upregulates IL-2 and IL-21, which are
cytokines that augment the function of CD8+ T cells during viral infection,160-162 and thus,
may have contributed to the sustained CAR8 T cell response that we observed in vivo.
Furthermore, it is reasonable to believe that CAR4 T cell help will benefit endogenous,
HIV-specific immunity. For example, previous studies have demonstrated that HIV98

specific cytolytic CD4+ and CD8+ T cells exhibit strong cooperativity to suppress infection
in vitro,163 and the addition of vaccine-primed HIV-specific CD4+ T cells reinvigorate the
proliferative capacity of CD8+ T cells isolated from chronic infection.164 Finally, since our
CAR4 T cells still express a functional TCR, it is likely that a portion of the infused CAR 4
T cells maintain specificity to other pathogens, and are able to confer help to immune
responses towards other infections including EBV, flu, and CMV. Interestingly, it was
reported that repeated TCR stimulation of CAR T cells results in exhaustion of CAR8, but
not CAR4 T cells,165 suggesting that CAR4 T cell-mediated help could be durable.
The ability of HIV-specific CAR4 T cells to control HIV replication, as well as
enable the function of other immune cells, highlights the therapeutic potential of this T
cell population. However, we expect that next-generation CAR4 T cells will need to be
infused into HIV-infected individuals as part of a defined formulation with CAR8 T cells to
achieve a synergistic antiviral effect, similar to the cooperativity between these T cells
during cancer treatment.149,166 Moreover, the potential of CAR T cell therapy alone to
engender positive clinical outcomes may only occur after ART cessation when sufficient
viral antigen is present to induce CAR T cell activation, as opposed to eliminating the
latent reservoir during ART when antigen is restricted. In this way, CAR T cell therapy
may resolve post-peak rebound viremia and contribute to an ART-free remission of HIV.
Collectively, the findings described herein provide insight regarding the potential of
engineered CD4+ T cells to both augment and restore the function of HIV-specific CD4+
T cells that is typically lost by virus-associated depletion, which could serve to
reinvigorate broad and enduring immune responses that enable immune control over
HIV.
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Materials and Methods
Ethics statement:
Humanized mouse experiments performed at the University of Pennsylvania
were approved by the University of Pennsylvania IACUC under the approval protocol
805606. All animal studies were carried out in accordance with recommendations in the
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.
Peripheral blood mononuclear cells and purified adult human CD8+ and CD4+ T cells
were obtained by the University of Pennsylvania Human Immunology Core/CFAR
Immunology Core from de-identified healthy donors.

Flow cytometry:
Surface staining was performed in 1X PBS containing 2% fetal calf serum and
2mM EDTA using anti-human antibodies from BioLegend: CD45 (2D1), CD3 (OKT3),
CD4 (OKT4), CD8 (RPA-T8), TIGIT (VSTM3), PD-1 (EH12.2H7), CD107a (H4A3), and
CD271/NGFR (ME20.4). Live cells were discriminated by staining with Fixable Viability
Dye eFlour 780 (eBioscience). Intracellular proteins were stained for with Cell Fixation &
Cell Permeabilization Kit (Invitrogen) according to the manufacturer’s instructions using
antibodies from the following sources: BD Bioscience: TNF (Mab11), IFN- (4S.B3), GMCSF (BVD2-21C11), MIP-1 (D21-1351), IL-21 (3A3-N2.1), Granzyme B (GB11), and
Active caspase-3 (C92605); BioLegend: IL-2 (MQH-17H12), IL-17A (BL168), IL-4 (8D48), IL-13 (JES10), IL-22 (2412A41), Perforin (B-D48), and Granzyme A (CB9);
eBioscience: Granzyme M (4B2G4); and Beckman Coulter: HIV-1 Core Antigen (KC57).
Flow cytometry data were acquired on a BD LSRFortessa and analyzed using FlowJo
software version 10.5.3 (TreeStar).
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HIV viral load quantitation:
Viral RNA was isolated from plasma (40 L) using the QiaAmp Viral RNA Mini Kit
(Qiagen). Viral loads were determined using quantitative RT-PCR using the QuantiFast
Syber Green RT-PCR Kit (Qiagen) as previously described.99 The limit of quantification
for this assay is 1.81 log RNA copies mL-1 plasma.

Plasmid construction:
The amino acid sequences for the HIV-specific CD4-based CAR constructs
containing the following intracellular domains: CD3-, 4-1BB/CD3-, CD28/CD3-,
CD27/CD3-, OX40/CD3- and ICOS/CD3- are described elsewhere.40 In this study,
each CAR was amplified from their original plasmid with the following primer: 5’CACGTCCTAGGATGGCCTTACCAGTG

and

5’-

GTGGTCGACTTATGCGCTCCTGCTGAAC and cloned into pTRPE plasmid using the
AvrII and SalI restriction enzyme sites. In this orientation, the CAR sequence is
downstream of GFP and a T2A sequence intervenes to permit expression of both
proteins. The amino acid sequence for the C34-CXCR4 construct is described
elsewhere.79 We introduced a single Asp mutation (D97N), which has been shown to
impair SDF-1 binding102 and limit CXCR4 internalization (Leslie et al. manuscript in
preparation). C34-CXCR4 (D97N) was cloned upstream of T2A and NGFR167 sequences
within the pTRPE backbone.

Lentivirus production and transfection:
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Lentivirus particles were generated using expression vectors encoding VSV
glycoprotein (pTRPE pVSVg-g), HIV Rev (pTRPE.Rev), and HIV Gag and Pol (pTRPE
g/p). The plasmids were synthesized by DNA 2.0 or ATUM (Newark, CA) and
transfected into HEK293T cells with pTRPE transfer vectors described above using
Lipofectamine 2000 (Life Technologies) as previously described.103 Transfected
HEK293T cell supernatant was collected 24 and 48 hours after transfection, filtered
through a sterile 0.45 m nylon syringe driven filter and concentrated by
ultracentrifugation at 25,000 rpm for 2.5 hours at 4°C. Supernatant was aspirated and
the virus pellet was resuspended in 800 L total volume and stored at -80°C.

Cell culture and selection:
To manufacture CAR T cells, CD4+ and CD8+ T cells from healthy adult human
donors were purified by negative selection using RosetteSep Human CD4+ or CD8+
Enrichment Cocktails (StemCell Technologies) according to the manufacturer’s
instructions. All cells were cultured at 106 cells mL-1 in complete RPMI (expansion
medium): RPMI 1640, 2 mM GlutaMax, 25 mM HEPES and 1% Penicillin-Streptomycin
from Life Technologies, and 10% fetal calf serum (Seradigm). T cell expansion medium
was supplemented with 10 ng mL-1 human IL-7 (R&D) and 5 ng mL-1 human IL-15
(BioLegend) or 100 U mL-1 human IL-2 (CLINIGEN). T cells were stimulated with
CD3/CD28 Dynabeads (Life Technologies) at a 3:1 bead-to-cell ratio at 37°C, 5% CO2
and 95% humidity incubation conditions. Roughly 18 hours after stimulation half of the
medium was removed and replaced with 200 to 300 L of concentrated lentivirus
supernatant for CAR transduction. On day 5, the Dynabeads were removed from cell
culture by magnetic separation. Expansion medium was changed every other day
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throughout cell culture spanning 8 to 10 days, or as necessary to adjust cell
concentration to 0.5x106 cells mL-1. For in vivo studies, on day 7 after activation, C34CXCR4-transduced T cells were positively selected using CD271/NGFR Microbeads
(Miltenyi Biotec) according the manufacturer’s protocol. Following selection, C34CXCR4+ T cells were placed in culture with expansion medium for one more day at the
adjusted cell concentration prior to infusion into humanized mice.

In vitro HIV suppression assay:
Two days after removing CD3/CD28 Dynabeads, activated CD4+ T cells were
infected with CCR5-tropic HIVBAL at a multiplicity of infection (MOI) of 1. 24 hours later,
HIV-challenged CD4+ T cells were washed with complete RPMI and mixed with the
indicated type of HIV-specific CAR T cell, or untransduced (UTD) T cell at effector-totarget ratios of 1:25, 1:50, 1:100 and 1:200. Cell mixtures were plated in duplicate and
the spread of virus replication was assessed by flow cytometry by sampling 100 L per
well for intracellular staining of HIV-1 Core Antigen (HIVGAG) at 2, 4, 6 and 8 days after
co-culture. Fresh complete RPMI was added to all wells after staining.

CD107a degranulation and intracellular staining assay:
The functionality of CAR T cells was measured in vitro after stimulating 2x105
CAR T cells or UTD T cells with 2x105 wild-type K562s (K.WT) or K562 cells expressing
HIVYU2 GP160 (K.Env). Anti-CD107a antibody was added at the start of stimulation
followed by the addition of 1X Brefeldin A and Monensin Solution (BioLegend) 1 hour
later. Cells were incubated for a total of 6 hours under incubation conditions. Detection
of cytokines and cytolytic proteins were assessed by intracellular staining with antibodies
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specific for human TNF, MIP-1, IFN-, IL-2, GM-CSF, Perforin, Granzyme B, Granzyme
A, Granzyme M, IL-17A, IL-4, IL-13, IL-21 and IL-22. The percentage of cytokine-positive
CAR T cells was calculated by subtracting background production after stimulation with
K.WT cells.

HIV-infected cell elimination assay:
This HIV-infected cell elimination assay is based on a previously described
protocol.104 Briefly, HIV-infected CD4+ T cells were prepared as detailed above. When
roughly 30% of total cells stained positive for intracellular HIVGAG, the cells were labeled
with CellTrace Violet (CTV; ThermoFisher) to distinguish target cells from effector cells.
CAR or UTD T cells were cultured with CTV+ target cells at various E:T ratios. After 24
hours, target cells were analyzed for the reduction of HIVGAG+ cells and the induction of
active caspase-3 by intracellular staining and flow cytometry. Elimination of HIV-infected
cells was calculated by quantitation of live (Fixable Viability Dye eFlour780 negative)
CTV+ CAR- HIVGAG+ cells. The percentage of residual HIV-infected target cells were
calculated by dividing the percentage of live CTV+ CAR- HIVGAG+ target cells at the
indicated E:T ratio by the percentage of CTV+ CAR- HIVGAG+ target cells at an E:T ratio of
0.

Humanized mice experiments:
NOD/SCID/IL2R-/- (NSG) mice (The Jackson Laboratory) were housed in a
pathogen-free facility at the University of Pennsylvania. Mice were maintained in
microisolator cages and fed autoclaved food and water. Humanized mice were
generated essentially as previously described.40 NSG mice were infused with 5x106
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healthy donor PBMCs depleted of CD8+ T cells using CD8 Microbeads (Miltenyi Biotec)
following the manufacturer’s protocol. Two weeks later mice initiated daily antiretroviral
therapy (ART) consisting of 1 mg kg-1 EFdA (4′-ethynyl-2-fluoro-2′-557 deoxyadenosine,
LeadGen Labs). After 1 day, mice were infused with 106 autologous HIVGAG+ CD4+ T
cells and mixed with 9x106 uninfected CD4+ T cells. Prior to infusion CD4+ T cells were
in vitro infected with HIVBAL (MOI 1) as described above and expanded in culture for 4
more days, where during the last 2 days 1 M EFdA supplemented the expansion
medium. Mice were bled 1 or 2 days after the infusion of HIV-infected cells, and then
allocated into groups (n=6-8) based on the concentration of peripheral blood CD4+ T
cells. Three days after the infusion of HIV-infected cells, mice were infused with HIVresistant (>90% C34-CXCR4+) CAR T cells as described above and ART was
interrupted. For the study described in Figure 3-11, each group of humanized mice
received an infusion of 2.5x106 CAR4 T cells expressing one of the six ICDs, or inactive
control CAR4 T cells expressing a truncated CD3 ICD. For the study described in
Figure 3-16, mouse groups received an infusion product consisting of either (CD28)
CAR8 T cells (2.5x106 CAR+ cells), 1:1 ratio of CAR4 (4-1BB) and CAR8 (CD28) T cells
(1.25x106 CAR+/cell type), or 1:1 ratio of inactive control CAR4 and CAR8 T cells
(1.25x106 CAR+/cell type) expressing the CD3 ICD. In another study shown in Figure
3-18, we recapitulated this experimental design, but the CAR8 T cells expressed the 41BB ICD instead of the CD28 ICD. For all studies the mice were bled weekly via retroorbital puncture following the CD4+ T cell engraftment bleed until study endpoint.

Statistical analysis:
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All statistical analysis was performed using GraphPad Prism, version 7 (San
Diego, CA). Comparison of means from unmatched samples were performed using the
non-parametric Wilcoxon rank sum test or Kruskal-Wallis test followed by Dunn’s test for
multiple comparisons. Comparison of means from matched samples was performed
using paired student’s t test or Wilcoxon matched pairs signed rank test. Bivariate
correlations were performed using Spearman’s rank correlation. Area under the curve
calculations were performed using either cell concentration normalized to one microliter
of blood or frequency of HIV-infected cells.
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Figures

Figure 3-1. Intracellular costimulatory domains differentially modulate HIV-specific
CAR4 T cell cytokine expression. (A) Schematic representation of each CAR construct
and FACS plots identifying HIV-specific CAR-modified CD4+ T cells (CAR4) as GFP+ and
CD4+ relative to untransduced CD4+ T cells (UTD4). Purified human CD4+ T cells from a
healthy human donor were activated with CD3/CD28 Dynabeads and transduced with
a lentiviral vector encoding one of six HIV-specific (CD4-based) CARs that express
unique intracellular domains (ICD) either CD3 (), 4-1BB, CD28, CD27, OX40 or
ICOS. Each CAR was linked to GFP by an intervening T2A sequence to facilitate in
vitro detection. (B) After 10 days of expansion, CAR4 T cells were in vitro stimulated
with HIVYU2 GFP160+ K562 cells (K.Env) and intracellular cytokine analysis was
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performed. Data are representative of 3 donors. (C) Heatmap showing the percentage of
responding CAR4 T cells for each of the indicated cytokines. (D) Polyfunctionality profiles
of combinatorial subsets for CAR4 T cells producing 0 to 5 human cytokines: TNF, IL-2,
IFN-, GM-CSF and MIP-1. (C-D) Data are average of 3 donors. (E) Summary data of 3
donors per CAR4 T cell population producing ≥ 2 cytokine functions after antigen
stimulation. Lines indicate mean and error bars show ± SEM.
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Figure 3-2. Distinct HIV-specific CAR4 T cell types differentially express cytokines
after in vitro antigen-specific stimulation. (A) FACS plots indicating the frequency of
cytokine expressing HIV-specific CAR4 T cells after in vitro stimulation with K.Env cells
10 days after activation with CD3/CD28 Dynabeads. Data are representative of 3
donors. (B) Summary data indicating the frequency of cytokine expressing CAR4 T cells.
Each symbol represents a distinct donor. The percentage of cytokine expressing CAR4 T
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cells was calculated by subtracting background production after stimulation with wildtype K562 cells. Lines indicate mean and error bars show ± SEM.
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Figure 3-3. Distinct HIV-specific CAR4 T cell types express low levels of Th17- and
Th2-associated cytokines. Summary data indicating the frequency of cytokine
expressing CAR4 T cells after in vitro stimulation with K.Env 10 days after activation with
CD3/CD28 Dynabeads. Each symbol represents a distinct donor. The percentage of
cytokine expressing CAR4 T cells was calculated by subtracting background production
after stimulation with wild-type K562 cells. Lines indicate mean and error bars show ±
SEM.
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Figure 3-4. CD4-based CAR containing the CD3z intracellular domain exhibits the
greatest surface expression on CD4+ T cells. Summary data indicates the geometric
mean fluorescence intensity (MFI) determined by flow cytometry of CD4 on GFP+ CAR4
T cells 10 days after activation with CD3/CD28 Dynabeads.
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Figure 3-5. Intracellular domains modulate CAR4 T cell-mediated control of in vitro
HIV replication. Each HIV-specific CAR4 T cell type and UTD4 T cells were mixed
separately with HIVBAL-challenged CD4+ T cells at the indicated effector-to-target (E:T)
ratios, and the level of virus spread was monitored by intracellular staining and flow
cytometry for HIVGAG antigen on 2, 4, 6 and 8 days after co-culture. (A) FACS plots
indicating the frequency of HIVGAG+ cells (CAR-) 8 days after co-culture with CAR4 or
113

UTD4 T cells at the 1:25 E:T ratio. (B) Summary of the frequency of HIVGAG+ cells at 2, 4,
6 and 8 days after co-culture at 1:25 E:T ratio. Symbols represents the average of 3
distinct donors in duplicate and error bars show ± SEM. (C) Cumulative infection
calculated by area under the curve from the frequency of HIVGAG+ cells at 2, 4, 6 and 8
days after co-culture at 1:100 and (D) 1:200 E:T ratios. Data are represented as box and
whisker plots and bars show min and max values. Symbols indicate unique donors
performed in duplicate. Kruskal-Wallis test and Dunn’s multiple comparison test was
used to determine significance (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001).
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Figure 3-6. HIV-specific CAR4 T cells durably suppress in vitro HIV replication.
HIV-specific CAR T cells and UTD T cells were mixed separately with HIVBAL-challenged
CD4+ T cells at the indicated effector-to-target (E:T) ratios, and the level of virus spread
was monitored by intracellular staining and flow cytometry for HIVGAG antigen on 2, 4, 6
and 8 days after co-culture. (A) FACS plots indicate the frequency of HIVGAG+ cells (CAR) 8 days after co-culture with each CAR4 T cell type or UTD4 T cells. (B) Summary of the
frequency of HIVGAG+ cells at 2, 4, 6 and 8 days after co-culture at 1:50, (C) 1:100, and
(D) 1:200 E:T ratio. For (B-D), symbols represent the average of 3 distinct donors in
duplicate and error bars show ± SEM. (E) FACS plots show the frequency of HIVGAG+
cells (CAR- CD8-) 8 days after co-culture with UTD8 or HIV-specific CAR8 T cells
expressing the 4-1BB intracellular domain. (F) Cumulative infection calculated by area
under the curve from the frequency of HIVGAG+ cells at 2, 4, 6 and 8 days after co-culture.
Data are represented as box and whisker plots and bars show min and max values.
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Symbols indicate unique donors performed in duplicate. Kruskal-Wallis test and Dunn’s
multiple comparison test were used to determine significance (ns; P>0.05).
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Figure 3-7. HIV-specific CAR8 T cells expressing the 4-1BBz ICD durably suppress
in vitro virus replication. UTD and HIV-specific CAR4 and CAR8 T cells expressing the
4-1BB intracellular domain were mixed separately with HIVBAL-challenged CD4+ T cells
at the indicated effector-to-target (E:T) ratios, and the level of virus spread was
monitored by intracellular staining and flow cytometry for HIVGAG antigen on 2, 4, 6 and 8
days after co-culture. (A) Summary of the frequency of HIVGAG+ (CAR-) cells at 2, 4, 6
and 8 days after co-culture. Symbols represents the average of 3 donors in duplicate
and error bars show ± SEM. (B) Cumulative infection calculated by area under the curve
from the frequency of HIVGAG+ cells at 2, 4, 6 and 8 days after co-culture. Data are
represented as box and whisker plots and bars show min and max values. Symbols
indicate unique donors performed in duplicate.
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Figure 3-8. HIV-specific CAR4 T cells exhibit cytolytic function against virusinfected CD4+ T cells. (A-E) CellTrace Violet labelled, HIVBAL-infected CD4+ T cells
(30% HIVGAG+) were cultured with HIV-specific CAR or UTD T cells at the indicated E:T
ratios. 24 hours later the frequency of HIVGAG+ cells (live CTV+ CAR-) was assessed by
intracellular staining and flow cytometry for HIVGAG antigen. (A) FACS plots show the
frequency of HIVGAG+ cells, and (B) summary data indicates the frequency of residual
HIVGAG+ cells after co-culture with UTD4 or CAR4 T cells expressing the CD3 ICD. (C)
Summary data of elimination assay at the 0.125:1 E:T ratio. (D) FACS plots and (E)
summary data show frequency of active caspase-3 within HIVGAG+ cells after co-culture
with UTD4 or CAR4 T cells expressing the CD3 ICD. (F) After 10 days of expansion,
CAR4 T cells were stimulated with K.Env or wild-type K562 cells (K.WT) and FACS plots
show upregulation of Granzyme B and TNF. Data are representative of 3 donors. (G)
Histogram and (H) mean fluorescence intensity (MFI) indicate CD107a mobilization in
CAR4 T cells after in vitro stimulation. (I) FACS plots and (J) summary data show the
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coordinated upregulation of perforin and Granzyme B in CAR4 T cells expressing the
CD3 ICD after in vitro stimulation. (B,E) Symbols indicate average of 3 donors
performed in triplicate. Error bars show ± SEM. (C) Data are represented as box and
whisker plots and bars show min and max values. Symbols indicate 3 donors performed
in duplicate. Kruskal-Wallis test and Dunn’s multiple comparison test were used to
determine significance. (H,J) Data shows 3 donors and significance was calculated
using paired student’s t test. For all data, *P<0.05 and **P<0.01.
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Figure S6. HIV-specific CAR4 T cells exhibit in vitro cytotoxic activity. CellTrace
Violet labelled, HIVBAL-infected CD4+ T cells (30% HIVGAG+) were cultured with UTD or
HIV-specific CAR T cells at the indicated E:T ratios. Frequency of HIVGAG+ cells (live
CAR- CD8- T cells) was assessed by intracellular staining and flow cytometry for HIVGAG
antigen 24 hours later. (A) Summary data indicates the frequency of residual HIVGAG+
cells that exist after co-culture with CAR T cells at the 0.25:1 and (B) 0.5:1 E:T ratio.
Data are represented as box and whisker plots and bars show min and max values.
Symbols indicate 3 donors performed in duplicate. Kruskal-Wallis test and Dunn’s
multiple comparison test was used to determine significance (*P<0.05, **P<0.01).
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Figure 3-10. HIV-specific CAR4 T cells differentially express Granzymes after in
vitro stimulation. After 10 days of culture, each CAR4 T cell type was in vitro stimulated
with K.Env or wild-type K562 cells (K.WT) and the intracellular expression levels of
Granzyme B, A and M were assessed. (A) FACS plots show the frequency of Granzyme
A and (B) Granzyme M expression in CAR4 T cells. Data are representative of 3 distinct
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donors. (C) Summary data showing the change in Granzyme B and (D) Granzyme A
levels after in vitro stimulation. Each symbol represents one donor.
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Figure 3-11. HIV-specific 4-1BB-costimulated CAR4 T cells mitigate HIV disease
progression post-ART. (A) Experimental design. NSG mice were infused with CD8depleted PBMCs from a healthy human donor. Two weeks later, mice initiated daily ART
for one week and were infused with autologous, in vitro HIVBAL-infected CD4+ T cells.
Mice were allocated into 7 groups (n=6-7) based on CD4+ T cell engraftment, and then
each mouse received 2.5x106 HIV-resistant (C34-CXCR4+) CAR4 T cells expressing one
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of the six intracellular domains (ICDs), or inactive control CAR4 T cells expressing a
truncated CD3 ICD followed by ART cessation. (B) Concentration of peripheral blood
CD4+ T cells prior to CAR T cell infusion. Data are represented as box and whisker plots
and bars show min and max values. (C) HIV RNA copies mL-1 plasma normalized to
contemporaneous peripheral blood CD4+ T cell concentration (CAR-) 12 days, (D) 19
days, and (E) 26 days post-ART removal. (F) Longitudinal concentration of CD4+ T cells
(CAR-) in peripheral blood. (C-F) Bars and symbols indicate mean and error bars show ±
SEM. Significance was calculated using Wilcoxon rank sum test (ns: P>0.05, *P<0.05,
**P<0.01).
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Figure 3-12. Manufacturing and in vitro functional evaluation of HIV-resistant CAR
T cells. HIV-specific CAR4 T cells were co-transduced with lentivirus encoding the HIV
fusion inhibitor C34-CXCR4 linked to NGFR by an intervening T2A sequence. Seven
days after activation with CD3/CD28 Dynabeads, T cells were positively selected for
NGFR expression using NGFR antibody coated magnetic beads as described in
Materials and Methods. (A) Schematic of the C34-CXCR4 construct used to confer HIVresistance to CAR4 T cells. (B) FACS plots indicate the purity of NGFR+ CAR4 T cells
following magnetic bead selection prior to infusion into HIV-infected humanized mice. (C)
HIV suppression assay as described in Materials and Methods. Viral outgrowth kinetics
when HIV-infected CD4+ T cells are co-cultured with either C34-CXCR4+ or C34-CXCR4125

CAR T cells expressing the 4-1BBz intracellular domain or UTD. Symbols indicate mean
and error bars show ± SEM.
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Figure 3-13. Plasma viral load comparison of normalized and non-normalized
values. (A) Viral loads of 4-1BB CAR4 T cell-treated mice compared to control
CD3 CAR4 T cell-treated mice (see also Figure 4). HIV RNA copies mL-1 plasma are
either normalized to contemporaneous peripheral CD4+ T cell (CAR-) concentration or
non-normalized (i.e raw concentration). (B) Cumulative viral load calculated by area
under the curve from 5, 12, 19 and 26 days post-ART removal. For all data, bars indicate
mean and error bars show ± SEM. Significance was calculated using Wilcoxon rank sum
text (*P<0.05)
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Figure 3-14. 4-1BB costimulation potentiates in vivo HIV-specific CAR4 T cell
expansion and persistence. (A) FACS plots show the detection of each CAR4 T cell
type in peripheral blood 26 days post-ART removal in HIV-infected humanized mice.
CAR4 T cells are identified by the co-expression of GFP and NGFR, which are linked by
intervening T2A sequences to the indicated CD4-based CAR and C34-CXCR4,
respectively. (B) Peripheral blood concentration of each CAR4 T cell type at 12, 19 and
26 days post-ART removal. (C) Cumulative peripheral CAR4 T cell persistence
measured by area under the curve from 5, 12, 19 and 26 days post-ART removal. (D)
FACS plots and (E) summary data show the frequency of TIGIT and PD-1 expression on
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each CAR4 T cell type 5 days post-ART removal. (F) Correlation between CAR4 T cell
concentration 19 days post-ART removal and contemporaneous viral load, and (G) CD4+
T cell (CAR-) concentration. Red symbols indicate 4-1BB-costimulated CAR4 T cells and
white symbols indicate the remaining CAR4 T cell types. (B,C) Data are represented as
box and whisker plots and bars show min and max values. Each symbol denotes one
mouse. Wilcoxon rank sum test and (F,G) Spearman correlation were used to test for
significance. For all data, *P<0.05, **P<0.01, and ***P<0.001.
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Figure 3-15. HIV-specific CAR4 T cells expressing TNFR family intracellular
domains exhibit lower inhibitory receptor expression post-ART. (A) Longitudinal
expression of TIGIT and (B) PD-1 on peripheral blood HIV-specific CAR4 T cells postART removal in HIV-infected humanized mice. Symbols indicate mean and error bars
show ± SEM.
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Figure 3-16. Co-injection of HIV-specific CAR4 T cells improves CAR8 T cell
expansion and post-ART control of HIV infection. NSG mice were infused with CD8depleted PBMCs from a healthy human donor. Two weeks later, mice initiated daily ART
for one week and were infused with autologous, in vitro HIVBAL-infected CD4+ T cells.
Mice were allocated into 3 groups (n=7-8) based on CD4+ T cell engraftment, and then
each group received either HIV-resistant (C34-CXCR4+) CAR8 (CD28) T cells (2.5x106
CAR+ cells/mouse), 1:1 ratio of CAR4 (4-1BB) and CAR8 (CD28) T cells (1.25x106
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CAR+/cell type/mouse), or 1:1 ratio of inactive control CAR4 and CAR8 T cells (1.25x106
CAR+/cell type/mouse) expressing the CD3 ICD followed by ART interruption. (A)
FACS plots show the frequency of peripheral CAR8 T cells identified by the
overexpression of CD4 on the CD8+ T cell surface. (B) Longitudinal concentration of
peripheral CAR8 T cells after ART interruption. (C) Cumulative peripheral CAR8 T cells
persistence measured by area under the curve from 5, 12, 19 and 26 days post-ART
removal. (D) HIV RNA copies mL-1 plasma normalized to contemporaneous peripheral
CD4+ T cell (CAR-) concentration 5 days, and (E) 12, 19 and 26 days post-ART removal.
(F) Longitudinal concentration of CD4+ T cells (CAR-) in peripheral blood. (B,C,F) Data
are represented as box and whisker plots and bars show min and max values. (D,E)
Bars indicate mean and errors show ± SEM. For all data, each symbol denotes one
mouse and Wilcoxon rank sum test was used to calculate significance (ns: P>0.05,
*P<0.05, **P<0.01).
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Figure 3-17. HIV-specific CD28-costimulated CAR8 T cells fail to expand post-ART
removal in vivo. Longitudinal concentration of HIV-specific CAR8 T cells expressing
either the CD28 or CD3 ICD in peripheral blood following ART withdrawal in HIVinfected humanized mice. Data are represented as box and whisker plots and bars show
min and max values. Each symbol denotes one mouse.
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Figure 3-18. Co-injection of HIV-specific CAR4 T cells improve early expansion
kinetics of 4-1BB-costimulated CAR8 T cells post-ART removal. NSG mice were
infused with CD8-depleted PBMCs from a healthy human donor. Two weeks later, mice
initiated daily ART for one week and were infused with autologous, in vitro HIVBALinfected CD4+ T cells. Mice were allocated into 3 groups (n=4-6) based on CD4+ T cell
engraftment, and then each mouse received either HIV-resistant (C34-CXCR4+) CAR8
(4-1BB) T cells (2.5x106 CAR+ cells), 1:1 ratio of CAR4 (4-1BB) and CAR8 (4-1BB) T
cells (1.25x106 CAR+/cell type), or 1:1 ratio of inactive control CAR4 and CAR8 T cells
(1.25x106 CAR+/cell type) expressing the CD3 ICD followed by ART interruption.
Longitudinal concentration of peripheral CAR8 T cells after ART interruption. Data are
represented as box and whisker plots and bars show min and max values. Each symbol
denotes one mouse and Wilcoxon rank sum test was used to calculate significance
(*P<0.05).
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Table 3-1. Statistical comparison of normalized plasma viral loads (P value)
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CHAPTER 4 - High-throughput characterization of CAR T cell manufacturing
criteria and cytotoxic potential using image-based cytometry
Parts of this chapter are previously published:
Maldini C.R., Love A.C., Tosh K.W., Chan L., Gayout K., Smith T., Riley J.L. (2020)
Characterization of CAR T Cell Expansion and Cytotoxic Potential During Ex Vivo
Manufacturing Using Image-based Cytometry. Journal of Immunological Methods (in
press).
Abstract
Since the FDA approval of two Chimeric Antigen Receptor (CAR) T cell therapies
against CD19+ malignancies, there has been significant interest in adapting CAR
technology to other diseases. As such, the ability to simultaneously monitor
manufacturing criteria and functional characteristics of multiple CAR T cell products by a
single instrument would likely accelerate the development of candidate therapies. Here,
we demonstrate that image-based cytometry yields high-throughput measurements of
CAR T cell proliferation and size, and captures the kinetics of in vitro antigen-specific
CAR T cell-mediated killing. The data acquired and analyzed by the image cytometer are
congruent

with

results

derived

from

conventional

technologies

when

tested

contemporaneously. Moreover, the use of bright-field and fluorescence microscopy by
the image cytometer provides kinetic measurements and rapid data acquisition, which
are direct advantages over industry standard instruments. Together, image cytometry
enables fast, reproducible measurements of CAR T cell manufacturing criteria and
effector function, which can greatly facilitate the evaluation of novel CARs with
therapeutic potential.
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Introduction
Adoptive immunotherapy involves the transfer of immunocompetent cells for the
treatment of pathologies with the goal to replace, restore or augment the biological
function of the native immune response.154 To date, the adoptive transfer of geneticallymodified, autologous Chimeric Antigen Receptor (CAR) T cells have significantly
improved

the

clinical

outcome

of

patients

with

treatment

refractory

B

cell

malignancies,47,48 culminating in two FDA-licensed CAR T cell therapies. CARs redirect
T cell responses through surface expression of an extracellular antigen-binding domain,
typically an antibody-derived single-chain variable fragment, fused to an intracellular
domain comprising the TCR signal transduction domain (CD3-) and one or more
costimulatory domains.37,46 Given the modular nature of CARs, each domain can be
switched permitting the generation of engineered T cells with new specificities and
functions. Due to recent success of CD19-targeted CAR T cell therapies many
researchers are investigating novel CARs for other disease indications; however,
preclinical evaluation including the simultaneous manufacturing and functional testing of
multiple CAR T cell products can be time-consuming and labor-intensive168 As such, the
ability to measure these criteria with a single instrument will likely accelerate the
development and evaluation of novel immunotherapies.
The adoptive transfer of CAR T cells relies on the large scale ex vivo activation
and expansion of genetically-engineered T cells, generating >1 x 109 CAR T cells for reinfusion into patients.169 This process involves activating purified, patient blood-derived T
cells by ligating CD3 and CD28 surface receptors through monoclonal antibodies
conjugated to beads170, or by co-culture with artificial antigen-presenting cells171,172.
Activated T cells can be transduced with a viral vector containing the CAR, and then
grow logarithmically in culture for 1 to 2 weeks prior to adoptive transfer into patients.
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Throughout the expansion phase, CAR T cells are routinely counted using automated
cell counters, which have largely replaced manual hemocytometers, given their ability to
accurately quantify cell number and size173. During this time, the culture volume is
continuously adjusted to lower the cell density and remove the buildup of waste products
such as lactate and ammonia174, which improves cell growth and viability. In addition to
measuring the growth rate, CAR T cells are screened for phenotypic characteristics such
as memory distribution and functionality, including antigen-specific cytokine release and
target cell killing. Collectively, these readouts represent critical measures of quality
control that need to be defined in order to ensure consistent manufacturing of a uniform
CAR T cell product.168
Here, we have developed an efficient image-based cytometry method using the
Celigo Image Cytometer (Nexcelom Bioscience LLC.) to overcome limitations of
conventional instruments used to measure CAR T cell expansion criteria and effector
function during the manufacturing process.175,176 We validated this novel technique
against industry-standard equipment and assays by generating a panel of distinct HIVspecific CAR T cell populations from multiple donors, and assessed the in vitro growth
kinetics and cytotoxic potential of these CAR T lymphocytes against antigen-presenting
target cells. Notably, image cytometry permitted the simultaneous evaluation of distinct
CAR T cell populations, which enabled us to directly compare the growth rate and
functionality of these cells. Image cytometry provided a sensitive, kinetic and highthroughput method to assess the physiological functions of CAR T cells, which could
improve the efficiency for identifying high-quality CAR T cell products with therapeutic
potential.
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Results
Image-based cytometry measures CAR T cell expansion criteria during
manufacturing
Image cytometry uses the bright-field channel and auto-focus feature to identify
individual cells that are seeded in a microwell plate (Fig. 4-1A), after which the well can
be imaged and analyzed using the Celigo software to calculate cell density. We
validated this cell counting method by comparing the image cytometer to the Multisizer 3
(Beckman Coulter), an automated cell counter and particle sizing instrument frequently
used in the hematology field that employs the coulter principle

177,178

. To do so, we

prepared a triplicate series of two-fold T cell dilutions from which cell counting
measurements were made by each instrument. The cell concentrations measured by the
image cytometer and Multisizer 3 maintained a high degree of linearity over the indicated
range of dilutions compared to the theoretical values (Fig. 4-1B), and were strongly
correlated with each other (r = 0.9996; Fig. 4-1C).
The image cytometer was then used to monitor the cell density of multiple CAR T
cell products, using a manufacturing process similar to one being employed in clinical
trials

179,180

. We generated seven distinct CAR T cell products per donor by transducing

CD3/CD28 bead-activated CD4+ T cells with single lentiviruses containing an HIVspecific CAR derived from the full-length CD4 extracellular region fused to an
intracellular domain (ICD) comprising the TCR CD3- () chain and one or more
costimulatory domains, including 4-1BB, CD28, CD28/4-1BB, CD27, OX40 or ICOS
(Fig. 4-2). Beginning 5 days after the initial stimulation, we calculated the number of
population doublings from baseline (day 0) using the cell density values measured by
the image cytometer and Multisizer 3. The expansion curves of each CAR T cell type
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generated by the image cytometer were nearly identical to the Multisizer 3 (Fig. 4-1D),
and no statistical differences were observed between the two methods comparing total
population doublings after 10 days of culture (Fig. 4-1E). Notably, we did not observe
any substantial differences in proliferation among the CAR T cell populations with the
exception of CAR T cells expressing the CD27/ ICD, which consistently exhibited fewer
population doublings (Fig. 4-1D,E).
Following cognate antigen stimulation, T cell size increases due to the
accumulation of biomass prior to cellular division

181

. As such, we simultaneously

quantified the size of expanding CAR T cells throughout manufacturing as a surrogate
readout of their activation state. However, to first validate the image cytometry-based
object sizing protocol, we measured the diameter of CD3/CD28 Dynabeads. The image
cytometer detected the beads using bright-field microscopy (Fig. 4-3A), and calculated
an average bead diameter of 5.2 µm (Fig. 4-3B), which approximates the manufacturer
(Gibco) listed width of 4.5 µm. This method was then applied to CAR T cells during the
manufacturing process, and we observed that CAR T cell size (area, μm2) peaked 6
days after the initial stimulation before gradually contracting to a smaller, ‘rested’ size on
day 10 (Fig. 4-3C-E). The cell areas of each CAR T cell population were roughly similar
during the expansion phase (Fig. 4-3F,G and Fig. 4-4), which was expected given their
comparable proliferation kinetics (Fig. 4-1E). Moreover, the cell areas calculated by
each method strongly correlated with one another (Fig. 4-3H). Together, the data
acquired by image cytometry were directly comparable to conventional technologies and
supported the use of this method to evaluate CAR T cell growth kinetics during the
manufacturing process.
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Image fluorescence microscopy captures the kinetics of in vitro CAR T cellmediated killing
To align with traditional assays used to quantify the in vitro functional potency of
CAR T cells, we determined if the image cytometer could detect antigen-specific effector
function. To do so, we set up a cytotoxicity assay using untransduced (UTD) and HIVspecific CD8+ CAR T cells expressing the CD3- ICD cultured at different effector-totarget (E:T) ratios with on-target K562 cells expressing the HIVYU2 GP160 protein
(K.Env) or off-target, wild-type K562 cells (K.WT). For this assay, we stably transduced
these target cell lines with a lentiviral vector containing GFP linked to click beetle green
luciferase by an intervening T2A sequence. The inclusion of GFP enabled the
enumeration of GFP+ target cells by using the image cytometer, followed by the
sequential detection of bioluminescence (BLI) from luciferase activity using the same set
of effector CAR T cells and K562 target cells. As such, we were able to directly compare
the extent of target cell killing measured by image cytometry to a standard BLI-based
assay routinely used to characterize cytotoxic potential 182,183.
The image cytometer accurately detected GFP+ target cells utilizing the brightfield and green fluorescent channels, and we observed substantial CAR T cell-mediated
reductions of on-target GFP+ K.Env cells (Fig. 4-5A), but not off-target GFP+ K.WT cells
(Fig. 4-6). We then calculated specific lysis values using the image cytometer and BLIbased assay at all E:T ratios 72-hours after co-culture. Both methods showed that CAR
T cells exhibited dose-dependent cytotoxicity at E:T ratios <1; this effect was HIVspecific as only limited off-target cytolysis occurred (Fig. 4-5B,C and Fig. 4-7A). In
contrast, UTD T cells induced minimal killing as we observed less than 20% target cell
lysis across all E:T ratios (Fig. 4-5D,E and Fig. 4-7B). Although the same cultures were
analyzed by both methods, the specific lysis values obtained by the BLI-based assay
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were marginally greater than the image cytometer (Fig. 4-7C), suggesting there may be
slight differences in sensitivity. However, the BLI-based assay also measured greater
off-target CAR T cell-mediated killing, likely resulting from background luciferase signals
(Fig. 4-5C and Fig. 4-7A). It is important to note that both methods measured negative
specific lysis, which indicated target cell growth in the control conditions, evidenced by
the accumulation of target cells in the absence of CAR T cells (Fig. 4-5A and Fig. 4-6).
Notably, image cytometry captured the kinetics of CAR T cell-mediated killing by
enumerating GFP+ target cells without further manipulation unlike end-point BLI-based
assays or the Chromium-51 release assay

182

. We imaged the cells at 0, 24, 48 and 72-

hours after co-culture and observed marked CAR T cell-mediated reductions of on-target
GFP+ K.Env cells beginning at 48-hours (Fig. 4-8A), and cell lysis increased through 72hours after co-culture indicating that CAR T cells were capable of sustained cytotoxic
function (Fig. 4-8B and Fig. 4-9A). Importantly, we observed limited off-target toxicity as
GFP+ K.WT cells continued to grow unabated when cultured with CAR T cells at the
indicated E:T ratios (Fig. 4-8B, and Fig. 4-9A,B). Taken together, these data
demonstrate that image cytometry is capable of quantifying in vitro antigen-specific CAR
T cell-induced cytotoxicity, and that the sensitivity of this method is comparable to
conventional assays that assess effector CAR T cell function.

Discussion
The ability to functionally characterize multiple CAR T cell products in a highthroughput and comparative manner can expedite the discovery of novel CARs with
therapeutic potential. Current methods to measure CAR T cell proliferation as well as
cytotoxic potential during the manufacturing process can be time-consuming and
requires the use of multiple equipment. The image-based cytometry method described
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herein was designed to eliminate these issues. In our study, we noted several
advantages of using image cytometry compared to conventional instruments. For
instance, the average time to scan, image and count T cells seeded in a 96-well
microplate by the image cytometer was 5 seconds per well compared to >30 seconds by
the Multisizer 3 from Beckman Coulter. Moreover, the bright-field and fluorescent images
acquired by the Celigo Image Cytometer led to the direct enumeration of multiple cell
types without manipulating the culture system, which can serve to bolster readouts from
assays that employ indirect, end-point assays to measure T cell proliferation (i.e. CFSE
dilution)184 or cytotoxicity.185
We first validated the image cytometer to measure the cell density of multiple
CAR T cell products during the manufacturing process compared to the Multisizer 3. The
cell concentration values from both instruments were nearly identical over the course of
expansion (10 days), validating that image-based cytometry identified and accurately
counted CAR T cells. Importantly, these data enabled us to expand CAR T cells at an
optimal density by adding new expansion medium to the culture, which also serves to
dilute the waste products that accumulate from cellular metabolism

186

. Interestingly,

despite each CAR T cell type expressing a unique intracellular costimulatory domain,
which are known to impart distinct functional properties,60 the CAR T cells exhibited
similar expansion kinetics over 10 days in culture. This contrasts data from the cancer
field demonstrating that some scFv-based CARs expressing distinct costimulatory
signals exhibit differential expansion kinetics during ex vivo manufacturing,39,81
suggesting that the HIV-specific CAR mediates limited ligand-independent signaling, a
property that may improve resistance to exhaustion.38
Furthermore, we measured the area of expanding CAR T cells as a surrogate
readout of cellular activation.181 Both instruments detected peak CAR T cell size 6 days
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post-activation (>350 m2) before contracting to a rested size on day 10 (<250 m2).
However, it is important to note that each instrument uses a unique method to calculate
cell size. For instance, the Multisizer 3 determines cell area by detecting the impedance
of an electrical current measured as a voltage or current pulse. This transient change in
impedance results as cells pass through the aperture a volume of electrolyte solution is
displaced from the sensing zone equivalent to the volume of the cell.187 In contrast, the
image cytometer calculates cell size by measuring the finite pixels of a cell imaged in 2dimensional space contained within the segmentation boundary, and then factors in the
resolution of the acquired image. This method produces a cross-sectional area, but for
CAR T cells and other spherical objects this measurement can be easily adjusted to
account for 3-dimensional area. Nevertheless, the cell sizes from both instruments
strongly correlated with one another, indicating that image cytometry captured the
pattern of cell size dynamics during CAR T cell manufacturing.
Effector cell-mediated cytotoxicity assays are commonly used to detect the in
vitro function of CAR-modified and other pathogen-specific T cells

185

. These assays

generally measure target cell death by 3 mechanisms: 1) the release of Chromium-51
(radioactivity),188

lactate

dehydrogenase

(enzymatic

reaction),189

or

calcein

(fluorescence)190 from dead cells into the culture supernatant; 2) the loss of viable target
cells by flow cytometry;191,192 and 3) cell-associated luciferase activity.182 All three
categories of assays typically provide a fixed end-point measurement of cytotoxicity and
consumption of samples. End-point assays necessitate that replicate experiments need
to be performed to capture the kinetics of T cell killing, which may require a large input of
both effector and target cells. However, we demonstrated that an image cytometrybased approach led to the reliable assessment of cytotoxic CAR T cell function over
time. Notably, we measured the kinetics of target cell lysis by directly enumerating GFP+
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target cells without disturbing or sacrificing cell samples, whereas the BLI-based assay
provided an indirect measurement of antigen-specific killing at a single time point (72hours after co-culture). Moreover, the image cytometry-based method utilizes cell counts
within the same well at 0-hours to normalize the specific lysis values at 24, 48 and 72hours after co-culture. In this way, the reduction of GFP+ target cells reference their
respective wells instead of separate control wells, thereby negating the potential
variability inherent to pipetting or differences in target cell input between treatment and
control wells. As such, the ability to assess and quantify cytotoxicity in a stringent, kinetic
manner is a distinct advantage of image cytometry.
In summary, with the advancements in camera, optics, and image analysis
technologies, image cytometry has taken root in providing quantitative results to various
aspects of biological assays.175,176,193,194 For CAR T cell therapy, conventional methods
evaluating manufacturing criteria and effector function have resulted in the development
of potent cellular products capable of inducing durable remissions for certain
malignancies,47,48 but newer technologies are perhaps needed to advance the rapid
development and evaluation of preclinical candidate therapies. Here, image cytometry
provided a novel, efficient, and high-throughput characterization of CAR T cells during
the manufacturing process, and offered several direct advantages over industrystandard equipment and routine assays. The findings described herein highlight the
utility of image-based cytometry to assess multiple attributes of CAR T cells, and show
the potential of this method to expedite the discovery and validation of novel CAR T cell
products.

Materials and methods
Ethics statement:
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De-identified, purified CD3+, CD8+ and CD4+ T cells from human donors were
obtained by the University of Pennsylvania Human Immunology Core/CFAR Immunology
Core under an institutional review board (IRB)-approved protocol.

Plasmid construction
The amino acid sequences for the HIV-specific CD4-based CAR constructs
containing the following intracellular domains: CD3-, 4-1BB/CD3-, CD28/CD3-,
CD28/4-1BB/CD3-, CD27/CD3-, OX40/CD3- and ICOS/CD3- have previously been
described.40 In this study, each CAR was amplified from their original plasmid with the
following

primer:

5’-CACGTCCTAGGATGGCCTTACCAGTG

and

5’-

GTGGTCGACTTATGCGCTCCTGCTGAAC and cloned into pTRPE plasmid using the
AvrII and SalI restriction enzyme sites. In this orientation, the CAR sequence is
downstream of GFP or iRFP670 and a T2A sequence intervenes to permit expression of
both proteins.

Lentivirus production and transfection
To generate the lentiviral particles, expression vectors encoding VSV
glycoprotein, HIV Rev, HIV Gag and Pol (pTRPE pVSV-g, pTRPE.Rev, and pTRPE g/p,
respectively) were synthesized by DNA 2.0 or ATUM (Newark, CA) and transfected into
HEK293T cells with pTRPE transfer vectors encoding the CAR using Lipofectamine
2000 (Life Technologies, Carlsbad, CA) as previously described.103 Transfected
HEK293T cell supernatant was collected at 24 and 48 hours, filtered through a 0.45 m
nylon syringe filter and concentrated by ultracentrifugation for 2.5 hours at 25,000 RPM
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and 4°C. The supernatant was aspirated and the virus pellet was resuspended in 800 L
total volume of RPMI 1640, and subsequently stored at -80°C.

Preparation of CAR T cells
Purified CD8+ and CD4+ T cells (RosetteSep, StemCell Technologies,
Vancouver, Canada) were obtained by the University of Pennsylvania Human
Immunology Core/CFAR Immunology Core from apheresis products of three deidentified healthy human donors (Donor 1, 2, 3). T cells were cultured at 1x106 cells mL-1
in complete RPMI 1640 with 10% FCS (Seradigm), 1% Penicillin-Streptomycin, 2 mM
GlutaMax and 25 mM HEPES buffer (Life Technologies). T cell expansion medium was
supplemented with 100 U mL-1 recombinant human IL-2 (Clinigen). T cells were
stimulated with CD3/CD28 Dynabeads (Life Technologies) at a 3:1 bead-to-cell ratio at
37°C, 5% CO2 and 95% humidity incubation conditions. Approximately 18 hours after
stimulation, half of the medium was removed and replaced with 200 L of lentiviral
supernatant encoding the appropriate HIV-specific CAR. 5 days post-stimulation, the
Dynabeads were removed from cell culture by magnetic separation. T cells counts (cells
mL-1) and size measurements (cell area, μm2) were measured daily using both the
Celigo Image Cytometer (Nexcelom Bioscience LLC, Lawrence, MA) and Multisizer 3
Coulter Counter (Beckman Coulter, Brea, CA) as described below. The cells were
adjusted to 0.5x106 cells mL-1 with complete RPMI every second day.

Preparation of K562 target cells
The K562 cell line stably transduced to express the HIVYU2 GP160 Envelope
protein (K562.Env) was a kind gift from Aimee Payne (University of Pennsylvania,
147

Philadelphia, PA) and wild-type K562 cell line (K562.WT) (ATCC CCL-243) were
maintained in complete RPMI 1640 at a density of 0.1x106 cells mL-1. Both K562 cell
lines were transduced with a lentiviral vector encoding GFP coupled to Click Beetle
Green (CBG) luciferase by an intervening T2A sequence. The K562 cell lines were
single-cell sorted on the Aria II (BD Bioscience) based on GFP expression. For each cell
line, an individual single-cell clone was selected based on uniform GFP expression and
subsequently propagated for use in the cytotoxicity experiments.

T cell dilution series
Approximately, 4x106 total T cells were transferred into a 96-well flat bottom plate
(Corning #3596) in 200 L of 1X PBS (Corning). Subsequently, 7 two-fold serial dilutions
were made by carrying over 100 L of liquid containing cells. After the dilution series,
100 L of 1X PBS was added to all wells for a final volume of 200 L per well. The
dilution series was performed in triplicate, where the cell concentration and average cell
size were determined by the image cytometer and Multisizer 3.

T cell proliferation and size measurement using image cytometry
The Celigo Image Cytometer (Nexcelom Bioscience) utilizes one bright-field (BF)
and four fluorescent (FL) imaging channels, blue (EX377/50 nm, EM470/22 nm), green
(EX 483/32 nm, EM 536/40 nm), red (EX 531/40 nm, EM 629/53 nm), and far red (EX
628/40 nm, EM 688/31 nm) for high-throughput cell-based assays

195-199

. The target and

effector cells seeded in standard multi-well microplates are auto-focused, imaged, and
analyzed using the Celigo software (version 5.1). The software consists of five major
steps START, SCAN, ANALYZE, GATE, and RESULTS, where the users can enter
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general information, setup imaging/analysis parameters, perform imaging/analysis of
cells, and view/export images and results.
The Celigo Application “Target 1” was used to measure beads with specific
diameter in the bright-field channel at an exposure time of ~2,800 s. The Celigo
Application “Target 1 + Mask” was employed for measuring proliferation by directly
counting total T cells in the bright-field channel in each well over time. Both Target 1 and
Mask channels were set to bright-field illumination with exposure times 1 and ~3,250 s,
respectively. The Mask channel allowed the dilation of the outline diameter to improve
size measurement of T cells. In addition, a specific image analysis template was used
from FCS Express 6 (De Novo Software, Pasadena, CA). The counted T cell data (.ice
files) were exported from the image cytometer software and imported into the FCS
Express (De Novo Software) template that automatically generated size histograms, cell
count, cell concentration, diameter (m), minimum and maximum cell size (m2), and
average cell size (m2). The average cell size values were multiplied by a factor of 4 to
account for the surface area of spherical objects. It is important to note that software
version 5.2 can directly export cell concentration and size data, as well as dilate the cell
outline diameter without a Mask channel.

T cell proliferation and size measurement using the Multisizer 3
40 L of cell culture was transferred into individual Accuvette ST vials (Beckman
Coulter) containing 20 mL of ISOTON II Diluent (Beckman Coulter). Vials were loaded
onto the Multisizer 3 one at a time and cell concentration (cells mL-1) was based on
volumetric sampling (500

L) under the following conditions: 70 m aperture, 1600 A

current, and a gain setting of 2. Cell size was determined by applying a manual gate to
149

all samples (range 150 m2 to 1500 m2). The cell concentration and average cell size
was determined by the Beckman Coulter Particle Characterization software (v3.51)
using the ‘Statistics’ function. Similarly, CD3/CD28 Dynabeads beads at 4.5 m
diameter (Gibco) were counted and analyzed following the procedure described above.

CAR T cell-mediated cytotoxicity assay
Untransduced (UTD) and CAR CD8+ T cells that expressed the CD3endodomain coupled with iRFP670 were manufactured as described above. Prior to
setting up the assay, CAR transduction efficiency was normalized across all donors
based on positivity for iRFP670 expression. For each donor, 2x104 CAR T cells were
seeded in complete RPMI, and then five 2-fold serial dilutions were performed in a 96well black polystyrene microplate (Corning #3603). 1x104 K562.Env.CBG.GFP or
K562.WT.CBG.GFP cells were added to each well with final E:T ratios of 0.500, 0.250,
0.125, 0.061, and 0.031:1. Target cells were also cultured in the absence of CAR T cells
to account for spontaneous death, while wells containing complete RPMI only were
included as a measure for maximal killing (used for BLI-based assay). Three technical
replicates were performed for each donor. Plates were cultured at 37°C, 5% CO2, and
95% humidity incubation conditions. The cytotoxicity measurements were analyzed at 0,
24, 48 and 72 h using the image cytometer and the Synergy H4 Hybrid Microplate
Reader (BioTek).

Cytotoxicity measurement using image cytometry
The Celigo application “Target 1” was used for CAR T cell-mediated cytotoxicity
assay, which utilized only the green fluorescence channel. Green fluorescent images
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were acquired with exposure times ranging from ~15,000 to 30,000 s. The image
cytometer was used to directly count the number of GFP+ target cells in the wells with
different donors and E:T ratios over time in triplicate for each condition. Since GFP
fluorescence is significantly reduced as the target cells are killed during co-culture due to
leakage, direct counting of the bright GFP+ cells represented viable cells in the well.
Specific lysis was calculated by the following: % Specific Lysis = 100 x (# cells in no
effector wells - # cells in treatment well) / (# cells in no Effectors – 0 (max killing). This
calculation was performed to align with the normalized RLU data from BLI-based assay.

Cytotoxicity measurement using BLI microplate reader
Immediately after imaging the plate with the image cytometer at the 72 hour time
point, D-Luciferin potassium salt was added to each well producing a final concentration
of 15 µg mL-1 (GoldBio) and incubated at 37°C for 10 min. Luminescence was measured
for 1 second with a luminometer (Synergy H4 Hybrid Microplate Reader) as relative light
units (RLU). Triplicate wells were averaged and the percent specific lysis was calculated
with the following equation
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specific lysis (%) = 100 x [(spontaneous death RLU -

treatment RLU)/(spontaneous death RLU - maximal killing RLU)].

Statistical analysis
All statistical analysis was performed using GraphPad Prism, version 7 (San
Diego, CA). Comparison of means from matched samples was performed using
Wilcoxon matched pairs signed rank test. Bivariate correlations were performed using
Spearman’s rank correlation.
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Figures

Figure 4-1. Image-based cytometry reliably measures the kinetics and magnitude
of in vitro CAR T cell expansion. A) Bright-field image and segmentation of individual
T cells (blue) seeded in a 96-well microwell plate using the Celigo Image Cytometer. B)
Triplicate serial dilutions of CD3+ T cells were counted by the image cytometer and
Multisizer 3 and mean cell densities were plotted against theoretical values. Slope of
each line is denoted as “m”. C) Cell density values measured by the image cytometer
and Multisizer 3 from (B) were plotted against each other. Spearman correlation test was
used to calculate significance. D) CD4+ T cells were activated with CD3/CD28
Dynabeads and 24-hours later were transduced with a lentivirus encoding an HIVspecific CAR containing the indicated intracellular domain (ICD). Population doublings
were calculated by measuring the total cell number in culture at the indicated time-points
using the image cytometer (square) and Multisizer 3 (circle). E) Comparison of paired
CAR T cell population doublings on day 10 post-activation measured by the image
cytometer and Multisizer 3. Wilcoxon matched pairs sign rank test was used to calculate
significance (NS, P>0.05).
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Figure 4-2. Schematic representation of HIV-specific CAR constructs. Activated
CD4+ T cells were transduced with lentiviral vectors encoding the HIV-specific CAR
expressing the CD4 extracellular domain fused to intracellular domains comprising CD3 (), 4-1BB/, CD28/, CD28/4-1BB/, CD27, OX40 and ICOS CD28 containing
CARs used the CD28 transmembrane domain, whereas the remaining CARs used the
CD8 transmembrane domain.
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Figure 4-3. Image-based cytometry quantifies changes in CAR T cell size postactivation. A) Bright-field image of

CD3/CD28 Dynabeads seeded in 96-well microwell

plate. B) Histogram of CD3/CD28 Dynabeads imaged in (A) shows average bead area
and diameter within min (10 m2) and max (40 m2) limits. C) Bright-field image of CAR
T cells on days 0, 6 and 10 post-activation. D) Histogram of CAR T cell area at days 0
(red), 6 (black), 8 (blue) and 10 (green) post-activation by image cytometry and E)
Multisizer 3. Data are representative of 2 donors. F) Longitudinal cell area of the
indicated CAR T cell types measured by image cytometry and G) Multisizer 3. Data are
representative of 2 donors. H) Correlation of cell size values from the image cytometer
plotted against Multisizer 3. Each symbol represents a unique CAR T cell type 7 days
post-activation. Spearman correlation test was used to calculate significance
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Figure 4-4. Longitudinal changes in CAR T cell size post-activation. CD4+ T cells
from a second donor were activated with CD3/CD28 Dynabeads and transduced with a
lentiviral vector encoding the indicated HIV-specific CAR. A) Longitudinal cell area of the
expanding CAR T cells measured by image cytometry and B) Multisizer 3 at the
indicated time points.
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Figure 4-5. In vitro HIV-specific CAR T cell-mediated killing assessed by imagebased cytometry. HIV-specific CD8+ CAR T cells expressing the CD3- intracellular
domain were mixed in triplicate with on-target K562 HIVYU2 GFP160+ cells (K.Env) or offtarget K562 wild-type cells (K.WT) at 0.5, 0.25, 0.125, 0.061 and 0.0306:1 effector-totarget (E:T) ratios. Target cells stably expressed GFP linked to Click Beetle Green
luciferase by an intervening T2A sequence. Cell lysis was determined by successive
imaging of target cells using image cytometry and bioluminescence (BLI). A) Bright-field
and fluorescence microscopy images of GFP+ K.Env cells and K.WT cells 72-hours after
co-culture acquired by the image cytometer. B) Specific lysis of on-target and off-target
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cells cultured with CAR T cells and measured by image cytometry and C) BLI. D)
Specific lysis of on-target and off-target cells cultured with UTD T cells and measured
with image cytometry and E) BLI. Specific lysis values were calculated as described for
each method in Materials and Methods. Symbols represent mean and error bars show ±
SD. All data are representative of 3 donors.
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Figure 4-6. HIV-specific CAR T cells exhibit limited in vitro off-target cytotoxicity.
HIV-specific CD8+ CAR T cells expressing the CD3- intracellular domain were mixed
with off-target GFP+ K.WT cells at the indicated E:T ratios. Bright-field and fluorescence
microscopy images are of off-target cells 72-hours post co-culture acquired by the image
cytometer. Data are representative of 3 donors.
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Figure 4-7. Comparison of CAR T cell-mediated killing using image cytometry and
Bioluminescence-based cytotoxicity assays. HIV-specific CD8+ CAR T cells
expressing the CD3- intracellular domain were mixed in triplicate with on-target K562
HIVYU2 GFP160+ cells (K.Env) or off-target wild-type K562 cells (K.WT) at 0.5, 0.25,
0.125, 0.061 and 0.0306:1 effector-to-target (E:T) ratios. Target cells stably express
GFP linked to Click Beetle Green luciferase by an intervening T2A sequence. Cell lysis
was determined by successive imaging of target cells using image cytometry and
bioluminescence (BLI). A) Specific lysis of on-target cells and off-target cells when
cultured with CAR T cells and B) UTD T cells at different E:T ratios. Specific lysis values
were calculated as described for each method in Materials and Methods. Symbols
represent mean and error bars show ± SD. C) Paired specific lysis values from image
cytometry and BLI-based assay at the indicated E:T ratios. Each symbol represents a
unique donor.
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Figure 4-8. Image-based cytometry captures the kinetics of in vitro CAR T cellmediated cytolysis. A) Fluorescence microscopy images of on-target GFP+ K.Env cells
alone, or mixed with HIV-specific CD8+ CAR or UTD T cells at 0.5:1 E:T ratio at the
indicated time points after co-culture acquired by the image cytometer. B) Enumeration
of on-target cells and off-target GFP+ K.WT cells mixed with CD8+ CAR or UTD T cells at
different E:T ratios at the indicated time points after co-culture. Symbols represent
average of triplicate values and error bars show ± SD. Data are representative of 3
donors.
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Figure 4-9. Kinetics of in vitro HIV-specific CAR T cell-mediated killing. A)
Enumeration of on-target GFP+ K.Env and off-target GFP+ K.WT cells mixed with CD8+
CAR or UTD T cells at different E:T ratios at the indicated time points post co-culture.
Symbols represent average of triplicate values and error bars show ± SD. B)
Fluorescence microscopy images of off-target K.WT cells alone, or mixed with HIVspecific CD8+ CAR or UTD T cells at 0.5:1 E:T ratio at the indicated time points after coculture acquired by the image cytometer.
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CHAPTER 5 - Conclusion

Research Summary
The CTL response to HIV infection can shape the trajectory of disease
pathogenesis. However, for most individuals HIV employs a variety of escape
mechanisms that renders CTLs, as well as other arms of antiviral immunity ineffective.
As such, HIV persists indefinitely by establishing latent reservoirs that necessitates
lifelong treatment to subdue virus replication and prevent disease progression. The HIV
cure field generally considers that reconstituting the HIV-specific CTL response will be a
critical component of an HIV cure strategy. Of late, adoptive T cell-based therapies,
specifically CAR T cells, have garnered significant attention for their ability to overcome
the limitations that prevent naturally-derived CTLs from controlling infection (summarized
in Table 1-1). This body of work represents an in-depth examination of CAR T cell
therapy for the treatment of HIV using small animal models of HIV infection that
recapitulates viral pathogenesis in humans. We leveraged in vivo models to describe the
underpinnings of both successful and failed CAR T cell interventions. The major findings
are addressed below:
BLT humanized mice are a viable approach to evaluate adoptive T cellbased therapies for HIV. BLT mice are generated by implanting human fetal thymus
and liver tissue into NSG mice, followed by the infusion of fetal liver-derived CD34+
hematopoietic stem cells, and over time, human immune cells of various lineages
repopulate the mouse. These mice have been extensively used to study various aspects
of HIV infection including the determinants of virus transmission,200 efficacy of new ART
regimens,67 and to a lesser extent the generation of HIV-specific immunity.96
Undoubtedly, the paucity of reports describing the development of antigen-specific CTL
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responses induced either through natural infection or immunization initially tempered our
expectations that these animals could support CAR T cell therapy. Nevertheless, we
focused our efforts on BLT mice because these animals offer substantial advantages
over less complex humanized mouse models, including the ability to recapitulate the
study design of autologous CAR T cell therapy that would be performed in HIV-infected
individuals (see in NCT03485963). We demonstrated that CAR T cells manufactured ex
vivo from BLT mice are functionally indistinguishable from their healthy adult human
donor-derived counterparts. After infusion into HIV-infected mice, these cells mount a
vigorous response, evidenced by profound antigen-specific proliferation and activation
during acute infection. Notably, CAR T cells expressing the 4-1BB/CD3- endodomain
did not resolve infection, and as a result, these cells sustained expression of multiple
inhibitory receptors (PD-1, TIGIT, 2B4) and transcription factors (Eomeshi, TOX, T-betlow)
associated with an exhausted T cell phenotype.201 Together, these data support that BLT
mouse-derived T cells are not functionally compromised, rather the immune response
mounted by CAR T cells mimics the response pattern of other virus-specific CTLs,
particularly in the setting of uncontrolled infection. Moreover, these data demonstrate
that ex vivo manufacturing and infusion of autologous antigen-specific T cells overcomes
the presumed defect in BLT mice that restricts the priming of de novo CTL responses to
combat virus infection.
The inclusion of multiple costimulatory signals into CAR T cells are
necessary to induce optimal antiviral activity. In addition to CD3-, costimulatory
signals are required to potentiate the in vivo activity of CAR T cells, including
proliferation, persistence and effector functions.37 The most common intracellular
costimulatory domains under investigation are derived from the CD28 receptor family
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(ICOS and CD28), and the tumor necrosis factor (TNF) receptor family (CD27, OX40
and 4-1BB), but alternative mechanisms to provide costimulation have been explored,
such as the co-expression of full-length costimulatory ligands (4-1BBL and CD40L).80,202
However, CD28 and 4-1BB remain the archetypal costimulatory signals used by secondgeneration CAR T cells, and each are incorporated into licensed CD19-targeted CAR T
cell therapies. In the context of aggressive B cell non-Hodgkin’s lymphoma (B-NHL),
CAR T cells with CD28 costimulation mediate higher response rates than 4-1BBcostimulated CAR T cells, despite limited in vivo survival, whereas in B-cell acute
lymphoblastic leukemia (B-ALL), 4-1BB costimulation induces longer progression free
survival rates, which correlates with the persistence of CAR T cells.55,58 These findings
suggest that favorable CAR T cell responses to B-NHL require rapid, cytolytic activity
mediated by CD28 costimulation, while B-ALL likely requires a durable, prolonged CAR
T cell-mediated response provided by 4-1BB costimulation. Together, this suggests that
the costimulatory domain that engenders optimal CAR T cell activity is disease-specific.
Here, we reconciled the differential functional attributes that CD28 and 4-1BB
costimulation impart on CAR T cells in the setting of HIV infection, by creating a novel
dual CD4-based CAR-transduced T cell population that independently expresses
CD28/CD3- and 4-1BB/CD3- endodomains on the same cell. In this way, we
hypothesized that the CD28 and 4-1BB domains have the opportunity to signal
autonomously in their native orientation when triggered. Indeed, Dual-CAR T cells
exhibited profound in vivo expansion that exceeded 4-1BB-costimulated CAR T cells,
and elicited effector functions, including ex vivo cytotoxicity and cytokine secretion, to
the same extent as CD28-costimulated CAR T cells. Moreover, only Dual-CAR T cells
were capable of mitigating HIV disease progression by preventing CD4+ T cell loss.
Notably, the in vivo activity of Dual-CAR T cells contrasts that of 3rd-generation (3G)
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CD4-based CAR T cells, which combine CD28 and 4-1BB costimulatory signals in a
linear manner on the same molecule. In fact, the in vivo proliferation and survival
exhibited by 3G-CAR T cells are similar to CD28-costimulated CAR T cells, suggesting
that the costimulatory domain proximal to the cell membrane (i.e. CD28 in the 3G-CAR
construct) exerts a dominant effect on T cell function, which has been demonstrated in
the context of several cancer-specific 3G-CARs.82,83 Collectively, these data highlight the
development of a new CAR T cell population with unique functional properties that can
be applied to treat a variety of different disease indications beyond HIV.
The susceptibility of CD4-based CAR T cells to HIV infection accelerates
disease progression. There exists several distinct antigen recognition moieties that
engage the HIVENV glycoprotein on virally-infected cells, including scFvs derived from
broadly neutralizing antibodies,42 carbohydrate recognition domains,133 and the CD4
extracellular domain.40 We initially chose the CD4-based CAR for several reasons: i)
demonstrated safety profile in humans;35 ii) greater in vitro antiviral potency than scFvbased CARs;40 and iii) minimized likelihood of HIV to escape from binding to CD4.131
Despite these advantages, the overexpression of a CD4-based CAR on CD8+ and CD4+
T cells renders these cells susceptible to HIV infection, but prior to this work the
consequences of infection were unknown. We hypothesized that the rate of CAR T cell
infection, and subsequent propagation of virions within expanding CAR T cells, negated
CAR T cell-mediated reductions in the frequency of virus-infected cells that contribute to
plasma viremia. To this end, we found that the infusion of CAR T cells into HIV-infected
mice both accelerated the replication kinetics and increased the magnitude of plasma
viremia compared to untreated mice. In addition, HIV-infected CAR T cells exhibited
weaker functional responses after ex vivo stimulation than their uninfected counterparts.
In contrast, only the infusion of CAR T cells expressing the HIV fusion inhibitor, C34165

CXCR4, delayed the onset and reduced the magnitude of acute virus replication, but this
effect was transient given that C34-CXCR4 does not confer sterilizing protection.79 As
such, we have concluded that stringent mechanisms of HIV resistance need to be
engineered into CAR T cells to prevent this treatment from worsening disease
progression.
HIV-resistant and HIV-specific CD4+ CAR T cells exert direct antiviral
activity and confer T cell-help to other lymphocytes. Given that HIV infection
depletes CD4+ T cells, which compromises global antiviral immunity, we reasoned that
reconstituting HIV-specific CD4+ T cells will be an essential component to an HIV cure
strategy. We know from the initial in-human clinical trials that the co-infusion of HIVspecific CD4+ CAR T cells were essential for the engraftment and survival of CD8+ CAR
T cells,34 but due to the study design and the lack of therapeutic efficacy, the individual
contribution of CD4+ T cells to treat HIV remains unknown. Herein, we explored the utility
of CD4+ CAR T cells with regard to their ability to directly control infection and aid in the
function other immune cells. In doing so, we identified an inverse relationship between
costimulatory domains that confer the greatest in vitro and in vivo antiviral CD4+ CAR T
cell function. Notably, only the 4-1BB costimulatory signal augmented CD4+ CAR T cell
expansion and persistence in vivo, and importantly, enabled CD4+ T cells to suppress
rebound viremia after ART cessation in humanized mice. These results were striking in
that CD4+ CAR T cells expressing costimulatory domains from the TNF receptor family
demonstrated inferior in vitro effector responses compared to CD4+ CAR T cells
expressing CD28 receptor family costimulatory domains. In addition, CD4+ CAR T cells
conferred T cell-help to co-infused CD8+ CAR T cells expressing the CD28 costimulatory
domain. Here, we observed significantly improved CD8+ CAR T cell expansion and
persistence in vivo relative to CD8+ CAR T cells that were infused alone. Given these
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promising results, we believe that CD4+ CAR T cell-help can be extended to reinvigorate
endogenous HIV-specific CTLs.
Furthermore, we investigated alternative applications of HIV-specific CAR T cells
through external collaborations. For instance, Christopher Peterson’s group at the
University of Washington and Fred Hutchinson Cancer Research Center previously
observed limited persistence of adoptively transferred CAR T cells into SHIV-infected
nonhuman primates (NHPs). Thus, as a means to boost the frequency of CAR T cells
prior to ART interruption, we successfully infused HIVENV expressing artificial antigen
presenting cells that induced marked in vivo antigen-specific expansion of NHP-derived
CAR T cells,203 which we previously observed in BLT mice. In addition, we applied
Therapeutic Interfering Particles (TIPs) developed in Leor Weinberger’s laboratory at the
University of California, San Francisco in HIV-infected BLT mice to determine whether
TIPs can reduce viremia by out-competing HIV for host machinery that is vital for virus
replication [Tanner, EJ., et al. under review]. We then combined the TIPs with HIVspecific CAR T cell therapy to determine if the addition of an antiviral immune response
can synergize with these particles to further suppress viremia. Overall, the lessons
learned from this body of work have demonstrated practical utility outside of our
immediate scope, as we have showed that our findings have the potential to bolster the
therapeutic efficacy of other treatment modalities being explored by external
investigators.

Future Directions
The results described in this work highlight the promise of CAR T cell therapy as
part of an effective HIV cure strategy. However, it is clear that additional studies are
necessary to advance the efficacy of HIV-specific CAR T cells, as currently, they only
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exert a modest impact on disease progression. As such, to achieve an ART-free HIV
remission we believe future efforts should aim to further optimize the CAR T cell product,
as well as investigate treatment protocols that combine CAR T cells with other
therapeutic agents. These future directions are discussed in detail below.
Initially, we engineered a more potent HIV-specific CAR T cell product by cotransducing T cells with independent lentiviruses encoding CD4-based CARs with 41BB/CD3- and CD28/CD3- endodomains. Despite expressing distinct intracellular
signaling domains, Dual-CAR T cells express two copies of the CD4-based targeting
moiety. Thus, it is possible that competition exists between the two CARs for binding to
the CD4-binding site of HIVENV, especially when antigen is limited, which may restrict fullactivation of 4-1BB and CD28 costimulatory signals. As such, the generation of multispecific Dual-CAR T cells should be employed to mitigate this concern. In this
scenario, we envision that the ideal Dual-CAR T cell expresses two distinct targeting
moieties in addition to the 4-1BB and CD28 endodomains. We believe it will be critical to
keep the CD4-based CAR constant, while the second CAR needs to target a separate
epitope on HIVENV. The second CAR will likely be derived from a broadly-reactive
antibody, as opposed to a broadly-neutralizing antibody (bNab), which is capable of
binding to diverse HIV strains. This scFv can be developed from any number of
monoclonal antibodies with known specificities; however, one attractive choice may be
an scFv that recognizes CD4-induced (CD4i) HIVENV epitopes. CD4i binding sites within
the inner domain of gp120 are normally occluded by gp41 and are only exposed after
gp120 engages CD4.204 In doing so, CD4i-targeted antibodies are known to inhibit the
binding of gp120 to CCR5 chemokine receptor after undergoing conformational changes
upon ligating CD4.205 Thus, the sequential binding of the CD4-based CAR followed by
the CD4i-targeted CAR may induce full CAR T cell activation in the absence of
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competition for the same epitope, and as an ancillary benefit the CD4i-targeted CAR
may prevent infection of CAR T cells by blocking access to the HIV coreceptors.
Moreover, we have shown substantial evidence that HIV infection of CAR T cells
compromises their ability to effectively control disease pathogenesis. For instance, we
demonstrated that infusion of HIV susceptible CAR T cells both accelerates the kinetics
and increases the magnitude of viremia. However, we observed the opposite trend when
infection of CAR T cells was mitigated by 1) administering CAR T cells into HIV-infected
mice concurrently with ART to prevent new rounds of virus replication, and 2) infusing
HIV-resistant CAR T cells that express the C34-CXCR4 fusion inhibitor. In the latter
case, expression of C34-CXCR4 clearly reduced the level of CAR T cell infection, but
this protection rapidly waned upon exposure to persistent viremia. Thus, HIV-specific
CAR T cells must be engineered with more stringent mechanisms of resistance to
improve control over virus replication. To do so, preventing viral entry by targeted
genetic disruption of the HIV coreceptors is likely the most effective strategy for
engineering HIV-resistant CAR T cells.
The finding that individuals who lack functional CCR5 expression are both
healthy and resistant to CCR5-tropic strains of HIV has prompted extensive investigation
to recreate this phenomenon in the majority of people who are susceptible to infection.
These HIV resistant individuals contain a naturally occurring 32 base pair deletion in
CCR5 leading to the production of a truncated, non-functional chemokine receptor that
does not permit HIV fusion.206,207 To date, several ex vivo gene-editing approaches have
been clinically evaluated to protect CD4+ T cells from infection,85,208,209 including using
zinc finger nucleases to genetically disrupt CCR5.87 More recently, gene-editing
strategies have used homology-directed repair (HDR) to introduce new gene cassettes
into specific genomic loci.210,211 One study, simultaneously disrupted CCR5 using site169

directed megaTAL nuclease and drove HDR using an adeno-associated virus donor
template encoding an HIV-specific scFv-based CAR.43 This method produced functional
HIV-specific CAR T cells lacking CCR5 expression, and these cells suppressed virus
replication in vitro to a greater extent than unprotected CAR T cells. Despite the ability
of various gene-editing approaches to attenuate CCR5 expression, the efficiency of
gene-modification are modest.212 As such, manufacturing CCR5-edited CAR T cells may
be the most significant challenge to successfully deploy this approach at a clinical scale,
as an overwhelming majority of the T cell infusion product must be HIV-resistant.
HIV-specific CAR T cells may also benefit from new advances made in the
cancer immunotherapy field to subvert T cell exhaustion. We thoroughly demonstrated
that CAR T cells progressively accumulated an exhausted phenotype in the presence of
persistent viremia in vivo. This phenotype was characterized by sustained co-expression
of PD-1, TIGT and 2B4 and transcription factor usage that was dominated by Eomes
and TOX expression, as well as attenuated effector functions. As a result, engineering
HIV-specific CAR T cells to overcome exhaustion will likely promote durable
immune responses that are necessary to control infection. Recently, emphasis has
been paced on CRISPR/Cas9 gene-editing, as this approach is a powerful tool for
multiplex genome editing.213 For instance, several groups have disrupted the expression
of PD-1 in cancer-specific TCR- and CAR-modified T cells to promote antitumor
immunity,214,215 and this technology has just been employed in a phase one clinical
trial.216 Moreover, another group has engineered exhaustion-resistant CAR T cells by
overexpressing the AP-1 family transcription factor, c-Jun.217 In doing so, these CAR T
cells maintained their functional capacity, diminished terminal differentiation, and
exhibited improved antitumor potency. These approaches can be adapted to HIVspecific CAR T cells, and when tested in BLT humanized mice we will be able to
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determine the extent to which anti-exhaustion mechanisms augment the durability of the
CAR T cell response.
In addition to engineering an HIV-specific T cell product that can induce potent
responses, CAR T cells have the potential to synergize with other treatment modalities
to cure infection. One approach is to combine CAR T cell therapy with broadly
neutralizing antibodies, where these bNabs have the ability to prevent new rounds of
infection by neutralizing virions, as well as Fc-mediated effector functions to eliminate
HIV-infected cells.218 To this end, we performed a proof of concept study where DualCAR T cells were combined with a bNab cocktail (10-1074 and 3BNC117) to accelerate
virus suppression under ART. 10-1074 and 3BNC117 engage HIVENV at distinct sites,
the V3 loop and CD4 binding site, respectively,219,220 and were included in this study for
their ability to delay virus rebound after ART interruption in humanized mice and
humans.221,222 However, when tested in combination with CAR T cells we observed no
synergistic effect on the kinetics of viral suppression relative to mice treated with only
CAR T cells or bNabs in the presence of ART [unpublished]. One possible explanation
for the lack of synergy may be that the 3BNC117 antibody and the CD4-based CAR T
cell were competing for the same binding site on the gp120 subunit of HIVENV. As such,
future studies should evaluate antibody cocktails that do not simultaneously target the
CD4 binding site, which could potentially interfere with the CAR T cell recognition of
infected cells.
Furthermore, one of the largest hurdles for a successful HIV cure is the presence
of a latent HIV reservoir. In this state, the virus genome stably integrates into the
chromatin of resting memory CD4+ T cells and avoids immunosurveillance by persisting
indefinitely in a transcriptionally quiescent state. Current eradication efforts, such as the
“shock and kill” paradigm, aim to reactive HIV production from latent reservoirs using
171

latency reversing agents (LRAs).223 It is hoped that reactivated cells will die by virusinduced cytopathic effects and/or be lysed by stimulating pre-existing or generating de
novo immune responses.224 However, LRA treatment alone has failed to measurably
reduce the size of the latent reservoir in HIV-infected individuals.225-227 These findings
imply that additional immune mechanisms may be required to destroy infected cells
upon latency reversal. Thus, there is an opportunity for HIV-specific CAR T cells to act in
concert with LRAs. Of particular interest, are treatment regimens that use an IL-15
superagonist,228 or stimulate toll-like receptors,229 or non-canonical NF-κB signaling.230
Given the critical role each of these pathways have in developing cell-mediated
immunity, it is likely that these approaches could synergize with CAR T cells by having
an ancillary, beneficial effect on cellular function in addition to inducing viral gene
expression.
In summary, this work culminated in major improvements to the HIV-specific
CAR T cell product that is currently under clinical investigation at the University of
Pennsylvania, ultimately leading to the generation of HIV-specific Dual-CAR T cells.
Notably, these findings may not have occurred if not for the rigorous in vivo testing using
BLT humanized mice, which provided a stringent environment necessary to study the
functional behavior of CAR T cells in the setting of virologic failure. We made step-wise
improvements to the HIV-specific CAR T cell product, where during this process the
susceptibility of CAR T cells to both exhaustion and HIV infection are critical hurdles that
must be addressed in future studies. However, this body of work demonstrates a clear
promise that CAR T cells can promote immune-mediated clearance of virus-infected
cells and contribute to a functional HIV cure.
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